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Emergence of multidrug-resistant tuberculosis (MDR-TB) renders the two most powerful and 
commonly used TB antibiotics, rifampicin and isoniazid, ineffective. There is an urgent need 
for the development of safe and effective strategies against drug-resistant TB. Based on 
previous studies, two novel antimicrobial peptides, namely D-LAK120-A and 
D-LAK120-HP13, both consist entirely of D-amino acid residues, have demonstrated 
inhibitory effect on MDR Mycobacterium tuberculosis (Mtb) strains when cultured in 
macrophages and potentiated the antimycobacterial activity of isoniazid in vitro. Here, the 
antimycobacterial activity of D-LAK peptides in combination with anti-TB drugs against 
MDR-TB clinical isolates was investigated. Furthermore, the mechanisms of action of the 
proline-containing and proline-free D-LAK peptides, anti-TB drugs alone or in combinations 
were studied using two mycobacterial models Mycobacterium smegmatis and the severely 
attenuated Mtb Bleupan. Finally, the applicability of these two microorganisms for 
mycobacterial studies was discussed.  
In vitro and ex vivo antimycobacterial assays revealed the synergy between D-LAK peptides 
and rifampicin or isoniazid against MDR Mtb strain. These findings suggested D-LAK 
peptide can facilitate the re-sensitization of MDR-TB clinical isolates towards rifampicin and 
isoniazid possibly through their surface activity. To gain further understanding on their 
mechanisms on mycobacteria, M. smegmatis was employed due to its fast-growing nature 
and widespread usage in TB studies. With confocal and transmission electron microscopy, 
the surface-active action of D-LAK peptides were observed which led to visible 
morphological changes in M. smegmatis. Using high-resolution magic angle spinning (HR-
MAS) nuclear magnetic resonance (NMR) metabolomics, trans-1,6-diphenyl-1,3,5-
hexatriene (DPH) and Laurdan fluorescence spectroscopy, it was shown that bacterial 
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metabolism was substantially altered when challenged with anti-TB agents, specifically by 
the remodelling of mycobacterial membrane. The proline-containing D-LAK120-HP13 and 
proline-free D-LAK120-A peptides demonstrated disparate behaviours in the initiation of 
membrane remodelling which provides possible rationale for their synergistic interaction 
with anti-TB agents. These techniques were then applied to the study of another potential 
mycobacterial model Mtb Bleupan which was selected for its safer nature as a Mtb surrogate. 
Changes in membrane components triggered by anti-TB agents were observed but the effect 
was subtler than that observed in M. smegmatis. These findings suggested the potential of 
using these biophysical techniques to study the action of anti-TB drugs on mycobacteria and 
to elucidate the underlying mechanism of synergy demonstrated in the combinations of D-
LAK peptides with anti-TB agents.  
Finally, the applicability of M. smegmatis and Mtb Bleupan to be exploited as a Mtb 
surrogate was evaluated. Some key differences in response to anti-TB agents were detected 
between Mtb Bleupan and M. smegmatis in terms of the changes in metabolism and 
membrane properties. These findings demonstrated Mtb Bleupan as a safe and desirable 
model for the generation of translatable findings for TB studies. Further optimization of the 
growth response study using Mtb Bleupan is essential for a more comprehensive 
understanding of anti-TB agent mechanism. 
Overall, this thesis concluded that the combinations of D-LAK peptides with rifampicin or 
isoniazid were effective against MDR clinical isolates and paved the next step to elucidate 
the mechanisms using a more reliable surrogate, Mtb Bleupan.  
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1.1 TUBERCULOSIS AND THERAPY 
 
1.1.1 TB Etiology and Global TB Crisis 
Tuberculosis (TB) is an ancient infectious disease that can be dated back thousands of years. 
The evidence of TB has been found in the remnant of a bison which lived in Wyoming, US 
17,000 years ago1. Tubercular decay has also been detected in the spines of Egyptian 
mummies, which date back to 3000-2400 BC2, whilst genome-based studies have also 
suggested the presence of TB in America since AD 1003. Tuberculosis, which was also 
known as the great white plague or phthisis, has claimed countless human lives ever since 
and still represents the second most life-threatening infectious disease worldwide in our era, 
after human immunodeficiency virus (HIV) infection. TB was demonstrated to be infectious 
by a French specialist Jean-Antoine Villemin in 18654. On 24th March 1882, the causative 
agent of the disease was identified as an eubacterium, named as Mycobacterium tuberculosis 
(Mtb) by a German researcher, Robert Koch who was later honoured with the Nobel Prize in 
1905 for his contribution in TB research. The World TB day was established then to 
commemorate his discovery5.  
Mycobacterium tuberculosis is a member of the Mycobacterium tuberculosis complex 
(MTBC), a group of closely related strains comprising another human-adapted species 
Mycobacterium africanum, as well as the animal-adapted Mycobacterium bovis, 
Mycobacterium microti and Mycobacterium caprae. Despite the wide spectrum of 
mammalian hosts, MTBC species possess over 99% of genomic homogeneity; this gives 
proof to their evolution from a single African origin that resembled Mycobacterium canetti 
strains6, 7. TB can infect any part of the body although disease manifestation is generally 
observed in the lungs. Apart from pulmonary TB, extra-pulmonary TB is mainly found in 
immunocompromised individuals which includes osseous tuberculosis found in the bones and 
tuberculous ulcer occurring on the skin8. 
Causing over a billion deaths in the past 200 years, TB has continued to present a grave 
challenge globally. The World Health Organization declared TB as a global health 
emergency in 1993. Effort has been concerted worldwide to tackle the disease, as a result of 
which, the global incident rate has dropped by 3% every year since 20009. Furthermore, the 
global mortality rate has declined significantly by 37% between 2000 and 2016 as reported 
by WHO in 2017. The decrease is mainly observed in developed countries in the Western 
Pacific Region and European Region. Despite the gains in tuberculosis control by the 
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implementation of effective strategies, TB remains acknowledged as a global emergency 
accounting for 10.4 million of new cases and 1.3 million of deaths in 2016. About 60% of the 
TB cases are found in India, Russian Federation, South Africa and China, where poverty, 
overcrowding, malnutrition and deficient healthcare systems are common9, 10. The problem of 
TB is exacerbated by the emergence of various drug-resistant strains. Those Mtb strains that 
have acquired different level of resistance are categorized as multidrug-resistant tuberculosis 
(MDR-TB), possessing resistance towards both of the first-line anti-TB agents: rifampicin 
(RIF) and isoniazid (INH); extensively drug-resistant tuberculosis (XDR-TB), defined as 
MDR-TB strains that display an added resistance to any fluoroquinolone and at least one of 
the second-line injectable aminoglycosides such as amikacin, kanamycin or capreomycin11; 
and totally drug-resistant tuberculosis (TDR-TB), known to be resistant to all available 
drugs12. It is reported that there were approximately 0.49 million new MDR-TB cases 
worldwide in 2016. The prevalence is especially high in Eastern Europe and Central Asia, 
where an estimated 190,000 people died from MDR-TB, accounting for 48% of the cases 
worldwide9. XDR-TB is calculated to make up 0.5% of global TB cases and has been 
reported in 91 countries throughout the world. New anti-TB drugs such as delamanid and 
bedaquiline, as well as shorter regimens, have been introduced to combat the problem of 
drug-resistant TB. Unfortunately, the treatment success rates were only 54% for MDR-TB 
and 30% for XDR-TB9. In addition to the emergence of drug-resistant strains, HIV co-
infection occurs in 10% of all TB-cases and caused 374,000 deaths in 2016. Co-infection 
with HIV is a major problem in African countries and presents an enormous pressure for TB 
treatment due to drug interactions. On the other hand, immunological tests have suggested 
that about 2 billion of the world population might be infected with latent TB, an 
asymptomatic infection by dormant Mtb, with 5-10% of the individuals going on to develop 
active TB during old age13, or when their immune systems are comprised. The existence of 
all these manifestations of Mtb complicates the treatment process, and therefore increases the 
challenge to combat this noxious disease.  
Since the discovery of Mtb being the primary causative agent of tuberculosis, huge efforts 
have been made towards to the development of antibacterial and antimicrobial compounds to 
eradicate this bacterium. In 1945, the first anti-TB therapeutic, streptomycin, was 
introduced14. Unfortunately, the overuse of streptomycin quickly led to the development of 
drug resistance, resulting in therapy failure. The most effective and affordable anti-TB four-
drug regimen [rifampicin, isoniazid, ethambutol (EMB) and pyrazinamide (PZN)] currently 
in use globally was introduced four decades ago. All these factors combined reflect the 
5 
 
challenges of TB treatment and anti-TB drug development, which in turn reveal the unique 
nature and behaviour of the bacteria.  
The exclusive abundance of lipids is recognized as the hallmark of Mtb, accounting for up to 
40% of the bacillus dry weight15, 16. Approximately 60% of these lipids are primarily long 
chain fatty acid (mycolic acids, MA) located on the outer layer of the mycomembrane. 
Compared with the Gram-negative cell wall with only 20% lipid content, the mycobacterial 
cell envelope is well known to have low porosity and therefore is impermeable to a wide 
range of antibiotics17. This lipid-rich, hydrophobic barrier not only hinders the entry of drugs 
but also accounts for greater resistance of Mtb to antibiotics18. The unusual structure and 
chemical composition of Mtb has also given rise to several intrinsic resistance mechanisms17. 
These mechanisms help Mtb to reduce their exposure to hostile host cell environment, 
neutralize drug compounds, adapt to the immoderately radical environment, and therefore 
increase the chance of survival. The extremely slow metabolism (doubling time 12-24 h) of 
Mtb has also hampered the efficiency of most conventional antibiotics which target specific 
steps in the metabolic cycle of the bacteria19. Moreover, the exceptional mode of 
pathogenicity of Mtb ensures their remarkably well-adapted interaction with the host presents 
another challenge on TB treatment. They can remain in the host system without being 
compromised via a vast repertoire of sophisticated pathways20. After inhalation, Mtb is 
ingested by alveolar macrophages. Instead of clearing by the first line innate immune system, 
Mtb can resist the degradation by phagosomes and persist or even replicate in the host, 
leading to the formation of granuloma21, 22. Besides, it was reported that Mtb can escape into 
host cytosol by inducing phagosomal rupture and uses the macrophage for its own replication 
process23, 24. In short, Mtb arrests the phagosomal maturation and acidification, and impairs 
the synthesis of lysosome-phagosome complex. Further, it inhibits not only apoptosis of the 
macrophages but also represses antimicrobial actions leading to death of host cell via 
necrosis17. The capability of Mtb to remain in a dormant state deep inside the respiratory 
tissues makes penetration of drug molecules difficult. Dormant Mtb is in a non-replicating 
state with low-to-absent metabolic activity. They are referred as persisters in the host as they 
survive through antibiotics treatment by remaining in the dormant state. A subpopulation of 
the dormant Mtb is thought to be accountable for the occurrence of an asymptomatic form of 
TB referred as latent TB infection (LTBI)25. As mentioned previously, almost a quarter of the 
world population is infected with LTBI26 while there is still no promising diagnostic tool or 
therapy developed. This further complicates the TB conundrum with the regular conversion 
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of LTBI to active infections especially in immunocompromised circumstances such as HIV 
co-infection.  
Another hurdle in combating TB owes to the emergence of drug-resistant strains. Misuse, 
interrupted and overuse of antibiotics result in the development of resistance in a proportion 
of bacteria conferring higher tolerance to anti-TB drugs27. Resistance is shown to be more 
likely to develop when patients do not complete the full prescribed therapy and the level of 
resistant infection is found to be positively correlated with antibiotics consumption28. 
Individuals with fully susceptible TB may progress to drug-resistant TB due to inadequate or 
low-quality medication29. The exposure to suboptimal drug dosage has facilitated Mtb strains 
to evolve into resistant strains through a various of mechanisms including compensatory 
evolution, decreased cell wall permeability, drug/target alteration and epistasis30 while 
horizontal gene transfer is controversial31, 32. The rapid emergence of drug-resistant Mtb strain 
has brought us into a rigorous circumstance in anti-TB drug development. Aiming to develop 
novel drugs to tackle drug-resistant tuberculosis, it is important to understand their resistance 
mechanisms in order to identify suitable targets. The hardly penetrable mycomembrane and 
other developed intrinsic as well as acquired resistances of Mtb are discussed in detail in 
section 1.2. 
Apart from the challenges in anti-TB drug development, the lack of diagnostic tools for 
MDR-TB, differences in public health systems, lack of regulation, education and control in 
using antibiotics especially in developing countries have led to the unequal distribution of 
MDR-TB incidence rate in the world. With the alarming figures of MDR-TB population and 
considering the underestimation due to inadequate of surveillance data, global efforts have 
been initiated by international organizations such as TB Alliance, World Health Organization 





1.1.2 Anti-TB Drug Development and Current Regimens 
An all-round anti-TB therapy aims to cure the patient, reduce complication and mortality, 
decrease reoccurrence and transmission to sensitive individuals, and avoid the emergence of 
drug-resistant strains. To achieve each of these aims, combination therapy is used for anti-TB 
treatment following lessons learnt at the very beginning of anti-TB drug development. 
Streptomycin was the first effective TB antibiotic isolated by Waksman and Schatz from 
Streptomyces grieus34. Resistance was quickly developed to this monotherapy, and most 
patients started to deteriorate after the first month of treatment35. To prevent the selection of 
resistance, the British Medical Council pioneered the first combination therapy of 
para-aminosalicyclic acid (PAS), an oral agent developed in 1944, with streptomycin for TB 
treatment36. Combination therapy not only reduced the emergence of resistance but also 
shortened the length of TB treatment. The discovery of rifampicin in the 1960s was a game 
changer for the development of TB combination therapy37. The inclusion of rifampicin to 
combination enables the shortening of TB therapy from 18 months or more to nine months38. 
A recent multi-stage randomized control trial has also shown the prominence of high-dose 
rifampicin in combination in treating TB patients39. With the addition of pyrazinamide (PZA), 
treatment length can be further reduced to six months40. 
During the 1990s, the WHO introduced the current standard six-month Directly Observed 
Therapy Short-course (DOTs) strategy for the treatment of fully drug-susceptible TB41. This 
program consists of two phases in which the first (intensive) phase involves two months with 
four oral antibiotics: isoniazid, rifampicin, pyrazinamide and ethambutol followed by a 
second phase (maintenance) of four months comprising isoniazid and rifampicin. The distinct 
mode of action of each drug in the combination enables the eradication of Mtb while 
minimizing emergence of resistance. Isoniazid is a prodrug which is activated by the bacterial 
catalase peroxidase enzyme (KatG). Isoniazid is reported to have multiple cellular targets 
although the most well-known function of isoniazid is its ability to bind to InhA, a NADH-
dependent protein reductase and thereby inhibits the synthesis of cell wall mycolic acid42. 
Rifampicin is a semisynthetic compound that belongs to the class of rifamycin initially 
isolated from Amycolatopsis mediterranei34. Rifampicin binds to the ß-unit of ribonucleic 
acid (RNA) polymerase and blocks the elongation of RNA at the length of two to three 
nucleotides43. Pyrazinamide, another prodrug, is derived from the same compound as 
isoniazid. The mechanism of pyrazinamide was suggested to be the disruption of proton 
motive force and membrane energetics of the bacteria44. Ethambutol, works by inhibiting the 
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arabinosyl transferase affecting cell wall synthesis43, also acts as a safeguard towards 
unidentified resistance towards to other three drugs45. This golden combination is highly 
effective for drug-susceptible TB and has brought a revolutionary decline in TB population 
since the 1990s.  
The emergence of drug-resistant TB has led to increased mortality and longer treatment 
involving more expensive drugs and injectables. The DOTs plus program is currently 
recommended in the WHO guidelines for the treatment of MDR-TB46. This standardized 
program extended the treatment duration to at least 20 months consisting pyrazinamide plus 
four core second-line drugs including one from group A and group B, and at least two from 
group C (Table 1.1)5, 43, 47.  
Table 1.1 Current medicines recommended for treatment of drug-susceptible and multidrug-resistant 
TB and their mechanisms of action. 
Types Group Drug Mechanism 
drug-susceptible TB   First-line oral drugs Isoniazid Inhibits cell wall 
mycolic acid synthesis 
Rifampicin Inhibits RNA 
polymerase/ RNA 
synthesis 
Ethambutol Inhibits arabinosyl 
transferase/cell wall 
synthesis 
Pyrazinamide Inhibits proton motive 
force and/or cell wall 
synthesis 







Streptomycin Inhibits ribosome/ 
protein synthesis Kanamycin 
Amikacin 
Capreomycin 
C. Other core 
second-line agents 
Cycloserine Inhibit peptidoglycan 
synthesis 
Ethionamide Inhibits InhA/ mycolic 
acid synthesis 
Linezolid Inhibits ribosome/ 
protein synthesis 
 
The protracted nature of treatment and daily injection of highly toxic second-line drugs 
reduces patient compliance and often serves as the major barrier to therapy nonadherence48.  
Peripheral neuropathy was reported in 31% of patients receiving linezolid49 whilst lengthy 
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and high dosage of amikacin therapy was associated with hearing loss in 62% of patients50. 
Other adverse effects, including hepatoxicity, hypoglycaemia, myocardial damage, 
respiratory complications and jaundice, were demonstrated to account for 30% of all TB 
treatment failure51. This trend of nonadherence not only increases the number of lost to 
follow-up patients but also heightens the chance for them to develop more severe and 
resistant forms of TB exacerbating the global TB burden. Attempts have been made to 
address this issue by shortening the length of treatment52, 53. Among them, the Bangladesh 
regimen involving seven drugs for a nine-month period has displayed promising treatment 
outcomes in the first observation cohort of 427 patients54. This regimen encompasses 
gatifloxacin, clofazimine, ethambutol, and pyrazinamide which was supplemented with high 
dose of isoniazid, kanamycin and prothionamid during the first four months. It has achieved a 
remarkable success having 87.9% of relapse-free patients among all who have used the 
gatifloxacin-based regimen (206 patients). It should be noted that these findings are yet to be 
generalized and randomized trials are underway. Besides, other issues including interactions 
with antiviral drugs such as rifampicin with nevirapine and nelfinavir55, absence of effective 
vaccine56, dosage variance and expensive medication pose additional challenges for an 
effective drug-resistant tuberculosis management57. Furthermore, it was demonstrated that the 
current TB treatment regimen has failed to generate minimal mycobactericidal concentration 
in all patients leaving the chance for the development of drug-resistant strain58. This 
suggested the influence of pathogen and host determinants on the bioavailability of drug in 
TB lesions renders the exposure of bacteria to sub-inhibitory drug concentration59 and 
thereby facilitating resistance evolution. Rates and spectrum of antibiotic resistance to 
existing second-line drugs are continuously growing60. Thus, the research and development 
of novel anti-TB agents with higher potency toward drug-resistant Mtb, adequate safety 
profile, minimal interactions with antimicrobial agent as well as a short treatment duration is 





1.2 MYCOBACTERIUM TUBERCULOSIS AND ITS RESISTANCE 
 
1.2.1 Mycobacterial Cell Envelope  
Mtb belongs to the phylum Actinobacteria and possesses a unique cell envelope conferring to 
unusually high antimicrobial resistance18. The acid-fast bacteria are impervious to Gram stain 
marking their extraordinary cell wall architecture compared with Gram-positive and 
Gram-negative bacteria (Fig. 1.1). The complexity of this cell wall offers mycobacteria a 
remarkably impermeable and hydrophobic armour. This complex network is composed of a 
capsule, a mycomembrane, an arabinogalactan layer, a peptidoglycan layer, followed by the 
innermost plasma membrane. Conglomerated with other proteins and polysaccharides, this 
sophisticated scaffolding becomes a highly difficult barrier for anti-TB agents to cross61. The 
mycomembrane coating is of particular interest as it is rich in mycolic acids (MAs) as well as 
those covalently-linked to arabinogalactan bestowing the adaption of Mtb to intracellular 
survival against the host immune responses. In essence, mycolic acid constituents have been 
associated with numerous physiological and biological properties in mycobacteria. Therefore, 






Figure 1.1 Comparison between mycobacterial cell envelope with Gram-positive and Gram-negative 
bacteria. Unlike Gram-positive and Gram-negative bacteria, the peptidoglycan layer of mycobacteria 
is covalently linked to a layer of arabinogalactan and further externally to a layer of mycolic acids. 
(Adapted from Silva et al. 62). 
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Evidence of the multi-layered cell envelope organization of mycobacteria has been provided 
by cryo-transmission electron microscopy63-65. Although a clear structural model for 
mycobacterial cell wall is still yet to develop, the principle components of mycobacterial cell 
envelope have been rationalized based on the structural model originally proposed by 
Minnikin et al.66. The mycobacterial cell envelope has a complex structure comprising 
multiple layers (Fig. 1.2). The innermost layer is a typical phospholipid bilayer plasma 
membrane (PM), then a peptidoglycan (PG) layer provides a sacculus support to the plasma 
membrane and it is linked externally to a layer of arabinoglactan (AG). Via the mycoloyl 
residues (mycolic acids), this covalent PG-AG complex is linked to the outer membrane 
(OM), also called the mycomembrane. This mycomembrane is presumably composed of 
some free extractable lipids including phthiocerol dimycocerosate (DIM), trehalose 
monomycolate (TMM), trehalose dimycolate (TDM), phosphatidyl insitol mannoside (PIM), 
sulfolipids and phenolic glycolipids. The outermost layer surrounding the mycobacteria is 
known as the capsule, consisting of glucan, proteins and glycolipids including lipomannans 
(LM), lipoarabinomannan (LAM) as well as mannose-capped lipoarabinomannan (Man-
LAM)63, 67.  
Synthesis of cell wall is mediated by the mycolyl transferases, namely the antigen-85 protein 
complexes8. These transferases catalyse the transfer of mycolic acid in the cytosolic 
compartment from TMM to form TDM and a free trehalose. Chiaradia et al.64 has reported 
the presence of TMM in plasma membrane suggesting the transport of molecules for 
mycomembrane biosynthesis. It is noteworthy that Mtb has a rough colony morphology 
which is due to the loss of trehalose-based lipooligosaccharides (LOS) production despite the 
presence of LOS synthesis gene remaining in the genome68. Boritsch et al. has shown this 
trait resulted through evolution of Mtb to be essential to its superior virulence. Increased level 
of virulence on M. canetti mutants without LOS production ability has been demonstrated in 
the guinea pig model. Respective essential roles played by each of the components in 




Figure 1.2 Schematic model of mycobacterial cell envelope. The outermost layer of cell envelope 
known as the capsule contains mainly polysaccharides (glucan and mannan) and proteins. Outer 
leaflet of the mycomembrane (Outer membrane, OM) consists of free glycolipids noncovalently linked 
to the mycolic acids such as TMM and TDM (in blue). Mycolic acid residues (in green) link to 
arabinogalactan and further to peptidoglycan layer forming a robust inner leaflet as mycolyl 
arabinogalactan-peptidoglycan (mAGP) complex. Chemical representation of TDM and mAGP 
express the “W-shape” folding  mostly found in Mycobacterium tuberculosis species. 69    
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The mycobacterial capsule was first described by Chapman et al. who observed the existence 
of a space between the phagosomal membrane of the infected macrophages and the outside of 
the Mycobacterium lepraemurium cell wall70. Conventional electron microscopy studies were 
further carried out to identify this layer as an electron transparent zone made up of a mixture 
of α-glucan, arabinomannan, proteins and 2-5% lipids in various mycobacterial species71. 
Recently, clear coatings of capsule (thickness ~30 nm) surrounding M. smegmatis and Mtb 
cell envelopes have been observed by Sani et al63 using plunge freezing cryo-electron 
microscopy. This capsule layer, is considered to have different composition in pathogenic 
and non-pathogenic bacteria, in turn plays a crucial role in the virulence of pathogenic 
mycobacteria with the presence of a variety of molecular components such as mannose-
capped glycolipids, ß-lactamase, hemagglutinin and catalase/peroxidase63, 72. To prevent 
clumping in mycobacteria cultures, detergents (tyloxapol or tween 80) and agitation are often 
involved. However, it is important to note that the capsular layer can be shed with treatment 
involving glass beads, the use of detergent and mechanical agitation 63, 73, 74 therefore 
affecting both the virulence and morphology of mycobacteria.  
Mycolic acids (MAs) are α-alkyl ß-hydroxyl long chain fatty acids which generally consist of 
two parts: the non-functionalized “mycolic motif” and the “meromycolate chain” containing 
up to two functional groups at the distal and proximal positions75 (Fig. 1.3). Unlike the other 
members under the suborder of Corynebacteriales, which usually possess short chains 
mycolic acids (C28-C40), Mycobacterium species depend fully on the long chain mycolic acids 
(C60-C90) for their growth and survival in vitro and in vivo76, 77. The occurrence of cis- or 
trans-double bonds, cyclopropyl functional groups or the supplementary oxygen functions 
located at the distal positions of the mero-chains classifies α-, keto-, methoxy-, hydroxy-, 
epoxy- and wax-ester-types of mycolic acids75. Interestingly, different mycobacteria contain 
different types of mycolic acids and these can act as a fingerprint. For instance, M. smegmatis 
contains mostly a homologous, α-series mycolic acids cyclopropane and/or alkene functional 
groups in the mero-chain and also epoxy- in trans configuration whereas α-, methoxy-, keto- 
and hydroxy-mycolic acids are found in Mtb78 (Fig. 1.4). The conformation of α-mycolic 
acids might relate to the mycobacterial resistance towards certain anti-TB agent. Strains 
containing higher percentage of trans double bond or cyclopropane at the proximal position 
including Mycobacterium chelonae, Mycobacterium fortinum and M. smegmatis tend to have 
higher tolerance towards lipophilic antibiotics such as rifampicin18. This has been explained 
by the decrease in cell wall fluidity and therefore permeability resulting from the crystalline 
arrangement of the trans-functionalized mycolic acids. On the contrary, trans-
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cyclopropanation of mycolic acids in Mtb was shown to suppress their virulence79. This has 
reflected the structural-functional complexity of mycobacterial mycolic acids and the 
necessity of deeper understanding.  
Mycolic acids are usually existed in mycobacteria in three different ways, (i) bound to AG in 
mAGP complex; (ii) in cell wall extractable ester as TDM and TMM; or (iii) as free mycolic 
acids. mAGP complex is the major structural material linking the mycomembrane and plasma 
membrane. Alterations in the proportion of different types of structural mycolic acids affects 
fundamentally the fluidity and therefore its permeability towards external agents80, 81. Yuan et 
al.82 demonstrated that the proportion of trans-substituted cyclopropane at the proximal 
position influenced the cell wall fluidity. Downregulation of hma gene in Mtb was shown to 
impair methoxy- and keto-mycolic acids production resulting in a reduced permeability for 
specific nutrients such as glycerol, leading to the attenuation of the mutant strain in mouse 
model83. Topping the mAGP complex are the TMM and TDM in which the latter, also known 
as the “cord factor”, is likely to be the most abundant glycolipid in mycobacterial cell wall84, 
and has been reported to have a define role in bacterial virulence75. This important role of 
TDM was established early in 1950s when reduced virulence was seen after washing the cord 
factor off drug-susceptible Mycobacterium tuberculosis H37Rv with petroleum ether85. TDM 
was described to be critical for intracellular survival of Mtb via inhibiting phagosome-
lysosome fusion and phagosomal acidification but the exact mechanism is still not fully 
understood. It was suggested recently the interaction of TDM with macrophage inducible C-
type lectin receptor induces signals modulating phagosomal maturation86. TDM was also 
proposed to cause the secretion of high level of proinflammatory cytokines such as TNF-α 
and IL-6 leading to tissue damage and necrosis87.  
Phthiocerol dimycocerosate (DIM) represents another cell wall lipid attributed to intracellular 
host-cell modulation. Astarie-Dequeker et al.88 reported, that in contrast to the wild type Mtb 
which mainly reside in non-acidic phagosomes, the majority of DIM knocked-down mutants 
were found in the acidic phagosome. The delayed acidification in mycobacteria was 
suggested to be via the inhibition of fusion between vacuolar proton-translocating ATPase 
and the phagosome89. This revealed the contribution of DIM in arresting phagosomal 
maturation and thereby facilitating intracellular replication. Moreover, the increased 
production of DIM exhibited a correlation not only with the increased access of Mtb into 
cytosol but also induced host cell death through necrosis90. Indeed, DIM was shown to act in 
concert with the ESX-1 secretion system to facilitate phagosomal rupture and cytosolic 
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access of Mtb24. ESX-1 is the most studied system among the five esx loci of ESX secretion 
systems in Mtb. It is responsible for the encoding of the 6 kDa Early Secretory Antigenic 
Target (ESAT-6) as well as the 10 kDa Culture Filtrate Protein (CFP-10) that are regarded as 
key virulence factors of Mtb91. The ESX-1 system was demonstrated to be essential for 
phagosomal rupture as the absence of ESX-1 (due to deletion of the RD-1 region) in M. bovis 
BCG resulted in the absence of cytosolic bacteria in differentiated THP-1 human monocytic 
cell line92. Furthermore, it was recently demonstrated that the production and export of intact 
DIM is required to ensure Mtb getting into cytosol and eventually led to the death of 
macrophages93. This further supported the hypothesis that blockade of acidification process 
by functional DIM is a pre-requisite for phagosomal rupture mediated by ESX-1 system.  
Likewise, PIM, Man-LAM and LAM are important glycolipids to regulate immunobiological 
processes during phagocytosis to enhance Mtb survival. Man-LAM was reported to be 
recognized by mannose receptors (MR), limiting the phagolysosome fusion while MR 
blockade reversed the inhibition of fusion during phagocytosis of both H37Rv and live Mtb 
Erdman strains94. Understanding of the exact role of free mycolic acids during natural 
infection is still awaited. In addition to the suggestion of free mycolic acids attracting 
cholesterol for the formation of biofilm, this was also used to explain the gathering of 
sufficient carbon source by intracellular Mtb to develop into slow growing, persistent strain95. 
Finally, sulfoglycolipids have a role in Mtb virulence by hampering the human innate 
response, appearing as competitive antagonists of TLR2 receptors96.   
 
 




Figure 1.4 Structural characteristics of mycolic acids in Mycobacterium tuberculosis and Mycobacterium smegmatis.78   
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1.2.2 Drug Resistance Mechanisms in Mycobacterium tuberculosis 
To tackle the global tuberculosis crisis and develop effective intervention strategies, it is 
necessary to gain better knowledge of the underlying mechanisms and driving forces behind 
antibiotic resistance in Mtb. Resistance is practically defined as the reduction in sensitivity of 
a particular strain to a significant degree that it is different from its wild type strain that has 
never been exposed to the drug10. Mycobacterium tuberculosis undergoes structural and 
functional modifications in response to changing environment resulting in the possession of 
various intrinsic resistances, limiting the number of anti-TB compounds available for 
treatment97. The exposure of Mtb to suboptimal drug concentration enables the bacteria to 
acquire further resistances through chromosomal mutations17. Distinctive intrinsic and 
acquired resistance mechanisms of mycobacteria towards first- and second-line drugs are 
described in Fig. 1.5. This part of the thesis summarizes these mechanisms with examples of 
drug resistance. 
 
Figure 1.5 Summary of anti-TB drug mechanisms and respective resistance mechanisms in 






Several intrinsic resistance mechanisms towards antibiotics have been described in 
mycobacteria. Examples of these mechanisms involving cell wall permeability, drug or target 
modification and putative efflux pump are listed in Table 1.2. The multiple layer lipid-rich 
mycomembrane as described in the previous section is a natural armour of Mtb that protects it 
from environmental stress and antibiotic attacks. This dense and thick hydrophobic layer also 
limits the entry of antibiotics98. It has been demonstrated that defects in the lipid barrier 
increased sensitivity of Mtb towards anti-TB drugs99. The inactivation of the renowned 
proteins of antigen 85 (Ag85) complex, responsible for the biogenesis of trehalose 
dimycolates, affected the integrity of mycomembrane in a pronounced manner resulting in 
increased permeability of Mtb cell envelope100. virS regulates the expression of 
monooxygenase operon which controls mycolic acid composition and cell wall integrity101. 
virS mutant was found to be more susceptible to rifampicin, isoniazid and ciprofloxacin due 
to the increased diffusion through more the permeable cell wall. Upregulation of proline-
glutamic acid (PE11) protein, a putative lipase involved in cell wall remodelling, modulated 
cell wall morphology and lipid composition reduced the diffusion of antibiotics in ex vivo and 
in vivo models102. Hydrophilic drugs are believed to traverse through the mycomembrane via 
water-filled porins. The presence of very few porin channels represents another intrinsic 
resistance mechanism of Mtb towards hydrophilic compounds44.  
Enzymatic degradation and modification by methylation or acetylation of drugs render them 
ineffective17. Intrinsic resistance of Mtb towards ß-lactam antibiotics mediated through the 
blaC gene was established in early studies103. On the other hand, acetyltransferase and 
phosphotransferase are two main classes of aminoglycoside-modifying enzymes with well-
described mechanism to protect Mtb against capreomycin and kanamycin104. Among them, 
the best characterized N-acetyltransferase (ACC2’) can acetylate all the aminoglycosides 
bearing 2’ amino group such as tobramycin, kanamycin, gentamycin and neomycin105. M. 
smegmatis was reported to be resistant to rifampicin due to the presence of an ADP-
ribosyltransferase106. Besides, drug target alteration plays an important role in reducing 
mycobacteria susceptibility. Methyltransferase erm37 encoded by the erythromycin 
resistance methylase gene in Mtb and M. bovis confers their resistance to various 
macrolides107. Binding of fluoroquinolones to DNA gyrase in Mtb was hampered by the 
mycobacteria fluoroquinolone resistance protein A (MfpA) encoded by mfpA gene108. Three-
dimensional structure analysis has revealed MfpA proteins resembles Mtb DNA in terms of 
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shape, size, conformation and overall surface charge suggesting the intervention operates via 
target mimicry109. Resistance to capreomycin and viomycin occurs through the loss of 
methylation on bacterial ribosome110. Mtb modulates the deactivation of methyltransferase 
TlyA resulting in the production of unmethylated ribosome making binding of 
aminoglycoside becomes impossible. RbpA in Mtb and M. smegmatis has been found to 
preferably bind to the RNA polymerase impeding the action of rifampicin111. Notably, only 
recently was relevant clinical significance observed of efflux pump of mono-resistant isolates 
that increased the attention to this machinery. The upregulation of major facilitator 
superfamily (MFS) pumps in Mtb resulted in increased resistance towards streptomycin, 
isoniazid and ethambutol112. Other identified putative efflux systems such as the resistance-
nodulation-cell division superfamily (MmpL5, MmpL7) and the small multidrug resistance 
family (Rv3065) are also associated with intrinsic resistance in Mtb. Furthermore, the low 
metabolic activities of dormant Mtb is implicated with decrease production of antibiotic 
targets and related machineries. Mtb tends to adopt dormancy when it is under a specific 
environmental cue such as antibiotics exposure or inside macrophages. Oxygen deprivation 
or heat shock induced Mtb dormancy was found to be associated with cessation of nucleic 
acids and proteins synthesis which subsequently reduced their sensitivity towards rifampicin 
and isoniazid113. Studies have demonstrated the re-sensitization of dormant Mtb towards 




Table 1.2 Intrinsic resistance mechanisms and the associated gene/protein in mycobacteria. 
Resistance Mechanism Gene/protein associated Resistance to Mycobacterial strain References 
Cell wall permeability Ag85 complex RIF M. smegmatis 115 
virS RIF, INH and ciprofloxacin  101 
PE11 protein   102 
MspA porin INH, EMB Mtb 44 
Drug/ target modification 
 
blaC ß-lactam Mtb 103 
N-acetyltransferase Tobramycin, kanamycin, gentamycin 
and neomycin 
Mtb, M. smegmatis 104, 105 
Rv0560c Pyrido-benzimidazole compound ‘14’ Mtb 116 
ADP-ribosyltransferase RIF M. smegmatis 106 
erm37 Macrolides Mtb, M. bovis 107 
MfpA Fluoroquinolones Mtb 108 
tlyA Capreomycin and viomycin Mtb 110 
RbpA RIF Mtb, M. smegmatis 111 
Efflux pump MmpL7 INH Mtb 117 
MmpL5 Azole compounds Mtb 118 
Rv2459 (jefA) INH, EMB, streptomycin Mtb 112 
Rv3065 (mmr) INH Mtb., M. smegmatis 119, 120 





Mtb strains generally acquired resistance towards existing anti-TB agents through 
spontaneous mutation in chromosomal genes. Table 1.3 summarizes the drug targets and 
possible corresponding resistance mechanism in mycobacteria. Mutation attributing to drug 
target mutation is frequently observed in Mtb against a wide range of antibiotics including 
first-line anti-TB drugs, fluoroquinolones and aminoglycosides. Over 95% of rifampicin-
resistant strains have a mutation within the 81-bp hotspot region at codon 507-533121. 
Mutation in inhA, which plays a key role in the fatty acid synthase II system involving in 
mycolic acid synthesis, hinders the binding of active drugs to their targets78. The most 
common high-level fluoroquinolone resistance usually occurs within a short sequence known 
as the quinolone resistance-determining region (QRDR) leading to protein structure alteration 
affecting fluoroquinolone  binding affinity122. Apart from intrinsic resistance mentioned 
earlier, acquired resistance through the inactivation of the tlyA gene has also presented in Mtb 
clinical isolates123. Prodrugs like isoniazid, pyrazinamide and delamanid require the 
conversion by bacterial enzymes into their active forms. Abrogation of prodrug activation 
renders them ineffective leading to resistance towards these powerful anti-TB agents. 
Isoniazid requires the activation by the catalase/peroxidase enzyme encoded by katG. 
Mutation, insertion, deletion and truncation of katG are the most common genetic alteration 
associated with high-level isoniazid resistance124. Gu et al.125 demonstrated that pncA 
mutation is highly associated with pyrazinamide resistance trait while resistance rate of 
XDR-TB was higher than MDR strains. Mutation in the promotor of drug target may cause 
inhibition of the drug due to the overabundance of the target17. InhA promotor mutation 
induces overexpression of inhA resulting in low-level resistance of Mtb towards isoniazid42. 
EMB has been reported to inhibit the activity of arabinosyl acid transferases, disrupting the 
formation of mycolyl-arabinogalactan-peptidoglycan complex thereby increasing the cell 
wall permeability126. AftA and ubiA are two cell wall-associated genes which were shown in 
several studies to acquire resistance through genetic mutation leading to the overexpression 
of EmbCAB proteins, contributing to high-level ethambutol resistance in Mtb127. Resistance 
developed through increased activity of efflux pumps is usually based on their basal 
expression, drug-induced expression or the overexpression due to chromosomal mutations128. 
Li et al.119 investigated the expression of efflux pump in MDR clinical isolates and found that 
eight out of nine strains possess at least one overexpressed efflux pump gene. This finding 
suggested the link between efflux pump and acquired resistance in Mtb and the possibility of 
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unknown mutations responsible for the phenomenon. More importantly, evidence of mutation 
in transcription regulator (Rv0678) has been identified in bedaquline-resistant Mtb isolates129. 
This brought about the upregulation of MmpL5 expression promoting drug efflux and 




Table 1.3 Summary of the first- and second-line anti-TB drug targets and corresponding resistance mechanisms in drug-resistant Mycobacterium tuberculosis. 
Agent Target gene Gene function Resistance mechanism References 
Rifampicin rpoB ß-subunit of RNA polymerase Drug target mutation 121, 130 
Isoniazid katG Catalase-peroxidase Abrogation of drug activation 121, 124 
inhA Enoyl-acyl carrier protein reductase Drug target mutation 124 
inhA promotor  Drug target overexpression 42 
Pyrazinamide pncA Pyrazinamidase Abrogation of drug activation 125 
Ethambutol embB Arabinosyl transferase Drug target mutation 126, 127 
Capreomycin rrs 16S ribosomal RNA Drug target mutation 131 
tylA rRNA methyltransferase Abrogation of drug target methylation 123 
Amikacin/ 
Kanamycin 
rrs 16S ribosomal RNA Drug target mutation 131 
eis promotor  Drug inactivating enzyme overexpression 132 
Streptomycin rrs 16S ribosomal RNA Drug target mutation 131, 133 
rpsL S12 ribosomal protein Drug target mutation 133 
Fluoroquinolones gyrA DNA gyrase subunit A Drug target mutation 122 
gyrB DNA gyrase subunit B Drug target mutation 122 
Ethionamide ethA Monooxygenase Abrogation of drug activation 134 
inhA Enoyl-acyl carrier protein reductase Drug target mutation 124, 134 
Cycloserine ald D-alanine/ glycine/ D-cycloserine proton 
symporter 
Overabundance of drug target substrate 32 
alr Alanine racemase Drug target mutation 32, 135 
Para-aminosalicylic 
acid  
thyA Thymidylate synthase Drug target bypassing 136 
folC Dihydrofolate synthase Abrogation of drug activation 136 
Linezolid rrl 23S ribosomal RNA Drug target mutation 137 
rplC 50S ribosomal protein Drug target mutation 138 
Delamanid ddn deazaflavin dependent nitroreductase Abrogation of drug activation 139 
Bedaquiline Rv0678 Transcription regulator Overexpression of efflux pump 129 
atpE ATP synthase Drug target mutation 140 
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1.2.3 New Treatment Strategies against MDR-TB  
TB is a global pandemic compounded by the emergence of MDR- and XDR-TB strains and 
demands a concerted response. Great endeavours have been put in developing and 
advancement of new anti-TB agents. At present, there are a number of new drug candidates at 
various stages of discovery, preclinical and clinical evaluations8. Focusing on new 
developments against drug-resistant Mtb strains, this section reviews promising anti-TB 
agents at different phases of clinical trial, including their background, chemical structures 
(Fig. 1.6), corresponding efficacy as well as mechanism of action. Recent studies on 
repurposing of existing FDA-approved drugs for MDR- or XDR-TB treatment are also 
discussed. Finally, the introduction of adjuvant and novel combinations of currently available 
drugs are described.  
 




Delamanid (DLM) and bedaquiline are two oral anti-TB medications that first gained 
FDA-approval since rifampicin in 1967. These two small molecule drugs were identified 
through drug screening for the treatment of MDR-TB without other indications141. This sole 
indication might be clinically advantageous as the restriction on mycobacterial use could 
reduce the chance for development of resistance.  
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Delamanid is the first member of the nitroimidazole class to enter clinical practice. 
Nitroimidazoles are derived from azomycin, which was a metabolite isolated from 
Streptomyces eurocidius in 195333. It is known to inhibit the production of methoxy- and 
keto-mycolic acid thereby disrupting the biosynthesis of mycobacterial cell wall with potent 
in vitro and in vivo efficacy against Mtb142. Delamanid is a prodrug that requires the 
activation mediated by the enzyme deaflavin dependent nitroreductase. This drug has 
physiochemical properties similar to another new drug candidate pretomanid while possesses 
an anti-TB activity that well surpasses the latter142. Strong activity of delamanid has been 
reported against MDR Mtb clinical isolates143. Notably, the bactericidal action of delamanid 
is found to be similar to that of rifampicin142. The fact that delamanid does not induce the 
expression of P450 enzymes encourages studies of its use in combination with anti-HIV 
drugs against TB/HIV co-infections144. Phase III clinical trials of delamanid for its safety and 
efficacy in TB/HIV co-infections and pediatric MDR-TB are on-going.  
Bedaquiline is a novel, chemically synthesized, diarylquinoline demonstrating potent 
activities against MDR/XDR-TB. Its action is highly selective, targeting energy generation 
pathway in mycobacteria, while eukaryotic cells are unaffected145, and it is ineffective to 
neither Gram-positive nor Gram-negative bacteria146. Hards et al.147 described its mode of 
action through binding to the subunit c of the bacterial adenosine triphosphate (ATP) 
synthase, resulting in a futile proton cycle. Bedaquiline has demonstrated superior activity 
against drug-resistant strains in vitro148. Moreover, a remarkable synergistic effect has also 
been displayed when it was used in combinations with pyrazinamide149. Although 
bedaquiline has been approved for the treatment of MDR-TB based on phase IIb results, 
phase III trials are still in progress as the occurrence of side effects including QT 
prolongation and the unexplained high mortality rate.  
 
Drugs under clinical trial 
 
Apart from the above mentioned newly-marketed anti-TB drugs, several other promising 
anti-TB agents are also in early clinical trial status. Sutezolid and SQ-109 are two new drug 
candidates currently under phase II trial. Sutezolid is a structural analogue of Group C anti-
TB agent linezolid. Its bactericidal action of limiting protein synthesis in Mtb was 
demonstrated both in vitro and in vivo150. Unlike linezolid which is associated with high bone 
marrow toxicity, this new analogue has been established to have a better safety profile as well 
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as a greater antimicrobial action151. SQ-109, identified from screening ethambutol analogues, 
is considered to be the next-generation drug replacing ethambutol as it displays potent actions 
in both in vitro and in vivo settings against drug-susceptible, MDR- and XDR-TB clinical 
strains152.  SQ-109 exerts antimycobacterial action through targeting the transmembrane 
reporter for trehalose monomycolate (MmpL3), intruding the formation of intact outer-
membrane of the mycobacterial cell envelope. It was also reported to act as an uncoupler, 
collapsing the inner mitochondrial membrane potential thereby blocking respiration and ATP 
synthesis153. It is also shown to be safe and well-tolerated by smear-positive TB patients, 
making the drug a prospective candidate to proceed in further trials. Other phase I registered 
anti-TB agents include Q203154 and PBTZ-169155 which have shown high efficacy against 
Mtb in murine models, and OPS-167832 is suggested to have a different mechanism as the 
existing anti-TB has promising action with a chemical structure that is yet to be revealed.  
 
Repurposing old drugs 
 
Commercially available medications, currently used for indications other than TB, might be 
applicable for fighting MDR-TB crisis. This can be facilitated by repurposing approved 
antimicrobial agents for TB therapy or repositioning neglected anti-TB agents that were once 
pursued156. Since this approach can shorten the process of drug development and clinical 
trials with the existence of ample human safety and pharmacokinetics data, it is especially 
essential for low-income high prevalence countries.  
Clofazimine is a lipophilic anti-TB compound developed in 1954. Its poor in vivo 
performance in a primate model discouraged its development and it was later repurposed to 
fight Mycobacterium leprae resistant to sulfones157. Its notable advantage of inhibiting 
resistance development to isoniazid in Mtb has attracted reinvestigation of its use in MDR-
TB treatment. Encouraging cure rates of MDR- and XDR-TB have been shown in 
corresponding studies in Bangladesh and Korea using clofazimine-containing regimens158. 
The regimen was demonstrated to have low-to-mild adverse effects such that only 0.1% of 
patients required discontinuation which is comparable to that of first-line TB regimen159, 160. 
However, high cost and low market availability are the biggest obstacles at present for its 
global use. Sulfonamides were developed between 1930 and early 1950s as monotherapy for 
anti-TB treatment161. Their use was then terminated due to the emergence of better options 
including isoniazid. Sulphamethoxazole (SMX) was later used in combination with 
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trimethoprim (TMP) for the prevention of Pneumocystis jirovecii infection in TB/HIV co-
infected patients162. This combination brought about its revival to be used in MDR-TB 
patients and demonstrated shorter sputum conversion time in two cohorts in Nigeria163. 
Clinical evidence of the potency of SMX/TMP regimens on MDR-TB treatment is still 
underway. Alsaad et al.164 reported eight out of 10 MDR-TB patients had successfully 
completed the combination therapy with good tolerance and no sign of reoccurrence in a 
median treatment period of 381 days. SMX has also shown efficacy on its own against Mtb 
and preliminary success on drug-resistant strains.  On the other hand, Minocycline, a leprosy 
drug, has shown anti-TB action in 1980165. Its activities on clinical isolates including MDR-
TB was demonstrated and suggested to be bacteriostatic, suitable to be used as adjuvant in 
TB-chemotherapy166. Despite the need of more validation studies and clinical trials of these 
drugs for the indications on TB, the amiable features such as low rates of adverse events, 
developed drug profile and relatively higher accessibility suggesting them as good candidates 




1.3 ANTIMICROBIAL PEPTIDES 
1.3.1 Nature and Properties of Antimicrobial Peptides 
The therapeutic effect of antimicrobial peptides (AMPs) was first discovered by Rene J. 
Dubois who isolated gramicidin from the soil bacterium Bacillus brevis during World War II. 
Gramicidin was found to be useful against infections caused by Gram-positive bacteria and 
therefore widely applied for wounds and ulcers on soldiers167. In the 1980s, two well-known 
mammalian AMPs, defensin and cathelicidins were identified and demonstrated the 
production of these endogenous protective compounds by the innate immune defence systems 
in animals168. This has initiated an increasing number of in-depth studies on the isolation and 
the synthesis of new AMPs as well as the understanding of their corresponding mechanisms 
for therapeutics development. To date, over 5000 AMPs have been discovered either from 
natural prokaryotes and eukaryotes or by chemical synthesis. The majority of these have been 
shown to possess antimicrobial activities towards both Gram-positive and Gram-negative 
bacteria, fungi, viruses or mycobacteria with ample potential to be developed into 
therapeutics169-172.   
AMPs are generally positively-charged amphipathic small peptides, composed of 12-50 
amino acid residues. They can be classified into four forms according to their secondary 
structures: α-helix, ß-sheet, extended and loop (Fig. 1.7)173. The possession of cationic amino 
acids including lysine and arginine confers a net positive charge on AMPs that is important 
for binding to anionic bacterial membranes. The amphipathic nature of AMPs refers to the 
availability of both hydrophobic and hydrophilic regions, facilitating partition into membrane 
interface as well as ensuring sufficient aqueous solubility. Natural occurring AMPs were 
initially neglected as therapeutic agents due to their vulnerability and instability towards 
proteolytic enzyme degradation which leads to poor bioavailability. With the continuous 
exploration and studies, newer technologies such as conjugation, formulation approaches and 
chemical modification were incorporated to improve the stability of endogenous AMPs 
whilst the production of synthetic AMPs was also made available174. These technological 
breakthroughs have enormously expanded the exploitability of AMPs in therapeutic 
applications. This section discusses the physicochemical properties and structural 
arrangements including length, conformation, hydrophobicity, net charge, charge angle of 
AMPs which could be further optimized to enhance their specificity, selectivity and 




Figure 1.7 Molecular modals of AMPs secondary structures. (a) α-helix, (b) ß-sheet, (c) extended and 
(d) loop173.  
 
The length of AMPs has a decisive role in their fundamental nature as a minimum of three to 
four amino acids are required for the formation of an amphipathic peptide possessing both 
hydrophobic and hydrophilic units. Besides, length affects the mode of action and secondary 
structure of AMPs, which consequently influence their ability to permeate through 
membranes. For instance, at least 22 units for α-helix and eight units for ß-sheet peptides are 
necessary for the penetration via the barrel-stave model175. Shorter AMPs are often shown to 
have lower toxicity and higher activity. A 15-residue synthetic melittin exhibited 
significantly lower toxicity (300%) on rat erythrocytes when compared to its original 26-
residue form176. Moreover, HP-A3 peptide, derived from N-terminus of Helicobacter pylori 
ribosomal protein L1 (RpL1), demonstrated enhanced antibacterial and antifungal action 
without any hemolytic effect177.  Juba et al.178 demonstrated the effect of peptide length in 
relation to respective antimicrobial activity. It was shown that full length 34-residue NA-
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CATH eliminated ~5% of E. coli and B. cereus while the 11-residue truncated peptide L-
ATRA-1A achieved 10-20% of growth inhibition on the bacterial species.  
A higher net positive charge of peptides can promote their antimicrobial activity. This 
cationic property is primarily responsible for the interaction with the negatively-charged 
bacterial membranes, rich in anionic components such as phosphatidylglycerol, 
lipopolysaccharides and teichoic acid. Studies with magainins and other α-helical peptides 
have portrayed the direct association between peptide net charge and antimicrobial 
activities179, 180. However, increase in charge beyond +8 induces undesirable effects on 
mammalian cells due to the higher hemolytic activity181. Therefore, it is essential to maintain 
a balance to obtain an optimal net charge for the high selectivity of AMPs towards microbes 
with the least toxicity on the host cells. Besides, charge angle subtended by the cationic helix 
domain is considered to be a measurement of proportion between polar to non-polar content 
in helical peptides182.  
AMPs may assume different secondary structures which is another extended key to determine 
their antimicrobial efficacy. The α-helix is the most common conformation adopted by AMPs, 
comprising around 27% of all AMPs with known secondary structures183. Reduction in 
peptide activity was shown with reduced helicity. This is because the helical structure enables 
the peptides to permeate bacterial membrane efficiently184. Paradoxically, presence or 
incorporation of proline residue which disrupts the helical conformation thereby altering the 
selectivity and efficacy of AMPs may affect their potency. Proline was found to be crucial for 
membrane permeation and intracellular targeting of buforin II. Substitution of proline 
resulted in the reduction of peptide activity185, 186. Proline may also enhance conformation 
flexibility and enable the formation of C-terminal α-helix, facilitating their translocation 
across the interior membrane187. It is evident that the position of proline influences the 
antimicrobial activities through altering the peptide conformation. Substitution of proline at 
central region led to significant increase in activity towards E. coli and P. aeruginosa188. Xie 
et al.185 also reported the relocation of proline towards either C- or N-terminal resulted in 
reduced buforin II transposition through membrane. 
Overall hydrophobicity affects the bioactivity of AMPs intensively. It represents the 
percentage of hydrophobic residues in the peptides and thus determining the partition ability 
into membrane. An increase in hydrophobicity generally increases the antimicrobial activity 
of α-helical AMPs189. Nevertheless, increase of hydrophobicity over a certain threshold often 
induces complications and reduces peptides bioactivity. Chen et al.190 analysed the impact of 
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hydrophobicity on α-helical AMPs and reported that an optimal hydrophobic window is 
critical to achieve high antimicrobial activity. Peptides with high hydrophobicity tend to self-
associate, forming dimers/oligomers, hindering their penetration into the bacterial cell wall19. 
However, aggregated peptides could still enter eukaryotic membranes leading to higher 
toxicity profile towards mammalian cells. Cytotoxicity towards murine macrophage RAW 
264.7 cells was significantly higher when exposed to peptides with higher hydrophobicity191. 
Moreover, optimization of hydrophobicity is important as it also influences other properties 
of the peptide. Several studies have suggested that there is a positive correlation between 
hydrophobicity and α-helicity190, 192. To tackle the hydrophobic scaffolding of mycobacteria, 
AMPs with increased proportion of hydrophobicity and helicity has been engineered to 
improve their mycobactericidal effect. Flow cytometry data revealed the enhanced rate and 
extent of membrane permeability by peptides displaying higher hydrophobicity and 
helicity193. Taken together, rational design of peptides involves not only a single element, but 
a good combination of various structural parameters. It is also obligatory to determine the full 
toxicity profile towards the host cells, ideally by in vivo experiments.  
Due to their promising antimicrobial activity, the investigation of AMPs for therapeutic 
applications is becoming popular with their superior advantages over other small molecule 
drugs. These include their broad-spectrum activity and direct killing mechanism, high 
specificity and selectivity, high affinity to bacterial membrane as well as the low rate of 
bacterial resistance emergence. However, AMPs also possess certain limitations such as 
tendency to aggregation and poor bioavailability through oral route, susceptible to enzymatic 
degradation, temperature and pH fluctuation, high hepatic clearance, difficulty in crossing 
physiological barriers and high production costs. Fortunately, extensive research has been 
undertaken to improve the formulations by rational design194. Different predictive software is 
available to evaluate physiochemical properties195. Incorporation with non-natural amino 
acids, conjugation with fatty acids and terminal modifications could improve bioavailability 
and stability. Also, performance of AMPs can be enhanced by delivery through inhalation 
and encapsulation into nanoparticle formulations. The production costs can potentially be 
reduced by commercial-scale platform using fungi and plants to produce recombinant AMPs 
at high yield196.  
Although the rate of development of resistance towards AMPs is lower when compared to 
small molecule drugs, pathogens exposed to externally administered or endogenous 
overexpressed AMPs may lead to the development of resistance eventually. It has already 
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been suggested that bacteria tend to alter their surface charge to reduce their susceptibility 
upon peptide challenges197. This can be modulated by a single gene which controls the level 
of dephosphorylation of LPS, therefore reducing the surface negative charge. Thus, 
continuous innovation in AMPs design, targeting strategies as well as combination 




1.3.2 Mechanism of Action  
Apart from the study of AMP design, better understanding of the mode of peptide action is 
also important to ensure successful development of therapeutics. Despite the little 
resemblance of amino acid sequence, AMPs adopt similar structural conformation and 
folding, suggesting the AMPs interact with bacterial membrane in a parallel orientation198. 
The interactions of AMPs and bacterial components are commonly based on electrostatic 
attraction and receptor-based interaction. In this section, two major mechanisms depicted in 
Fig. 1.8: (i) direct antimicrobial action involving cell envelope and intracellular targets and 
(ii) immunomodulatory effect, exerted by AMPs are discussed.  
 
Direct antimicrobial actions 
 
Disruption or pore formation of the bacterial cell wall is the most well-known activity of 
AMPs. This activity is caused by their mostly α-helical or ß-sheet conformation which 
enhance their cationic and secondary amphipathic properties. Integration of a non-polar 
region of AMPs brings about the accumulation of peptide into the membrane, promoting its 
permeability, leading to the loss of barrier functions, leakage of cellular components, 
resulting in cell death199. This direct killing effect of AMPs targeting cell membrane was 
mostly postulated by three different models (Fig. 1.9): (i) barrel-stave model; (ii) carpet 
model; and (iii) toroidal model. Barrel-stave model describes the accumulation of peptides up 
to a threshold at the membrane surface, thereby initiating the penetration by arranging the 
hydrophobic region of AMPs in line with the lipid core and hydrophilic regions towards the 
interior of the membrane creating transmembrane channels. In the carpet model, strong 
interactions of peptides and the outer leaflet of bacterial membrane takes place. The peptide 
carpet damages the curvature of bilayer and causes complete degeneration of membrane. In 
toroidal model, peptides are inserted into the membrane causing the lipids to tilt from the 
usual lamellar structure; the inner and outer leaflets are forced to connect forming a toroidal 
hole.  
AMPs can induce cell wall permeability not only by mechanical disturbance but also by 
targeting cell surface elements. Through binding to cell-wall proteins such as ATPase, AMPs 
could interfere with cell ion exchange and lead to imbalanced cell pH homeostasis, thereby 
impairing mycobacterial growth200, 201. Antimicrobial peptide LLAP was shown to inhibit 
50% of Mtb growth through targeting basal ATPase activity of the mycobacterial 
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membrane202. It is also reported that AMPs can exhibit more than one mode of action against 
Mtb. The dual mode of action of lantibiotics such as nisin was characterized by Carroll’s 
group and reported to involve membrane pore formation as well as cell wall synthesis 
disruption after binding to peptidoglycan precursor203.  
After translocating across the bacterial membrane, some AMPs also play a role in 
manipulating intracellular processes via targeting proteins or nucleic acids. Human neutrophil 
peptide-1 achieved in vitro and ex vivo killing of Mtb H37Rv by binding to the unprotected 
genomic DNA without causing significant damage to the membrane204. The same group also 
reported mycobactericidal action of a series of synthetic antimicrobial peptides, targeting 
mycobacterial nucleic acids and thereby impeding replication and transcription processes, 
leading to cell death205. Heat shock protein, which is essential for chromosomal replication in 
bacteria, might also be a potential target for AMPs such as pyrrhocoricin and drosocin206.  
 
Immunomodulatory effect  
 
The other advantage of employing AMPs as anti-TB therapeutic is their multifunctional 
characteristics. In addition to their direct killing abilities, some AMPs can also regulate the 
immune defence system to eliminate invaded bacteria. Release of pro- and anti-inflammatory 
cytokines can be triggered by AMPs during the infection. LL-37 promoted the secretion of 
anti-inflammatory cytokines IL-10 and TGF-β in Mtb-infected macrophages which was 
shown to be triggered by the mycobacterial antigens207.  Recently, recombinant human and 
mouse lactoferrin was found to reduce the production of inflammatory cytokine IL-12p40 in 
vivo, which in turn, effectively reduced Mtb TDM-induced pathological granulomas and 
therefore critical to lessen disease progression208. Endogenous cathelicidins, mostly expressed 
in leukocytes and epithelial cells, were also shown to modulate induced autophagy as another 
mechanism to clear intracellular Mtb in various studies209, 210. Further, innate defense 
regulators (IDRs) have attracted immense interest of researchers with their high efficacy at 
low and non-toxic concentration211. Their ability to trigger proper endogenous expression of 
chemokines and downregulate inflammatory signals gives rise to the promising role in the 




Figure 1.8 Diverse mode of action of AMPs against mycobacteria. Two major mechanisms of AMPs 
(1) direct antimicrobial action involving disturbing cell envelope permeability and intracellular 
targets and (2) immunomodulatory effects which can induce downstream proinflammatory or anti-








Figure 1.9 Schematic illustration of models describing underlying membrane active mechanism of 
AMPs. Three models demonstrating the membrane disruption action mediated by AMPs. Barrel-stave 
model initiates the penetration by the accumulation of AMPs, carpet model damages the membrane by 
the arrangement of AMPs in a carpet fashion, toroidal model inserts the AMPs into the membrane and 
initiates the formation of a toroidal hole. (Adapted from Salditt et al.213).   
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1.3.3 AMPs and Combination Strategy as Anti-TB Therapeutics  
Despite the underestimation of the AMPs’ potential in early years and various difficulties 
encountered for their clinical applications, peptide-based drugs have successfully entered the 
market as treatment of different diseases including infectious diseases, cancers, diabetes and 
cardiovascular diseases. Currently, there are over 160 peptides and proteins drugs approved 
by the FDA194. The emergence of drug-resistant Mtb strains demands novel strategies which 
could be an appropriate role that AMPs fit in. For example, Mtb acquired resistance towards 
isoniazid and ethambutol targeting mycolic acid synthesis. Subsequently, dermcidin, a human 
sweat glands peptide, which was suggested to inhibit mycolyl transferase, was shown to be a 
potential adjuvant or replacement therapeutic214. Khara et al.215 studied a range of unnatural 
amino acid analogues of the I(LLKK)2I peptide and showed their good safety profile with 
potent antimycobacterial activity against MDR clinical isolates. Pin 2 variants, derived from 
pandinin 2, displayed high efficacy against MDR Mtb strains through membrane disruption216. 
Another α-helical peptide with 26 amino acid residue, D-V13K, was also demonstrated to be 
active against MDR strains due to the determining substitutions of valine and lysine 
promoting hydrophilicity and positive charge of the peptide199. Human ß-defensins (HBDs), a 
family of endogenous AMPs with a broad spectrum of bactericidal action, have been studied 
using computational approaches. Among the discoveries, HBD3-M-HBD2 was shown to act 
effectively against MDR-TB strains at a non-hemolytic concentration, signifying the anti-TB 
potential of this peptide217. Efficacy studies of MDR-infected murine model was also 
performed using peptide candidates with proved efficacy in in vitro and intracellular settings. 
Semisynthetic peptides E2 and E6 displayed stronger inhibitory effect on Mtb H37Rv than 
LL-37 and mouse CRAMP in vitro169. More importantly, these two AMPs significantly 
reduced lung bacillary burden in the MDR-TB infected model whilst the activities of the 
parent cathelicidins were not significant. IDR-1018, with its profound immunomodulatory 
functions without apparent cytotoxic effect suppressed MDR-TB bacilli growth in vivo and 
simultaneously reduced pneumonic region of infected mice211. L-isoleucine was reported to 
be a highly specific ß-defensin inducer and this effect was shown to be therapeutically 
applicable against Mtb218. Administration of L-isoleucine intratracheally led to significant 
increased expression of ß‐defensins 3 and 4 and lower lung bacillary load in both drug-
sensitive and drug-resistant in vivo models219.  Notably, lung histopathology was also 
improved in L-isoleucine-treated mice as compared with control animals. 
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Despite the immense potential expressed by these multifunctional AMPs, high dosage is 
required to attain an adequate antimycobacterial effect. This possibly elevates toxicity, 
degradation complications as well as formulation difficulties. Therefore, instead of using 
AMPs as single treatment, combination formulations have been introduced to maximize the 
capability of anti-TB agents using the concept of synergy.  
As described previously, the extreme hydrophobicity of the mycobacterial cell wall 
contributes to its pathogenicity and is an impediment to the ingress of chemotherapeutic 
agents. Interestingly, the membrane active characteristics of AMPs can act as an adjuvant to 
enhance the activity of conventional anti-TB drugs. Using M. smegmatis as model, full-length 
cathelicidins and its shortened version, ATRA-1A with membrane permeable ability, were 
shown to interact synergistically with rifampicin, killing 75% and 68% of intracellular 
bacteria as compared with less than 40% when using rifampicin alone220. Khara et al.193 
observed similar synergistic interaction in synthetic α-helical (LLKK)2 peptide with 
rifampicin against M. smegmatis. Flow cytometry analysis provided further support to the 
peptide-induced pore formation, thereby potentiating the action of rifampicin. Kalita et al.221 
tested human neutrophil peptide (HNP-1) as an adjunct to isoniazid and rifampicin in vitro, 
ex vivo and in vivo. They reported synergism between the combinations and reduction of 
efficient concentration down to 1/8 MIC against intracellular Mtb H37Rv. A remarkably 
significant reduction in bacillary load in infected mice was also resulted. This was explained 
by the increase in permeability of mycobacterial cell envelope by HNP-1, facilitating the 
access of anti-TB drugs to intracellular targets. HBD-1 was shown to have an enhanced effect 
against MDR-TB clinical isolate when treated in conjunction with isoniazid222. The 
bactericidal efficacy of the combination was significantly higher than when isoniazid was 




In this thesis, one of the techniques employed to study the mechanism of various anti-TB 
agents and their combinations is nuclear magnetic resonance (NMR) metabolomics. This 
section will give a brief introduction on metabolomics and discuss more in detail the 
principle of NMR metabolomics as well as its use in TB studies.  
Metabolomics represents a means of comprehensive identification and quantification of low 
molecular weight metabolites (< 1 kDa) present in biological systems such as a cell, tissue, 
organism, or culture media223. It records the unique set of physiological, biochemical and 
pathophysiological processes occurring in a life form at a specific time point, with the 
employment of highly sensitive analytical methods together with bioinformatics. As an 
extension of genomics, proteomics, and transcriptomics, metabolomics allows the 
examination of a variety of metabolome containing substances including amino acids, lipids, 
sugars, cofactors, nucleotides and xenobiotics, in an unbiased analytical systems-based 
approach. In contrast to other “omics” techniques, metabolomics is commonly exploited to 
define phenotypes224. This is attributed to the capability of this technique to measure the 
direct result of changes in the activity of a protein or enzyme while such biological activity 
does not necessarily correlate to the level of certain gene expression225. Thus, metabolomics 
can provide an objective picture of how the system responds to the environment stressor or 
disease state.   
Metabolomics offers biological and technical advantages over other “omics” sciences in 
providing fundamental knowledge in investigating biochemical networks. The full metabolic 
profile associated with all biological processes can provide a more complete understanding of 
cellular dysfunction caused by various disorders and environmental challenges. Instead of 
disease predisposition, metabolomics can clarify the disease development, progression and 
adaptation by tracking the changes of metabolites with time226. Furthermore, it can help to 
identify early perturbation in cellular metabolism through their responses to internal or 
external stress factors. Due to its simplicity, high information content and universal 
application, metabolomics is an appealing tool in disease-related and medicinal research.  
The investigation of a given metabolome can follow two different approaches: targeted and 
non-targeted. A targeted approach is effectively used to observe changes of specific 
metabolites based on prior studies or hypothesis, whereas non-targeted metabolomics 
discovers unknown metabolites or metabolic pathways that are triggered by external stimuli 
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or genetic variation227. In other words, untargeted approach aims to monitor the entire 
collection of metabolites and obtain a comprehensive depiction of the treatment effect or 
disease progression. Several analytical techniques are routinely used for metabolomics 
studies. Notably, each of the techniques possesses advantages, limitations and differing 
predictive power which are summarized in Table 1.4. Liquid chromatography mass 
spectrometry (LC-MS) and gas chromatography mass spectrometry (GC-MS) have high 
sensitivity that can produce data with better spectral resolution, mass accuracy and separation 
efficiency. On the other hand, non-destructive NMR assay offers high selectivity and 
reproducibility as well as more quantifiable data renders it preferable for intact organism 
analysis228. High-resolution magic angle spinning (HR-MAS) is the NMR assay for semi-
solid state sample such as whole cells and soft tissue which will be discussed in detail in the 
next section.  
Table 1.4 Comparison of NMR, HR-MAS, Liquid Chromatography (LC-MS) and Gas Chromatography 
(GC-MS) Mass spectrometry for metabolomics studies. 
Technique Strengths Weaknesses 
NMR  Nondestructive technique 
 Versatility for analyzing 
metabolites in biofluids, 
tissues, or in vivo 
 Reproducibility and 
repeatability 
 Rapid analysis  
 Low sensitivity (only 
metabolites with relatively high 
concentration [micrograms] can 
be detected) 
 Overlap in peaks and high 
chemical degeneracy (different 
metabolites have resonances in 
the same spectral region) 
 
HR-MAS  Whole-cell experiment 
possible 
 Lower sensitivity 




 High-resolution capacity 
 Very sensitive (picogram 
quantities) 
 Lower reproducibility (within 
and across laboratories) 
 Slow analysis 
 Destructive to sample 
 
For more than 100 years, the study, diagnosis and treatment of TB was limited to culture-
based technology. Owing to the slow growth and complex culture procedures of different TB 
species, extensive time and specialized laboratories are required. Entering the genomic era, 
the emergence of new and powerful instrumentations has brought about enormous 
improvement in developing TB treatment and diagnostic strategies. The unprecedented 
investigation of drug mechanisms and their side effects is made possible by the identification 
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of metabolic biomarkers. Although the drug-susceptible TB regimen has been standardized, 
the exact mode of action and xenobiotic mechanism of the drugs remain poorly understood. 
Applying an ultra-performance liquid chromatography/time-of-flight mass spectrometry 
metabolomics approach, Li et al.229 characterized the metabolism of isoniazid in human and 
suggested that isoniazid inhibited growth of Mtb by an additional mechanism of disrupting 
essential amino acid metabolism. Using a similar approach, Loots et al.230 investigated the 
toxicity of combined anti-TB drugs (rifampicin, isoniazid and pyrazinamide), Rifater. They 
reported an increase of oxidative stress in treated-rats which was relieved with the application 
of an antioxidant, melatonin. Their findings provided reasonable explanations for the side 
effects such as hepatotoxicity reported for Rifater which can be caused by an extensive 
oxidative stress. Metabolomics can also be used to elucidate molecular mechanisms 
associating with the resistance phenotype in Mtb strains. Du Preez et al.231 pioneered the 
characterization of rifampicin resistance with fatty acid metabolism in rpoB mutants and wild 
type Mtb strains using GC-MS metabolomics. Their study indicated the reduced production 
of various types of cell wall lipids in drug-resistant strains and the switching of metabolism to 
the consumption short-chain fatty acid as an alternative carbon source. Another application of 
metabolomics is the monitor of anti-TB treatment efficiency and outcome. By comparing the 
metabolic profiles of biofluid samples at different times, it is possible to decide whether the 
treatment is suitable for certain patients, therefore shortening the time for trial-and-error 
therapy and reduces the chance for resistance development. Lastly, metabolomic biomarker is 
useful for the evaluation of new anti-TB drugs. Tuberculostearic acid (TBSA) in sputum 
sample was demonstrated to be a potential quantitative biomarker for Mtb growth232. TBSA 
was found to correlate positively with the number of colony and persistent in the culture but 
is not accumulating when bacteria stopped replicating. However, due to its low stability in 
nonviable bacteria, the need of a secondary biomarker was suggested. With the great capacity 
of Mtb to synthesize lipids, lipidomics, which seeks to scrutinise lipid metabolites, is also a 
popular subfield in mycobacterial metabolomics research233. Thanks to the continuous rapid 
development in mycobacterial metabolomics, more evidences have shown the capability of 




1.5 NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY 
NMR spectroscopy is a powerful, interdisciplinary analytical technique discovered in 1940s. 
Since then, the application of this technology has largely expanded, including spectroscopy 
and magnetic resonance imaging. NMR spectroscopy has been applied to metabolite studies 
of liquid-state, solid-state systems and intact organisms. As a result of the unique sample 
properties of different systems, especially induced by their particular spin interactions that 
greatly affect the NMR spectrum, disparate techniques are used in corresponding 
experiment234. The principle of NMR technique is briefly discussed, with the emphasis on 
HR-MAS, followed by their application to TB studies.  
 
1.5.1 Principle 
The theory of NMR and the nuclear-spin dynamics is fully established and can generally be 
interpreted by classical models. An in-depth explanation requires the knowledge in quantum 
mechanics which is beyond the scope of this thesis.  Classical vector models are used here to 
introduce the fundamental concepts of NMR.  
Magnetism: Matter is composed of atoms which possess nuclei with a characteristic 
proton/neutron composition. The atomic nuclei are positively charged and carry magnetic 
properties. This property arises from the angular momentum which is known as ‘spin’ of the 
nuclei. In essence, nuclear spins are of discrete values owing to the quantum nature of atoms. 
The total nuclear spin depends on the nucleon content thereby the number of protons and 
neutrons. Possession of even number of protons and neutrons results in a total spin of zero 
(12C, 14C, 16O…) while odd number of either or both results in non-zero total spin (1H, 13C, 
15N, 19F…) which creates a magnetic moment. NMR spectroscopy takes advantage of this 
magnetic moment of atomic nuclei.  
When exposed to an external static, homogenous magnetic field B0, the magnetic moment 
aligns along B0 according to Boltzmann distribution, with the ones aligning parallel to the 
field in the lower energy level. At the same time, the nuclei precess in the magnetic field with 
a resonance frequency named as the Larmor Precession frequency fο (Fig. 1.10a). This 
frequency uses to classify NMR spectrometers is denoted in equation 1.  
Equation 1 
f0 =  
γ
2𝜋
 × B0 
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where γ is the gyromagnetic ratio of atom (1H = 26.7522128x107 radT-1s-1). In reality, there 
are many nuclei in the sample so due to the static averaging of all magnetic moments, the 
effect on a net magnetisation M0  is visualized. For the generation of NMR signals, an 
electromagnetic radiation, B1-pulse, equals to the Larmor frequency is applied and this is 
when resonance occurs. Consequently, the net magnetisation absorbs the energy from the 
wave and is tilted orthogonal to B0 to the x-axis and reaches a higher energy state. The energy 
required to bring about the flipping between the two energy states depends on the external B0 
(Fig. 1.10b) and is described as  
Equation 2 
∆𝐸 = 𝛾ℎB0 / 2π 
where h is the Planck’s constant = 6.63x10-27 Js. According to Bohr condition, the resonant 
frequency fA can then be written as  
Equation 3 
fA = 𝛾 B0 / 2π 
 
 
Figure 1.10 Nuclear spin precession and energy difference between spin states. (a)Precession of the 
magnetic moment in two possible spin states of +1/2 and -1/2 (also denoted by nuclear spin quantum 
number, m) around external magnetic field B0. M0 represents the net nuclear magnetization resulting 
from the vector sum of all individual magnetic moments. (b) Relative energy of both spin states as a 




Signal Detection: When the B1-pulse is removed, M0 relaxes and precesses back to their 
lower energy state. As such, this relaxation releases energy as a radio waves which induces a 
voltage in the receiver coil of the magnet. The voltage is directly proportional to the number 
of spins precessing with f0. This signal generated as a decaying wave function over time is 
known as Free Induction Decay (FID). Through Fourier transform, the wave function is 
mathematically transformed into a function of frequency appearing as peaks in NMR spectra 
(Fig. 1.11).  
 
 
Figure 1.11 NMR signal generation by Fourier transformation of Free Induction Decay curve. 
Relaxation of M0 recorded as a wave function of time known as Free Induction Decay. FID curve is 
then Fourier transformed into a function of frequency236.  
 
Chemical Shift: Due to the diamagnetism of electron clouds surrounding the nuclei, a small 
magnetic field is induced which opposes the external B0. The nuclei, therefore experience a 
small change in local magnetic field as compared to the B0 field; this phenomenon is referred 
as electron shielding of the nuclei. As a result, the fA of a nucleus is determined by the 
effective magnetic field it experiences and in turn its surrounding chemical environment. This 
information is represented by the value (fA – f0)/ f0 x106, measuring in parts per million (ppm) 
with respect to B0, is called chemical shift. Any factor changing the electron density around 
the nucleus will induce shielding or deshielding effect, leading to up-field or down-field 
shifting of the peaks in NMR spectra. For example, presence of electronegative species draws 
electrons away from the protons, this deshields the protons and therefore, their chemical 
shifts increase and appear at higher ppm in the NMR spectrum. Definition of f0 is usually by 
means of a reference compound such as Trimethylsilylpropanoic acid (TSP). Noteworthily, 
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chemical shift is independent of the external B0, so comparison of data is possible from 
spectrometers of different field strength.  
Despite its high reproducibility, NMR has the major limitation of low sensitivity. This is 
inherited from the small difference between spin population in the higher and lower energy 
levels236. According to Boltzmann’s law, this difference has a linear relationship with 
external B0. As stated in Eq. 3, resonant frequency increases with increasing B0, thus peaks 
become narrower at higher field strength and less overlapping occurs rendering higher 
resolution. Besides employing a more powerful magnet, sensitivity can be enhanced by the 
number of nuclei (e.g. sample concentration or volume) or the configuration of the detection 
devices237. NMR experiments described in this thesis were performed at 1H frequencies of 
600 and 700 MHz.  
 
1.5.2 High-Resolution Magic Angle Spinning (HR-MAS) 
The most obvious difference between solid-state and liquid-state NMR spectrum is the 
multiple line broadening effect in solid-state systems. This is attributed to the unaveraged 
anisotropic interaction of the molecules primarily through dipolar coupling, the interaction 
between the dipolar magnetic fields induced by each magnetic moment or spin. This issue is 
not seen in liquid state samples as fast tumbling action of molecules effectively averages the 
dipolar coupling to zero234. Line broadening in solid-state NMR causes a loss of spectral 
resolution, limiting the usage of the technique in tissues and cells. Thanks to the work of 
Andrew and Lowe, who discovered that spinning the sample at an angle of 54.74° could 
largely remove the dipolar coupling, high-resolution magic angle spinning (HR-MAS) NMR 
technique was then developed (Fig. 1.12). This magic angle is the angle of the cross diagonal 
of a cube. Any point on this diagonal has identical x, y and z coordinates and therefore the 
anisotropic information is lost. Further, spectral resolution can be improved by increasing the 
spinning rate238. Another merit of HR-MAS is the visibility of both lipid components as well 
as small polar molecules. With the high versatility and much improved resolution, HR-MAS 
has become a popular tool for the study of complex biological tissues and whole cell 
samples239, 240. Nonetheless, the experiment of whole cell sample may result in the 
overlapping of polar and non-polar metabolite which accounts for one of the major practical 
drawbacks of the technique. Hence, careful experimental design should be done according to 
the properties of the sample, other analytical options like lipid extraction for lipidomics 




Figure 1.12 Schematic diagram of magic angle spinning (MAS) and static NMR spectra comparison. 
(Left) Sample spinning along the axis tilted at the magic angle of 54.74° with respect to the external 
magnetic field B0. (Right) Comparison of human brain proton NMR spectra acquired with (a) static 




1.5.3 Data Processing 
Data pre-processing: As an intermediate step prior to data analysis, pre-processing is 
necessary to reduce noise and transform the data to facilitate subsequent analyses and 
modelling. It includes baseline adjustment, phasing, alignment and binning as well as 
normalization and scaling.  
Baseline distortion arising from the non-linearities of the electronic detection process is 
usually corrected by subtracting a tailored polynomial from the raw spectrum. Phasing aims 
to correct the imperfections in the consequence of frequency-dependent factors237. Automatic 
as well as manual correction of processes are required to ensure reliability as artefacts in 
spectra can only be identified visually. Alignment of spectra avoids the misinterpretation of 
results because of peak shifting arises from changes of pH, salt concentration, temperature, 
overall dilution of samples and many more. The icoshift algorithm was chosen in experiment 
described in this thesis for its faster processing speed. In addition to alignment, binning or 
bucketing is another method applied to lessen peak shifting (Fig. 1.13). Equidistant binning is 
used by vast majority of 1D 1H-NMR studies in which the spectra are split into evenly spaced 
integral region with defined spectral width237. This produces smaller sets of variables which 
also reduces the data size for quicker subsequent processing procedures. Furthermore, 
normalization generates data that allows direct comparison and accounts for variations of the 
overall concentration of samples attributable to the difference number of cells, biofluid 
volume and size of tissue. Finally, scaling methods can be used to avoid the domination of 
signal with the highest intensity during data analysis243. Feature selection for pre-processing 
is critical and should be done appropriately in order to improve the reliability of models 




Figure 1.13 Illustration of binning on a 1H NMR spectrum of a rat urine sample. Using a bin spectral 
width of 0.04ppm, the number of data variables reduced from 65,536 to 312, facilitating further 
multivariate analysis. (A) original spectrum, (B) 0.04ppm binning, (C) resulting spectrum244.  
 
Multivariate analysis: Each 1D NMR spectrum contains thousands to tens of thousands of 
data points. The analysis of this staggeringly high information content is of high complexity; 
the challenge of generating relevant biological conclusions from such variable datasets 
indeed requires specialized and robust methods of statistical analysis. For this purpose, 
multiple methodologies have been developed and extensively reviewed244, 245. The hallmark 
of analysing metabolomic data is the use of multivariate analysis methods. Among all, 
principal component analysis (PCA), partial least squares (PLS) and orthogonal projection to 
latent structure (OPLS) are the most popular methods.  
The primary goal of all these methods is to identify differences between classes, despite class 
variability. PCA is an unsupervised algorithm for exploratory analysis to find pattern in the 
multivariate dataset. It aims to reduce the number of dimensions and achieve a linear 
transformation that preserves the most variance in the original data246. This unbiased method 
reveals differences only when within-group variation is sufficiently less than that of between-
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group. The transformed variables are uncorrelated called the principal components which 
explain the largest possible variability in the data. The data can be plotted into ‘score plot’ in 
two or three dimensions orthogonal to each other, thus, each principal component denotes 
independent variations in the data. The contribution of each variable to the principal 
component can also be visualized in the ‘loading plot’. In this way, identification of certain 
variable/NMR resonance contributing to the variations can be primarily determined. 
Meanwhile, variables that are co-located away from the origin in the loading plots might infer 
correlations. This gives initial clue of the metabolites exerting an effect in the data.  
PLS and the extension version OPLS are supervised form of discriminant analysis that allows 
identification of significant spectral features by making an explicit use of class membership. 
The creation of a linear regression model allows more apparent separations between classes 
in scores space. However, both methods have an innate tendency of over-fitting the models, 
even in the scenario of totally random variables247. Over-fitting is a general issue in “omics” 
studies as the number of variables almost always immensely out-scale the number of 
biological samples. This increases the risk of inclusion of random noise as true signals. 
Hence, it is important to perform validation for the assurance of model reliability. Cross 
validation is a standard method which partitions the data into a training set, to generate a 
model to make prediction of the remaining data, known as the test set. Double cross 
validation is used in the analysis preformed in this thesis, in which the samples are randomly 
assigned to be training, test and validation sets. Merit of this method is the fact that models 
constructed is in absolute absence of test set248. The training set creates a preliminary model 
that is tested on the validation set to determine the optimal number of components for model 
construction. Afterwards, the test set assesses the predictive ability of the model generated by 
training and validation sets combination. This process is repeated at least a thousand times to 
ensure reliability of the model.  
 
1.5.4 Applications of NMR Metabolomics on TB Treatment Research 
With regards to the application of metabolomics on TB, NMR, being a non-destructive 
technique, is widely applied to study various aspects relating to the disease. Studies of anti-
TB drug toxicity with biological matrix such as urine, plasma and serum reduce the 
complication of sample preparation and produce comprehensive profile. Halouska et al.135 
applied 1H-13C NMR to determine the minimum inhibitory concentration of anti-TB drug D-
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cycloserine and its effect on peptidoglycan biosynthetic pathway. Cycloserine was shown to 
inhibit several cell wall enzymes in M. smegmatis, particularly D-alanine-D-alanine ligase 
(Ddl), the main enzyme for peptidoglycan synthesis. The same group conducted a follow-up 
study which demonstrated that cell growth was inhibited when the production of Ddl is halted, 
indicating Ddl is a promising target for anti-TB drug development249. Stress response 
mechanism can also be determined using NMR. Behrends et al.250 demonstrated that M. 
smegmatis produces free glucosylglycerate under nitrogen depletion. This revealed an 
alternative mechanism adopted by mycobacteria to sustain their viability by reducing rate of 
growth and intake of ammonium. Biomarkers might also be identified by means of 1H NMR 
for mycobacterial infection diagnosis. Sera of calves infected by Mycobacterium avium 
subsp. paratuberculosis (MAP) was found to be distinctly separated from non-infected 
samples using discriminant analysis. Increased isobutyrate and fat metabolism were observed 
in infected cattle regardless infectious burden251. For pathological significance of lipid 
components in Mtb, different functional modes of NMR can rapidly generate qualitative and 
quantitative profile of clinically relevant lipids found in mycobacteria. Engy et al.252 
pioneered the usage of 2D 1H-13C heteronuclear single quantum coherence (HSQC) NMR to 
analyse mycobacterial cell wall lipids of 13C-enriched Mtb clinical isolates. The group 
underscored the utility of this technology to identify specific virulence factors especially non-
polar lipids of low abundance for instance, phenolic glycolipids (PGLs). This finding has 
introduced a powerful usage of NMR on TB lipidomics. Lastly, anti-TB drugs with similar 
modes of action demonstrated similar metabolomic profile and resulted in distinct clustering 
pattern which correlates with in vivo drug activity253. Therefore, NMR metabolomics is also 
























2. AIMS AND OBJECTIVES 
The requirement of highly toxic second-line drugs and long duration of treatment of MDR-
TB leads to a serious concern in anti-tuberculosis therapy. While enormous effort has been 
put to develop new drugs in the pipeline52, 156, efficacy and toxicity studies are still ongoing 
whereas resistance towards certain new drugs has already been reported139, 140. This renders 
an urgent need to improve current treatment. One of the strategies is to enhance the efficacy 
of existing antibiotics against MDR-TB.  
Novel D-LAK peptides have demonstrated synergistic mycobactericidal activity with 
isoniazid, re-sensitizing MDR strain GB2 towards this first-line antibiotics. Therefore, the 
overall aim of this thesis was to further investigate the strategy of using the novel D-LAK 
peptides in combination with existing anti-TB agents against mycobacteria, and to understand 
the basis for such synergy. The thesis is divided into three parts with specific objectives:  
 
Study 1:  The bioefficacy of D-LAK120-A and D-LAK120-HP13 peptides in combination 
with rifampicin and isoniazid was investigated on a series of MDR-TB clinical isolates and 
the severely attenuated Mtb Bleupan strain. The cytotoxicity of the D-LAK peptides and their 
combinations was also examined on mammalian cell lines. 
 
Study 2: The mechanism of action of D-LAK peptides, existing antibiotics and their 
combinations was elucidated, using M. smegmatis as a surrogate model. In particular, the 
biophysical and fluorescence techniques for studying the mechanism of anti-TB agents and 
their membrane activity were established. 
 
Study 3: The mechanism of action of D-LAK peptides, existing anti-TB agents and their 
combinations was studied on severely attenuated Mtb Bleupan strain, using the techniques 



























3.1 MICROBIOLOGICAL ASSAYS AND CELL CULTURE  
 
3.1.1 Antibiotics and reagents 
 
The following antibiotics and reagents were purchased from Sigma Aldrich: rifampicin (RIF) 
(Cat.# R3501), isoniazid (INH) (Cat.# I3377), capreomycin sulfate from Streptomyces 
capreolus (CAP) (Cat.# C4142), colistin sulfate salt (CST) (Cat.# C4461), dimethylsulfoxide 
(DMSO) (Cat.# D8418), phosphate buffered saline (PBS) (Cat.# P4417), formaldehyde 
solution (Cat.# 252549) and tyloxapol (Cat.# T8761). Delamanid (DLM) (Cat.# ABE5876) 
was purchased from Source BioScience (Nottingham, UK).  
 
3.1.2 Antimicrobial peptides 
 
Two structurally similar D-LAK peptides (Table 3.1) were custom synthesized by China 
Peptides Co. Ltd. (Shanghai, China), stored at -20°C in lyophilized form. The purity of 
synthesized peptides was confirmed to be >85% by reverse-phase high performance liquid 
chromatography (HPLC) and electrospray-ionization mass spectrometry (ESI-MS). All 
peptides were amidated at the C-terminus. Consensus hydrophobicity index was used to 
determine average hydrophobicity of peptides. Peptide stock solutions at 1 mM were 
prepared in distilled water and stored at -20°C before use. 
 
Table 3.1 The sequence and physiochemical properties of D-LAK peptides studied. (A-alanine, H-
histidine, K-lysine, L-leucine, P-proline, W-tryptophan) 







D-LAK120-A KKLALALAKKWLALAKKLALALAKK-NH2 +9 -0.02 120 





3.1.3 Cell Culture 
 
Adenocarcinomic human alveolar basal epithelial A549 cells (ATCC®  CCL-185™) were 
maintained in Dulbecco's modified eagle's medium (DMEM) (Life Technologies, USA) 
supplemented with 10% (v/v) fetal bovine serum (FBS) (Invitrogen, Cat.# 10270-106) and 
Antibiotic−Antimycotic solution (containing final concentration of 100 units/ml of penicillin, 
100 µg/ml of streptomycin and 0.25 µg/ml of Fungizone® ) (Invitrogen, Cat.#  15240-096). 
Human monocytic THP-1 cells purchased from the American Type Culture Collection 
(Manassas, Virginia, USA) were used as a macrophage model after they were differentiated 
into macrophage-like cells by treating with 100 nM phorbol 12-myristate 13-acetate (PMA) 
(Sigma Aldrich, Cat.# P8139). Roswell Park Memorial Institute medium (RPMI-1640) 
(Invitrogen, Carlsbad, California, USA, Cat.# 31800-022) supplemented with 10% (v/v) FBS, 
Antibiotics−Antimycotic solution, and additional supplements as follows: 0.05 mM 
2-mercaptoethanol (2-ME) (Invitrogen, Cat.# 21985-023), 2 g sodium hydrogencarbonate 
(NaHCO3) (Sigma Aldrich, Cat.# S5761), 1 mM sodium pyruvate (Sigma Aldrich, Cat.# 
P2256) and 10 mM 4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic 
acid, N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES) (Sigma Aldrich, 
Cat.# H3375) were used to maintain the THP-1 cells in the ex vivo mycobactericidal assay 
covered in section 3.1.9.  All cells were cultured in a humified atmosphere at 37°C and 5% 
CO2.  
Regarding the additional supplements in RPMI-1640, sodium pyruvate is used by cells as an 
easily accessible carbohydrate source. Additionally, it is involved with amino acid 
metabolism and initiates the Kreb's cycle. 2-ME is proposed to enhance uptake of cysteine 
and consequently the maintenance of intracellular glutathione levels. This protects the cells 
from oxidative damage, enhances antigen presentation and reduces clumping254.  
3.1.4 Mycobacterial strains and growth conditions 
 
To investigate the antimicrobial capacity and mechanism of action of anti-TB agents, this 
study used several mycobacterial species and exploited a series of biological, microscopic 
and biophysical techniques. For the ease of understanding, Table 3.2 summarized the details 















3.1.5 Strain Provenance  x x 
3.1.7 
In vitro bacterial inhibitory assay 
(Resazurin)c 
x x  
3.1.8 In vitro mycobactericidal assay x   
3.1.9 Ex vivo mycobactericidal assay x   
3.1.10 
In vitro bacterial inhibitory assay 
(Bioluminescence)d 
  x 
3.1.11 In vitro time-kill assay   x 
3.2 
Transmission electron and Confocal 
Microscopy 







 x x Nuclear magnetic 
resonance (NMR) 
metabolomics 
a MDR- multidrug-resistant Mycobacterium tuberculosis clinical isolates. 
b Mtb Bleupan- Severely attenuated Mycobacterium tuberculosis Bleupan strain. 
c Detection performed by Resazurin microtiter assays. 




Multidrug-resistant Mycobacterium tuberculosis clinical isolates, drug-susceptible 
Mycobacterium tuberculosis H37Rv and Mycobacterium smegmatis mc2155 
Five Mycobacterium tuberculosis strains were employed in this study, including four MDR 
clinical isolates and one standard laboratory strain H37Rv. Mycobacterium smegmatis mc2 
155 was the biosafety 1 species used in the mechanistic study (section 3.2). All the bacterial 
strains were kindly provided by Dr WC Yam from Department of Microbiology, The 
University of Hong Kong, Hong Kong. Antibiograms (Table 3.3) of the Mtb strains used in 
the study were previously determined using the agar proportion method according to Clinical 
Laboratory Standard Institute (CLSI) recommendations. The cultures were routinely 
maintained on Lowenstein-Jensen (LJ) solid medium (bioMérieux, Craponne, France) at 
room temperature with continuous aeration. In vitro assays were performed either in 
Middlebrook 7H9 broth (Difco, Detriot, Michigan, USA, Cat.# 271310) supplemented with 
10% (v/v) oleic acid-albumin-dextrose-catalase (OADC) enrichment (Becton Dickinson, 
Franklin Lakes, New Jersey, USA, Cat.# 212240) and 0.2% (v/v) glycerol (Sigma Aldrich, 
Cat.#G-5516) or on 7H10 agar (Difco, Cat.#271310) supplemented with 10% (v/v) OADC 
enrichment and 0.5% (v/v) glycerol. All the Mtb experiments were conducted in the 
University Pathology Building P3 Laboratory, The University of Hong Kong.  
 
Severely attenuated Mtb Bleupan and Mycobacterium smegmatis mc2155 
Mycobacterial strains were provided by Dr Robertson group from Imperial College London 
(ICL), United Kingdom. Frozen stocks in 10% (v/v) glycerol were prepared in ICL and 
transported to store in King’s College London for bacterial assays. Mycobacteria were 
maintained either in Middlebrook 7H9 broth (Sigma Aldrich, Cat.# MO178) supplemented 
with 10% (v/v) oleic acid-albumin-dextrose-catalase (OADC) enrichment (US Biological 
Life Sciences, Cat.# M3895-01) and 0.2% (v/v) glycerol (Sigma Aldrich, Cat.# G-5516) or 
on 7H10 agar (Sigma Aldrich, Cat.# MO 303) supplemented with 10% (v/v) OADC 
enrichment and 0.5% (v/v) glycerol. Additional supplement of 10 mg/ml L-Leucine (Sigma 
Aldrich, Cat.# L8912), 24 mg/ml calcium pantothenate (Sigma Aldrich, Cat.# C8731), 25 
µg/ml kanamycin sulfate from Streptomyces kanamyceticus (Sigma Aldrich, Cat.# K1377) 
and 50 µg/ml hygromycin B (FluoroChem,U.K. Cat.# M01839) were used to maintain the 
bioluminescent Mtb Bleupan. M. smegmatis mc2155 and Mtb Bleupan were grown to mid-log 
phase in supplemented 7H9 broth in falcon tubes. The cultures were incubated at 37 ̊C for 48 
h for M. smegmatis or six weeks for Mtb without agitation or detergent to minimize the 
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external manipulation on the structure of the bacteria such as their cord-forming ability255. 
Aeration, vortexing and 1 ml of fresh medium replenishment were done twice-weekly to 
maintain the growth of Mtb Bleupan. Subcultures were performed at initial Optical Density 
(O.D.) = 0.05 for both strains. This M. smegmatis mc2 155 from KCL was used in bacterial 
inhibitory assay (section 3.1.7) and growth response assay (section 3.3-3.5). 
Table 3.3 Antibiogram of mycobacterial strains. Information provided by Department of Microbiology, 
The University of Hong Kong, boxes marked with “--" indicate details not available. (R- resistant, S-
susceptible; INH-isoniazid, RIF-rifampicin, EMB-ethambutol, STR-streptomycin, PZA-pyrazinamide, 
OFX-ofloxacin, AMI-amikacin, CAM-chloramphenicol, CYC-cycloserine, ETH-ethionamide, KAN-
kanamycin) 
Sample ID H37Rv GB2 08M 03M 08MB 










Sex -- M M -- -- 
Age 60 38 -- -- -- 
Isolation 
date 
-- 2005 2008 2003 2008 
INH S R R R R 
RIF S R R R R 
EMB S S S S S 
STR S S S R R 
PZA S S S -- -- 
OFX -- S S S -- 
AMI -- S S -- -- 
CAM -- S S -- -- 
CYC -- S S -- -- 
ETH -- S S S -- 




3.1.5 Strain Provenance  
Before conducting experiment at King’s College London, the provenance of severely 
attenuated Mtb Bleupan and M. smegmatis mc2 155 was verified at Imperial College London 
by the following methods. 
DNA extraction 
Mtb Bleupan: Bacterial cells were harvested from suspension culture by centrifugation. 
Supernatant was discarded into detergent vesphene (STERIS Solutions Limited, U.K.) and 
the pellet was resuspended in Tris-EDTA (TE)a. An equal volume of chloroform:methanol 
(2:1 by volume) was added, followed by rocking for 5 min. The suspension was centrifuged 
at 4200 rpm for 10 min at room temperature. Both the aqueous and organic phases were 
removed. The remaining solid bacterial mass was air-dried inside the cabinet for 2 h. After 
drying, the pellet was resuspended in 5 ml TE containing 0.1 M Tris (pH9). Lysozyme was 
added to the final concentration of 100 µg/ml. The tube was then placed in a metal canister 
and incubate at 37 ̊C for 1 h. Followed by adding 0.1 volume of 10% (w/v) SDS and 100 
μg/ml proteinase Kb, the mixture was left heated for 3 h at 50 ̊C. This viscous solution was 
transferred to mix thoroughly with an equal volume of phenol:chloroform (1:1 by volume). 
The mixture was left for 30 min and then subjected to rocking for another 30 min at room 
temperature. The pellet was collected by centrifugation at 13,000 rpm for 15 min. The 
aqueous phase was transferred to a new tube and mixed again with an equal volume of 
chloroform. The aqueous phase was retrieved after centrifugation, and the DNA was 
precipitated with 0.1 volume of 3 M sodium acetate and an equal volume of isopropanol. The 
DNA was washed by 70% (v/v) ethanol and resuspended in 40–100 µl of TE.  
M. smegmatis: The culture was harvested and centrifuged; the bacterial pellet was 
resuspended in 400 µl of TE and incubated for 20 min at 80°C. After cooling at room 
temperature, 50 µl of 10 mg/ml. lysozyme was added and the mixture was vortexed and 
incubated for 1 h at 37°C. Followed by adding 75 µl of SDS/Proteinase K MIX c, the mixture 
was incubated for 10 min at 65°C. NaCl (5 M) and CTAB/NaCl solutiond (100 µl each) 
                                                     
a TE: 10mM Tris/HCl, pH 8, 1mM EDTA. Dissolve in distilled water. Autoclaved and store at room 
temperature. 
b Proteinase K: 10mg proteinase K/mL in distilled water. Store at-20°C. 
c SDS/Proteinase K MIX: 5 µL proteinase K 10 mg/mL in 70 µl of 10% (w/v) SDS per sample.  
d CTAB/NaCl solution: Dissolve 4.1 g NaCl in 80 mL distilled water. Add 10 g CTAB (Cetyl 
trimethylammonium bromide) while stirring. If necessary, heat at 65ºC for complete dissolution. 




preheated at 65°C were added, followed by vortexing and 10 min incubation at 65°C. 
Chloroform:isoamilic alcohol (24:1 by volume) (750 µl) were added, the mixture was 
vortexed and centrifuged 5 min at 13,000 rpm. The aqueous phase was transferred to a new 
tube and the previous step was repeated once again. The aqueous phase is transferred to a 
new tube and the DNA was precipitated with a 0.6 volume of isopropanol. The DNA was 
then centrifuged for 15 min at 13,000 rpm at 4°C, washed with 70% (v/v) ethanol, 
centrifuged again for 2 min and air-dried or dried using a DNA concentrator (miVac, Fisher 
Scientific, U.S.A.). Finally, the DNA is resuspended in TE.  
Polymerase chain reaction (PCR) 
In each independent PCR assay, test results were compared with the results of one positive 
and one negative control. The positive controls included the DNA of H37Rv strain provided 
by Colorado State University, Fort Collins, USA, (Contract No 1-A1-40091). The negative 
control included PCR grade water. 
Identification of strain provenance was done using specific pair of primers designed to 
amplify MSMEG 3582, Leu D and RpfC sequences in the mycobacterial DNA and the primer 
sequences and amplicon size are described in Table 3.4. A 50 μl reaction buffer contained 
10 × assay buffer (Bangalore Genei, Bangalore, India), 10 mM dNTP's (Bangalore Genei), 
10 pmol of each primer (SIGMA-GENOSYS, USA), 2.5 units Taq DNA Polymerase 
(Bangalore Genei) and 5 μl of extracted DNA. Amplification was carried out in a thermal 
minicycler (peqlab Biotechnologie GmbH, Erlangen, Germany), which involved 40 cycles of 
denaturation at 94°C for 2 min, annealing of primers at 68°C for 2 min, and primer extension 
at 72°C for 1 min. The amplification products were separated on 2% (w/v) agarose gels, 
visualized on a UV-light transilluminator (Biotech R & D Laboratories, Salem, India) and 
photographed. 
Table 3.4 Respective amplicon size (bp) of primers used to identify gene expression in corresponding 
mycobacterial strains. 













2340 bp -- -- 










-- 528 bp 528 bp 
aR, reverse primer; F, forward primer. 
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The examination of Mtb Bleupan DNA through polymerase chain reaction amplification 
concluded its possession of a shortened leucine D and a signature Mtb RpfC gene with the 
absence of a signature M. smegmatis sequence MSMEG 3582 (Fig. 3.1). This confirms the 
identity of the bacteria as Mtb while bearing a characteristic deletion of Mtb Bleupan. In 
addition to the deletion in leucine D sequence, Mtb Bleupan was characterized by another 
deletion in the pantothenate sequence rendering it a double auxotroph. Therefore, a 
phenotypic growth assay was further performed for validation. Bacteria were incubated in the 
conditions with or without the two additional nutrient supplements: leucine and pantothenate 
for a week. Obvious growth was observed in the medium with additional supplement whereas 
a clear medium showing limited growth was resulted in the condition without supplements 
(Fig. 3.2). This matches the phenotype of Mtb Bleupan as a double auxotroph arising from 
the deletions in leucine D and pantothenate CD sequences256. These results confirmed the 
sample is Mtb Bleupan strain. As a result, this validation process enables the proof of identity 
of Mtb Bleupan strain and reassurance of adequate level of biosafety facilities for the 






Figure 3.1 Agarose gel electrophoresis on amplified DNA extracted from various mycobacterial 
strains. DNA extract of M. smegmatis (lane 1,4,7), attenuated Mtb Bleupan (lane 2,5,8) and 





Figure 3.2 Phenotypic growth evaluation of the severely attenuated Mtb Bleupan strain. Growth of 
Mtb Bleupan strain supplemented with Leucine and Pantothenate (left) or without leucine nor 




3.1.6 Cytotoxicity study 
 
D-LAK peptides, rifampicin and isoniazid were assessed for their cytotoxicity on A549 cells. 
A549 cells were seeded in sterile 96-well culture plates at a density of 1 × 104 cells per well. 
The cells were incubated for 24 h to allow attachment. Rifampicin, isoniazid or peptides at 
designated concentrations, prepared in DMEM supplemented with 10% (v/v) FBS, were 
added to the cells. Their cytotoxic eﬀects were evaluated using the 3- (4,5-cimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide (MTT) cell viability assay after 24 h of incubation. 
Culture medium was discarded from each well and replaced by MTT solution (0.8 mg/ ml in 
PBS) followed by incubation at 37°C for 2 h. The precipitated formazan crystals were 
dissolved in absolute isopropanol and kept at 4 °C for 30 min. Absorbance was measured at 
595 nm using a microplate reader (Bio-Tek Microplate Reader, Winooski, VT, USA). 
Percentage of viable cells was calculated based on the equation shown below in which 
untreated cells were taken as control with 100% cell viability.  
𝑐𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =  
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 𝑤𝑒𝑙𝑙
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑤𝑒𝑙𝑙
× 100% 
The results were expressed as mean ± SD of three independent measurements in triplicates. 
 
3.1.7 In vitro bacterial inhibitory assay  
 
Minimum inhibitory concentrations (MICs) of the anti-TB agents (rifampicin, isoniazid, 
D-LAK peptides, capreomycin, and colistin) on different mycobacterial strains were 
determined using broth micro-dilution assay in 96-well plates. Bacterial colonies from LJ 
slants were scraped and re-suspended in 7H9 broth medium. Homogeneous mycobacterial 
suspension was prepared in sterile water, vortexed with glass beads (1-5 mm) for 5 min. After 
15 min for aerosol settlement, the colony-forming unit (CFU) of the suspension was 
determined by the measurement of optical density (OD) using the SmartSpecTM Plus 
spectrophotometer (BIO-RAD, CA, USA) at 620 nm. D-LAK peptides were first prepared by 
two-fold serial dilutions (1 µM to 128 µM) in Middlebrook 7H9 medium supplemented with 
OADC and glycerol as aforementioned. Anti-TB drugs were serially diluted to a range of 
concentrations: RIF from 0.4 µM to 24 µM, INH from 5.5 µM to 730 µM, CAP from 1.1 µM 
to 150 µM and CST from 0.65 µM to 87 µM. The prepared D-LAK peptides or drug stock 
solutions were added to an equal volume (100 µl) of mycobacterial suspension to obtain the 
final concentration of 1 x 107 CFU/ml for Mtb strains or 5 x 104 CFU/ml for M. smegmatis. 
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The untreated bacterial suspension and sterile medium were used as positive and negative 
growth controls. The plates were then incubated at 37°C (in 5% CO2 for Mtb strains) for 7 
days for Mtb strains or 24 h for M. smegmatis. A volume of 30 µl of 0.02% (w/v) resazurin 
dye was added to each well at the end of the incubation period. The color change was 
evaluated after 48 h for Mtb strains or 24 h for M. smegmatis. Resazurin assay is a 
colorimetric assay in which the viable cells reduce blue resazurin into fluorescent pink 
resorufin. MIC of each anti-agent on H37Rv and clinical isolates was determined visually 
and defined as the lowest concentration remained in blue. For M. smegmatis mc2 155, 
fluorescence was measured by excitation at 530 nm and emission at 590 nm using the BioTek 
Synergy HT Multi-Mode Microplate Reader (Vermont, U.S.A.). MIC50, refers to the 
minimum concentration to inhibit 50% of bacterial growth, was determined using sigmoidal-
response (variable slope) in GraphPad Prism 7.04 (GraphPad Software, CA, USA). 
Experiments were carried out in triplicate on three separate occasions.  
Antimicrobial interactions between D-LAK peptides and rifampicin or isoniazid were 
evaluated via chequerboard assay with modification193. The 96-well plate was set into x- and 
y-axis which were designated for D-LAK peptides and anti-TB drugs, respectively (Fig. 3.3). 
For Mtb strains, each anti-TB agent [x-axis: D-LAK peptides (1 µM to 32 µM); y-axis: RIF 
(0.8 µM to 48.6 µM) or INH (2.3 µM to 146 µM)] was added into the designated wells to 
give combination treatments. For M. smegmatis, anti-TB agents were prepared as follows, 
x-axis: D-LAK peptides (0.03 µM to 4 µM); y-axis: RIF (3.8 µM to 122 µM) or INH (23 µM 
to 730 µM) or CAP (0.2 µM to 7.5 µM) or CST (0.5 µM to 17 µM). Mycobacterial 
suspension was prepared, seeded in each well and incubated as aforementioned. The 
untreated bacterial suspension (B) and sterile medium (S) were used as positive and negative 
growth controls, respectively. After 7 days for Mtb strains or 24 h for M. smegmatis, 
resazurin assay was performed and fractional inhibitory concentration (FIC) of the 
combination treatment was determined as the lowest combination concentrations remained in 
blue. Synergistic interactions between anti-TB agents in combination treatment is denoted by 
the Fractional inhibitory concentration index (FICI). FICI of each combination was 
calculated by the following formula: 
FIC index = FICA + FICB = [A] in combination/ MICA + [B] in combination/ MICB 
Where [A] is the lowest inhibitory concentration of D-LAK peptides in the presence of the 
anti-TB drug, MICA is the MIC of D-LAK peptides treated as single agent and FICA is the 
FIC of D-LAK peptides; [B], MICB and FICB are the corresponding values for the anti-TB 
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drug. The interpretation of anti-TB agent interactions according to Caleffi-Ferracioli et al. 
defines synergy to occur when FIC index is < 0.5; additive when values are between 0.5-4.0 
and > 4.0 as antagonistic257. Experiments were carried out in triplicate on three separate 
occasions.  
 
Figure 3.3 Schematic diagram of chequerboard assay on 96-well plate. X-axis and y-axis denote the 
two-fold decreasing concentration of D-LAK peptide and anti-TB drug respectively, B is the untreated 
bacterial growth control and S is the sterile negative control.  
 
MIC and FIC experiments were also performed in the presence of 0.025% (v/v) tyloxapol on 
M. smegmatis to evaluate the effect of the surfactant. Tyloxapol, a non-ionic liquid surfactant 
commonly used to culture mycobacteria to prevent clumping of colonies in broth medium, 
was chosen instead of Tween 80 since the de-esterification of the later can furnish 
mycobacteria with oleic acid258. This potentially introduces an external factor in the carbon 
metabolism of the bacteria which interferes with the subsequent metabolomics study, 
therefore a nonhydrolyzable detergent, tyloxapol was used.  
 
3.1.8 In vitro mycobactericidal assay on MDR clinical isolates 03M and 08MB 
 
In vitro mycobactericidal assay of individual anti-TB agent was performed by treating Mtb 
strains with anti-TB agents at their respective ½ x, 1x and 2x MIC for seven days. After 
seven-day incubation of anti-TB agent and mycobacterial inoculum, 50 µl contents from each 
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well was plated out on a 60 mm Middlebrook 7H10 agar plate enriched with OADC and 
glycerol. Two dilutions of 1x and 10x or 10x and 100x were made and spread on plates in 
duplicates. All plates were incubated at 37°C with 5% CO2 for 3 to 4 weeks before CFUs 
were counted.  
In vitro mycobactericidal assay of D-LAK120-A or D-LAK120-HP13 in combination with 
RIF or INH against Mtb strains was performed in 96-well plate. After day 7 of incubation, 
four wells of lowest combination concentration showing no apparent bacterial growth 
visually (remain clear) were plated out on 7H10 agar as mentioned above for CFU counting 
after 3 to 4 weeks of further incubation at 37°C with 5% CO2. The percentage growth of Mtb 
of each treatment group compared to the control group was calculated.  
 
3.1.9 Ex vivo mycobactericidal assay on MDR clinical isolates 03M and 08MB 
 
Anti-TB agents and their combinations were studied in the intracellular mycobactericidal 
assay. The method was described in the previous study with modification259. THP-1 cells at a 
density of 1 x 105/well were differentiated by treating with 100 nM PMA in RPMI-1640 with 
10% (v/v) FBS in 24-well plates for 24h without the presence of Antibiotic-Antimycotic 
solution. Afterwards, the cells were washed with PBS and incubated with RPMI-1640 with 
10% (v/v) FBS overnight. Differentiated THP-1 cells were challenged overnight with MDR 
Mtb strains 03M and 08MB (Day 1) suspended in RPMI-1640 Antibiotic-Antimycotic-free 
medium at a multiplicity of infection (MOI) of 1 (bacterium-to-cell ratio 1:1). On the day of 
experiment (Day 0), infection medium was discarded and the cells were washed with 
phosphate buffered saline (PBS) thrice to remove the extracellular mycobacteria. Individual 
anti-TB agent or combination treatment at designated concentrations were prepared in RPMI-
1640 Antibiotic-Antimycotic-free medium and added into respective wells. Infected cells 
treated with RPMI-1640 antibiotic-free medium alone served as growth control. On day 7, 
cells were lysed with 1 ml of 0.1% (w/v) sodium dodecyl sulfate (SDS). Two dilutions of 1x 
and 10x or 10x and 100x were plated out on Middlebrook 7H10 agar plates in duplicates. 
Following incubation at 37°C and 5% CO2 for four to six weeks, bacterial colonies were 
enumerated and data were expressed as the percentage growth of Mtb in each treatment group 
compared to the control group. Experiments were performed in triplicates on two 




3.1.10 In vitro bacterial inhibitory assay on bioluminescent Mtb Bleupan  
 
MIC of the anti-TB agents (rifampicin, isoniazid, D-LAK peptides and capreomycin, colistin 
and delamanid on bioluminescent Mtb Bleupan was determined by the measurement of 
luminescence in 96-well plates. D-LAK peptides were first prepared by two-fold serial 
dilutions (1 µM to 128 µM) in Middlebrook 7H9 medium supplemented with OADC and 
glycerol as aforementioned. Each anti-TB agent was serially diluted as follows, RIF (0.01 
µM to 12 µM), INH (0.07 µM to 73 µM), CAP (0.01 µM to 15 µM), CST (1.7 µM to 1730 
µM) and DLM (0.01 µM to 9 µM). Mycobacterial suspension was prepared in 7H9 broth 
supplemented with OADC. Diluted mycobacterial culture, with an inoculum size of 
1 x 107 CFU/ml, was added to an equal volume (100 μl) of each anti-TB agent solution. 
Untreated bacterial suspension and sterile medium were treated as growth controls. The 
plates were then incubated at 37°C and 5% CO2 for 7 days. Viability of bacteria was assessed 
by bioluminescence measurement. Bioluminescence of Mtb Bleupan expressing the lux 
operon was measured for 1s using the Envision 2105 Multimode Plate reader (Perkin Elmer, 
MA, USA). Bioluminescence was expressed as relative light units (RLU). MIC was defined 
as the lowest drug concentration resulted in 1-log reduction in bioluminescence compared 
with the untreated control260. MIC50 was determined using sigmoidal-response (variable 
slope) in GraphPad Prism 7.04 (GraphPad Software, CA, USA). Experiments were carried 
out in triplicate on three separate occasions. 
FICs of the combination treatment of rifampicin, isoniazid or capreomycin and D-LAK 
peptides were determined using chequerboard assay. Synergistic interactions between anti-
TB agents in combination treatment was determined as mentioned above. Two-fold serial 
dilutions of each anti-TB stock solution [x-axis: D-LAK peptides (1 µM to 32 µM); y-axis: 
RIF (0.02 µM to 1.2 µM), INH (0.6 µM to 36.5 µM) or CAP (0.19 µM  to 12 µM ] was 
added into the designated wells to give six different combination treatments as follows: D-
LAK120-A + RIF, D-LAK120-A + INH, D-LAK120-A + CAP, D-LAK120-HP13 + RIF, D-
LAK120-HP13 + INH and D-LAK120-HP13 + CAP. Mycobacterial suspension was 
prepared as forth mentioned and 1 x 107 CFU/ml was seeded in each well. After seven days, 
measurement of bioluminescence was performed and FICI of each combination was 




3.1.11 Time-kill assay 
 
Mtb Bleupan were seeded in 96-well plates at O.D. = 0.02. The bacteria were incubated at 
37°C until RLU > 10,000 in all wells (Day 0). Antimycobacterial agent (100 μl) alone or in 
combination at ½ x, 1x, 2x, 4x MIC was added in the designated wells. Luminescent 
measurements were taken daily for 7 days with the Envision 2105 Multimode Plate reader. 
Data were plotted by Log RLU over time. All experiments were performed in triplicates on 
three independent occasions.   
 
3.2 MICROSCOPIC TECHNIQUES 
 
3.2.1 Transmission electron microscopy study 
 
M. smegmatis mc2 155 was treated with D-LAK peptides at 1x MIC for 5, 15 and 30 min. 
Samples were then washed thrice with PBS and cell pellets were collected by centrifugation. 
Cell pellets were fixed in 2.5% (v/v) glutaraldehyde until further processing. Samples were 
rinsed thrice with piperazine-N,N’-bis(ethanesulfonic acid); 1,4-piperazinediethanesulfonic 
acid (PIPES buffer) (Sigma Aldrich Cat.# P6757) followed by second fixation in 1% (v/v) 
osmium tetroxide (OsO4) (Sigma Aldrich Cat.# 75632) for 1 h at room temperature. The first 
embedding into agar was done to reduce sample loss. Pellets were then dehydrated using 
ethanol (EtOH) [50, 70, 90% (v/v) for 10 min each and then 100% thrice for 20 min]. After 
dehydration, samples were infiltrated using 1:1 epoxy resin/ propylene oxide mixture 
overnight at 37 °C. The next day, pellets were infiltrated with fresh epoxy resin for 1 h at 
37 °C followed by polymerization at 60 °C overnight. Samples were viewed using CM100 
TEM (Philips, U.S.A) equipped with a TENGRA 2.3K X 2.3K camera. 
3.2.2 Confocal microscopy study 
 
Effect on membrane permeability of peptides using confocal microscopy was studied 
previously261 with modification. M. smegmatis mc2 155 cultures grown up to mid-log phase 
was treated with 250 µg/ml 150 kDa FITC-labelled dextran (Sigma Aldrich, Cat. #46946) 
and D-LAK peptides or first-line drugs (RIF or INH) at ½ x, 1x and 2x MIC for 20 min. 
Bacterial cells treated only with FITC-dextran was used as control.  Following the treatment, 
the bacterial cells were centrifuged at 7500 rpm for 10 min and washed thrice with PBS to 
remove the unassociated dextran. Cells were then fixed in 2% (v/v) formaldehyde at room 
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temperature for 20 min. After fixation, cells were washed twice and re-suspended in PBS. A 
volume of 20 µl sample was then allowed to air-dry on microscope slides overnight. FITC 
was excited with a 488 nm laser and detected with a 505 nm long-pass filter. Samples were 
imaged with a 65x oil-immersion objective lens using a Zeiss LSM-510 inverted confocal 
microscope (Carl Zeiss Inc., Germany).  
 
3.3 MYCOBACTERIAL GROWTH RESPONSE ASSAY  
 
3.3.1 Mycobacterial growth response study 
 
To elucidate the mechanism of action of anti-TB agents on mycobacterial growth, sub-MIC 
challenge assays were conducted to observe the growth response of M. smegmatis mc2 155 
and Mtb Bleupan. For M. smegmatis, 1% inoculum in the presence of 0.025% (v/v) tyloxapol 
or ¾  MIC of each anti-TB agent, alone or in combination, was cultured in 10 ml 
supplemented 7H9 broth medium at 37°C for 5 days. For Mtb Bleupan, two challenge 
conditions by each anti-TB agent, alone or in combination were studied: i) six weeks 
challenge of 1% inoculum with ¼  MIC of anti-TB agents and ii) 72 hours challenge of six-
week cultured bacteria with ½  MIC of anti-TB agents. The bacteria were processed and 
subjected to trans-1,6-diphenyl-1,3,5-hexatriene (DPH) fluorescence assay, Laurdan 
fluorescence assay and nuclear magnetic resonance (NMR) metabolomics analysis. 
 
3.4 FLUORESCENCE ASSAYS  
 
3.4.1 Laurdan fluorescence assay 
 
At the end point of the growth response assay mentioned above in section 3.3.1, tubes with 
mycobacteria were vortexed to break down the biofilms and de-clump the bacterial lumps. 
O.D. of the bacteria suspension was measured at 600 nm. The average of triplicate 
measurements was taken. Bacterial suspension (3 ml) at OD = 0.6 was made by diluting with 
PBS. The remaining suspension was kept for metabolomics studies. The 3 ml bacterial 
suspension was then fixed by 0.25% (v/v) formaldehyde [4% (v/v) for Mtb Bleupan] for 1 h 
at room temperature. After fixing, the bacterial cells were pelleted by centrifugation at 5, 000 
rpm, 4 ̊C for 8 min and washed by PBS once (thrice for Mtb Bleupan samples). The samples 
were kept at -20 ̊C until further studies. Laurdan (6-dodecanolyl—N,N-dimethyl-2-
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napthtylamine) was prepared by dissolving in complete methanol. Bacteria were re-
suspended in PBS and stained by 2.5 µM Laurdan fluorescent probe. All tubes were wrapped 
with foil to prevent photodegradation of the dye and incubated at 37 ̊C for 1 h. Samples were 
added into the cuvette and excited at 350 nm using fluorescence spectrophotometer (Varian 
Cary Eclipse, Mulgrave, Victoria, Australia). Measurements were performed at 37 ̊C and 
signals were collected at emission wavelength range of 400-600 nm (no. of scans = 20). 
General polarization (GP) value corresponding to the order of membrane was calculated as 






3.4.2 Trans-1,6-diphenyl-1,3,5-hexatriene (DPH) fluorescence assay 
 
Mycobacterial cells were harvested, fixed and washed with the same procedure as for 
Laurdan assay. Bacteria cells were re-suspended in PBS and stained by 2.5 µM DPH 
fluorescent probe. All tubes were wrapped with foil and incubated at 37 ̊C for 30 min. 
Samples were added into the cuvette and excited at 358 nm using the fluorescence 
spectrophotometer (Varian Cary Eclipse, Mulgrave, Victoria, Australia). Signals were 
collected by single wavelength scanning at emission wavelength 430 nm. The spectral 
bandwidth of the emission monochromator and the measurement of emission spectra were set 
at 10 nm. Steady-state fluorescence anisotropy, r, was calculated as 




where IVV and IVH are the parallel and perpendicular polarized fluorescence intensities 
measured with the vertically polarized excitation light, IHV and IHH are the same fluorescence 
intensities measured with the excitation light horizontally polarized, and G is the 




3.5 NUCLEAR MAGNETIC RESONANCE (NMR) METABOLOMICS 
 
3.5.1 NMR sample preparation  
 
After the end of the designated challenge period, mycobacterial cells were harvested by 
centrifugation at 5,000 rpm, 4 ̊C for 8 min. Supernatant was collected and filtered through 
0.22 µm membrane filters to remove remaining bacterial cells. Metabolic activities in the 
supernatant was quenched immediately by freezing at -80 ̊C and stored until further use. 
Bacterial cells were washed twice with PBS. PBS was aspirated to obtain a bacteria pellet 
which was then snap frozen in liquid nitrogen for 3 min. The pellet was lyophilized at -50°C 
overnight using an Alpha 1-2 LD plus freeze dryer (Martin Christ, Germany). For Mtb 
Bleupan samples, the harvested cells were fixed with 4% (v/v) formaldehyde for 1 h at 4 ̊C. 
The pellet was washed twice with PBS after fixation. Samples were prepared according to the 
procedures above. The lyophilized pellets were stored at -20 ̊C.  
 
3.5.2 NMR data acquisition 
 
Prior to NMR acquisition, the lyophilized cell pellet were re-suspended in 40 µl D2O 
containing Trimethylsilylpropanoic acid (TSP) for at least 2 hours before data acquisition to 
provide a deuterium lock signal. This is to ensure the complete rehydration of cells in order to 
avoid larger spectral linewidths. The re-suspended pellet was placed in Kel-F insert (Bruker, 
Rheinstetten, Germany) and then in the 4 mm Zirconia Magic Angle Spinning (MAS) rotor 
and preserved with a Kel-F cap. The filtered supernatant samples were prepared with 10% 
(v/v) D2O with TSP and transferred to NMR tubes. Complete D2O was not used since the 
7H9 broth medium contains a considerable amount of ferric ion which interfere with NMR 
data acquisition.  
For HR-MAS NMR, spectrum acquisition was performed on a 600 MHz Bruker Avance III 
spectrometer equipped with a 4mm 1H/13C HR-MAS probe (Bruker UK Limited, Coventry, 
UK). The temperature was kept at 310 K. The magic angle spinning frequency was 5 kHz. 
1D 1H NMR spectra were collected with a pulse-acquire with pre-saturation (zgpr) pulse 
sequence in order to avoid the water signal. The spectrum width was 12.01 ppm, relaxation 
delay (d1) was 3 s and 1H 90 pulse length was 5.025 µs. Before recording acquisition data, 
eight dummy scans were performed. Total acquisition time was 1.14 seconds with a pre-scan 
delay of 6.5 μs and Tau delay (d20) of 200 µs. The size of raw spectrum was recorded with 
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131k data points. A total of 128 scans and 10 min were used to obtain each of the NMR 
spectra. Free induction decay was multiplied by an exponential function with line broadening 
of 0.3 Hz. For liquid state NMR, data were recorded under automation on a Bruker Avance II 
700 NMR spectrometer (Bruker BioSpin, Coventry, United Kingdom) equipped with a 5-mm 
helium-cooled quadruple resonance cryoprobe and a cooled SampleJet sample changer. The 
samples were kept at 4 ̊C before inserting into the magnet. 1D 1H spectrum acquisition was 
done at 298 K and 700 MHz using a Carr-Purcell-Meiboom-Gill pre-saturation (cpmgpr1) 
pulse sequence. Spectra were acquired after four dummy scans with 64 transients, a spectrum 
width of 20.1 ppm, 65 k data points and a relaxation delay of 4 s. Free induction decays were 
multiplied by an exponential function equivalent to a 0.3-Hz line broadening factor, followed 
by Fourier transformation and calibration to the methyl peak of TSP-d4 set to 0.0 ppm. Phase 
correction of spectra was performed manually using Brucker Topspin 3.5 Software, and 
automatic baseline correction was applied. Due to the inherit variability in biological samples, 
nine samples from three experimental replicates were collected for each of the treatment 
condition to achieve a robust statistical analysis. For assignment purposes, two dimensional 
(2D) spectra of 1H-1H correlation spectroscopy (COSY) (cosygpprqf) spectra were acquired 
for selected samples.  
 
3.6 STATISTICAL ANALYSIS 
Data analysis was performed using GraphPad Prism version 7.04 (GraphPad Software, La 
Jolla California USA, www.graphpad.com). ANOVA test followed by Dunnett’s or 
Bonferroni’s Multiple Comparisons Test or Tukey’s post-hoc test was used to establish 
statistical significance. Student’s t-test was performed for pairwise comparison. Values are 
expressed as mean ± standard deviation (SD). Differences were determined as statistically 
significant with probability value p ≤ 0.05. All experiments were performed in triplicates.   
3.6.1 NMR metabolomics data pre-processing and multivariate analysis 
 
NMR metabolomics data processing and analysis were performed using a set of software 
previously developed in the Mason laboratory, Kings College London by Dr Louic Vermeer 
together with MVAPACK262 and an open source Octave library. Python 3, used in the in-
house script, is a programming language allows the integration of mathematical Numpy, 
SciPy extension and Metplotlib for the visualization of principal component analysis (PCA) 
and Orthogonal Partial Least Squares/Projection onto Latent Structures (OPLS) plots263. 
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Proper preprocessing of metabolomics data is vital to attain a meaningful interpretation 
through the generation of reliable PCA, Orthogonal Partial Least Squares-Discriminant 
Analysis (OPLS-DA) models. Pre-processing procedures generally includes removal of noise 
regions, normalization, data scaling, binning and alignment. As a result, the residual water 
resonances (4.46-4.87 ppm) were excluded. The NMR spectrum regions below 0.2 ppm and 
above 10 ppm containing the reference TSP peak and noise were also removed to eliminate 
any undesired variations. The processed NMR data were reduced into spectral regions of 
0.005 ppm in the octave environment using the icoshift alignment and optimized binning 
algorithm. Probabilistic quotient normalization (PQN) was employed to normalize the data 
set based on the assumption that changes in the concentration of a particular analytes only 
affect a section of the spectrum while the effect overall concentration dominates the influence 
of the whole spectrum264. PQN was carried out via the calculation of median spectrum 
thereby the median quotient and finally dividing each data point by the median quotient264. 
Autoscaling was then performed by mean centering the data points and then divide the 
standard deviation for the variable. This treatment prevents the intense peaks from having a 
dominating effect in the multivariate analysis.  
Louic’s Metabolomics Thingy’ developed by Dr Louic Vermeer used for metabolomics data 
processing and analysis was featured in several publications in the past years263, 265. This 
software is equipped with a PyQT front end Graphical User Interface (GUI) which allows the 
import of raw NMR spectra and transformation into PCA and OPLS-DA plots, facilitating 
processing and analysis of data for non-experts. All reduced data matrices were initially 
analyzed by PCA to examine the intrinsic variation of in the data set, identifying general 
trends and outliers. PCA involves the mathematical procedures that transform the large 
number of possibly related variables (metabolites) into smaller number of unrelated variables 
known as Principal Components (PC). PC1 always account for the greatest variance of the 
data set and the accountability of the variance in the remaining data would be accounted by 
subsequent PCs266. OPLS-DA was employed to further extract useful information by 
maximizing the separation between control and each treatment condition. Double cross 
validation was used to provide a robust assessment for the generation of statistical models. 
Leave-One-Out Cross-Validation (LOOCV) using a 7-fold method in which one sample is 
left out of the training set and is used to validate the model, therefore, 85% of the samples 
were used as the training set while the other 15% served as the test set. The quality 
assessment statistics (Q2) is typically used to report the result of cross validation. Although 
there is no standard comparison or critical significant value for Q2, the normal practice is to 
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compare to its theoretical maximum of 1 or empirically acceptable value of  ≥ 0.4 in 
biological models247. Thus, a higher Q2 (closer to 1) indicates a better predictability of the 
model generated. The procedure was repeated for 1000 times with samples randomly chosen 
in the training sets and test sets, a total of 7 x 1000 models was generated. For further 
validation, random permutation test of 1000 repeats were exploited to test the null hypothesis 
for a model’s Q2.  This allows another point of comparison of Q2 in which a more reliable 
model would yield a significantly larger Q2 when compared to that generated from the 
random models (permutated) from the same data set244. The processed data were illustrated as 
plots of back-scaled loadings, Q2 histogram, the principal components histogram, the 
prediction per sample and the predicted residual error sum of squares (PRESS)/sample. A 
representative visual output of cross-validated OLPS-DA is shown in Fig. 3.4. 
 
Figure 3.4 Representative visual output of OPLS-DA cross-validation data. The data as shown are 
taken from the M. smegmatis grown in the presence of 0.025% (v/v) tyloxapol surfactant. Processed 
results are plotted in which the blue represents the sample data while the grey is the random 
assignment of classes denoted as the permutated data. Top left: Scores plot from the double cross-
validation strategy. Each point represents an individual NMR spectrum of a sample and are plotted 
according to their score of the predictive and orthogonal components. This plot depicts the separation 
between control (blue) and treatment (red) classes when using variables that can distinguish between 
classes. These variables are the metabolic resonances that have the most discriminatory importance in 
the data which is illustrated in the Back-scaled loadings plot. This plot is generated with the 
covariance of the metabolic resonance associated with the class; correlation weights are differentiated 
using color. Top right: Principal components histogram shown the number of components used to 
create the OPLS-DA models with each iteration of cross-validation. Bottom left: PRESS/sample is a 
dot-plot of sample and permutated data for the further inspection of extreme outliers in accordance 
with the Prediction per sample plot (Bottom right). Bottom middle: Q2 histogram allows the 
visualization of the model predictability by comparing the values between sample and permutated data. 
This combination of plots gives an overview of the predictability of the generated OPLS-DA model.  
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Assignment of metabolic resonances were made with the aid of literature267-270, the Biological 
Magnetic Resonance Bank (BMRB)271, Chenomx software and the ranges of 2D NMR 
spectra. Representative figures for peak assignment are shown in appendix A. 
MultiExperiment Viewer (MeV), a part of the TM4 Microarray Software Suite272 was used to 
generate heatmaps with the quantified variation in metabolite concentrations. Hierarchical 
cluster analysis using the Euclidian distance algorithm was employed to evaluate the 
differences in changes of metabolites and compute the clustering relationship of the treatment 
conditions. 
For volcano plots, significant results from OPLS-DA analysis justified univariate analysis of 
peaks associated with predictive value in the multivariate models. Therefore, the integrals of 
assigned NMR peaks were analyzed using non-parametric univariate methods. Volcano plots 
were used to compare the fold change in metabolite values between each treatment condition 
and the untreated control. Fold change was calculated as the ratio between the two conditions 
(Treatment/Control). Mann-Whitney U test was exploited to compare means and associated 
p-values were False Discovery rate adjusted using the Benjamini-Hochberg method (α = 
0.05). Volcano plots were generated using custom scripts in Python with Numpy, Pandas, 
Matplotlib and Seaborn packages. Partial least-squares (PLS) Regression was performed in 
Python using the PLS Regression function in the scikit-learn software package. Only one 
component was necessary for best model performance as determined in the initial model 
assessment. Increased number of components led to a decrease in Q2. Monte Carlo cross-
validation of models was employed through the random splitting of data into 70/30 
training/test set splits. The procedure was repeated 1000 times to avoid bias by sample 
separation and R2 and Q2 values were computed to evaluate model performance. R2 denotes 
how well the model describes the training data set while Q2 demonstrates the predictability of 
model on the test set. Spearman correlation coefficient was used to measure the strength of 
the relationship between the changes in selected influential metabolites and the respective 














4 Chapter 4 Combinations of 
D-LAK peptides and anti-TB 
drugs against drug-resistant TB 






Mycobacteria possess the intrinsic resistance to many antibiotics that are effective against 
other bacteria, and this is deemed possible owing to the superior protection offered by the 
lipid-rich mycolic acid-containing mycobacterial cell envelope18. Anti-TB drug research has 
been focused on identifying candidates capable of breaching the cell wall of mycobacteria in 
order to tackle the problem arises from the emergence of resistance to the limited number of 
existing antibiotics for TB. This approach may provide a means to kill the mycobacteria 
directly or re-sensitize them to existing first-line anti-TB agents. 
To this end, increasing interest has been drawn to the use of AMPs for their rapid 
antibacterial actions which involve direct membrane disruption and membrane penetration to 
target important intracellular functional sites67. The salient features of net positive charge and 
amphipathicity possessed by AMPs render them useful to target and kill bacteria. The action 
of AMPs often leads to rapid cell death which reduces the chance of bacteria to develop 
resistance towards AMPs, making them a potential candidate for TB treatment19, 62. In 
essence, the anti-TB ability of AMPs have not only been studied in isolation, but also in 
combination with first-line anti-TB drugs such as rifampicin and isoniazid against both drug-
susceptible and drug-resistant MDR-TB strains222, 261. Among these peptides, those containing 
all-D-amino acids demonstrated better stability due to their resistance to proteolytic 
degradation and therefore improved mycobacterial selectivity and antimicrobial activities in 
vitro and in vivo as compared to the L-form190, 215, 273.  
The development of a range of highly cationic D-LAK AMPs has been reported in recent 
publications for their action against Gram-negative bacteria, attenuated Mtb H37Ra and 
MDR Mtb strains188, 259. These amphipathic D-LAK peptides consist of 25 amino acids 
residues including leucine (L), alanine (A) and lysine (K) in their D-conformation. D-LAK 
peptides were rationally designed to adopt an α-helix conformation when interacting with the 
bacterial membrane188. They possess a charge angle subtended by the positively charged 
lysine residue (Fig. 4.1) which can be modified to enhance disruption on anionic bacterial 
membranes188. According to the structural-activity studies, D-LAK peptides with a charge 
angle of 120° demonstrated the highest potency against attenuated Mtb strain H37Ra. 
Furthermore, the effect of conformational flexibility and hydrophobicity were evaluated by 
substitution of various amino acid residues including histidine (H) and proline (P) in the 
parent LAK peptide sequence (KKLALLALKKWLLALKKLALLALKK-NH2). 
Conformational flexibility is a key property that is associated with better membrane 
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penetration and intracellular targeting ability of AMPs188. The incorporation of proline 
residue at position 13 was shown to enhance conformation flexibility and displayed efficient 
killing effect on Plasmodium falciparum while mitigating hemolytic toxicity188. This is 
supported by a transcriptomics and NMR metabolomics study which revealed the improved 
membrane penetration of the proline-containing D-LAK120-HP13 peptide274.  
 
Figure 4.1 Schematic diagram of α-helical peptide with a charge angle of 120° subtended by positively 
charged lysine residues in blue.  
 
In a previous study, six promising D-LAK peptides possessing the nominal charge of +9 at 
neutral pH, namely D-LAK120, D-LAK120-H, D-LAK120-A, D-LAK120-P13, 
D-LAK120-HP13 and D-LAK120-AP13, were selected to evaluate their activity against 
MDR and XDR Mtb strains259. These D-LAK peptides demonstrated a de-clumping effect 
which enabled the disruption of colonies of MDR-TB strains. This resulted in inhibition of 
mycobacterial growth in vitro and in differentiated THP-1 macrophage-like cells. Moreover, 
the D-LAK peptides were able to potentiate the activity of first-line anti-TB drug isoniazid 
in vitro. Among the six peptide candidates, D-LAK120-A and D-LAK120-HP13 were found 
to show the highest efficacy in inhibiting the growth of drug-resistant Mtb clinical isolates259. 
These findings revealed that D-LAK peptides have the potential to act as an adjuvant in 
combination with other anti-TB agents to potentiate the antimicrobial effect towards Mtb.  
Furthermore, due to the lack of a safe and reliable surrogate model for the study of anti-TB 
drug action to date, a severely attenuated Mtb Bleupan strain was included, to evaluate its 
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potential as an applicable surrogate model. The severely attenuated Mtb Bleupan strain is a 
Mtb mutant derived from the virulent drug-susceptible H37Rv strain. This strain was named 
Mtb Bleupan as it was created through the deletions of two loci in Mtb, the essential leuD 
(Mtb H37Rv gene number Rv2987c) and panCD (Rv3602c and Rv3601c)256. As an early 
attempt to be developed as vaccine candidate, the combination of these two independent, 
attenuating and non-revertible mutations render the strain auxotrophic for both leucine and 
pantothenate and highly attenuated in vivo. This double auxotroph therefore provides a safer 
means for studying Mtb biology and drug screening. The attenuation of this strain enables it 
to be used in biosafety level 2 (BSL 2) containment rather than biosafety level 3 (BSL 3) 
which increases operator safety and enables the performance of experimental assays which 
otherwise are difficult under BSL 3 conditions. As a derivative of the H37Rv strain, studies 
on Mtb Bleupan can potentially generate findings in closer resemblance to the virulent parent 
strain in terms of cell metabolism, membrane remodeling and morphological changes upon 
stimulation by drug treatment. Recently, Vilchèze et al. generated triple auxotrophic MDR 
Mtb mutants with their drug-resistant and persistence characteristics well-retained, providing 
attractive candidates relevant to most types of MDR Mtb studies and circumventing the need 
for BSL 3 facilities275. 
Another merit of the Mtb Bleupan strain is its expression of the full luxCDABE operon 
from Photorhabdus luminescens276, giving rise to autoluminescence of luciferase in the 
bacteria. The biochemical requirements for light production including reduced flavin 
mononucleotide (FMNH2) cofactor and oxygen, are generated in the cytosol of mycobacteria 
growing aerobically277. In viable bacteria, the α and ß subunits of the heterodimeric catalase, 
luciferase, is encoded by luxA and luxB respectively; luxC, luxD, and luxE are responsible for 
the encoding of a reductase, transferase and synthase, respectively, to form the reaction 
substrate278. Bioluminescence is produced through the oxidation of FMNH2 using the 
endogenously generated long-chain fatty acid aldehyde substrate. Other transcriptional 
reporter strains based on fluorescent proteins, firefly luciferase (FFluc) and bacterial 
luciferase from Vibrio harveyi (luxAB) have been commonly employed in Mtb studies279-281. 
However, fluorescent reporters exhibit low signal-to-noise ratio in microtiter plates; 
luciferase enzymes FFluc and luxAB offer relatively higher signal-to-noise ratio but require 
the addition luciferin substrate which is time-consuming and destructive, leading to endpoint 
measurements282. Autoluminescent Mtb Bleupan precludes the need for substrate addition, it 
can therefore overcome these limitations and enables real-time in vitro and ex vivo monitor of 
antibiotics efficacy with high sensitivity260, 283. Furthermore, these Mtb Bleupan 
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characteristics also revealed their advantage over the conventional measurement of bacterial 
optical density or resazurin fluorescence in the detection of bacterial inhibitory activity of 
anti-TB agents. Detection of bacterial turbidity is a convenient method but it fails to 
distinguish dead and live cells, and the clumping nature of Mtb poses further issues. 
Moreover, without the need of resazurin dye addition, assay protocol can be simplified and 
any interaction between the dye and drug molecules can be avoided284. In fact, the changes in 
bacterial metabolism demonstrated in M. smegmatis revealed the ability of some antibiotics 
to trigger oxidative stress responses. Due to the sensitivity of resazurin dye to redox 
environment, detection of bioluminescence in Mtb Bleupan eliminates the uncertainties and 
therefore serve as a superior model.   
The aim of this chapter was to extend the investigation of bioefficacy of the combinations of 
existing anti-TB agents with D-LAK peptides to a series of MDR-TB clinical isolates. In this 
study, cytotoxicity of D-LAK peptides, rifampicin and isoniazid used alone or in combination 
was determined using 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
assay. Antimicrobial activity of D-LAK peptides and anti-TB agents, when used alone or in 
combination, were assessed in MDR-TB clinical isolates and Mtb Bleupan. In vitro bacterial 
inhibitory assay was performed on MDR clinical isolates and Mtb Bleupan; the inhibitory 
concentrations were detected by resazurin dye and bioluminescence respectively. In vitro and 
ex vivo mycobactericidal assay were also carried out on MDR clinical isolates and the results 
were determined by colony-forming unit (CFU) counting method. Time-kill assay against 
Mtb Bleupan by anti-TB agents alone and in combination was also performed through 





4.2.1 Cytotoxicity assay 
In this study, cytotoxicity of anti-TB agents alone and their combinations was assessed using 
3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay on A549 cells. 
D-LAK120-A demonstrated higher toxicity than D-LAK120-HP13 (Fig. 4.2). Both D-LAK 
peptides displayed significant toxicity (p < 0.0001) at 16 μM or above. D-LAK120-A 
displayed significant cytotoxicity at the concentration of 8 μM, resulting in 56.6 ± 7.7 % of 
viable cells, while the viability of cells treated with D-LAK120-HP13 at the same 
concentration was not significantly different from the control.  Both peptides were not 
cytotoxic at the concentration of 4 μM or below on A549 cells with cell viability over 90%. 
In a previous study, the cytotoxicity of D-LAK peptides was assessed on differentiated THP-
1 cells and mouse monocytic macrophage cell line RAW 264.7 using the lactate 
dehydrogenase (LDH) 259 and MTT assay188 respectively. Significant cytotoxicity was 
observed at concentrations ≥ 12.5 μM for D-LAK120-A and ≥ 3.13 μM for D-LAK120-HP13. 
Both studies suggested the peptides have low cytotoxicity on mammalian cells at 4 μM or 
below. Here, the IC50 of D-LAK120-A and D-LAK120-HP13 were found to be 7.89 ± 0.21 
μM and 12.2 ± 3.85 μM, respectively, on A549 cells. The cytotoxicity of rifampicin and 
isoniazid was also measured on A549 cells (Fig. 4.3A-B). No significant cytotoxic effect was 
demonstrated by the rifampicin and isoniazid up to 91.1 μM and 2190 μM, respectively. Cell 
viability significantly dropped to below 55% (p < 0.0001) when the cells were exposed to 
rifampicin at 182 μM or higher. In contrast, isoniazid did not induce any significant cytotoxic 






Figure 4.2 Cytotoxicity study of D-LAK peptides on A549 cells. The cells were incubated with 
D-LAK120-A or D-LAK120-HP13 at various concentrations for 24 h before MTT assay was carried 
out, data were presented as mean ± SD (n=3).  Significant difference was determined by two-way 
ANOVA analysis followed by Dunnett’s or Bonferroni’s Multiple Comparisons Test, ^ represents 




Figure 4.3 Cytotoxicity study of RIF (A) or INH (B) on A549 cells. The cells were incubated with the 
drug at various concentrations. MTT assay was carried out after 24 h of incubation. Data were 
presented as mean ± SD, (n=3).  Significant difference was determined by one-way ANOVA followed 





As reported in previous studies, the combination of D-LAK peptides with isoniazid reduced 
the effective concentration of both agents against MDR strain GB2259, therefore reducing the 
risk of toxicity. Combinations of D-LAK peptides (up to 8 μM) and rifampicin (up to 12.2 
μM) or isoniazid (up to 72.9 μM) were subjected to MTT assay after 24 h of incubation 
(Fig. 4.4 to 4.7). The studied concentration for the combinations was chosen based on their 
effective concentrations. For the combination of D-LAK120-A and rifampicin, no significant 
cytotoxicity was observed when the concentration of the peptide was used at 4 μM or below 
(Fig. 4.4). Interestingly, when the peptide concentration was increased to 8 μM, the 
combinations became cytotoxic except the one contained the highest concentration of 
rifampicin of 12.2 μM. Similar to D-LAK120-A in combination with rifampicin, when the 
peptide was combined with isoniazid, no significant cytotoxicity was observed when the 
concentration of the peptide was at 4 μM or below (Fig. 4.5). Significant cytotoxicity was 
demonstrated in this combination when the concentration of D-LAK120-A was used at 8 μM. 
No significant cytotoxicity was displayed by the combinations of D-LAK120-HP13 with 





Figure 4.4 Cytotoxicity study of combinations of D-LAK120-A and RIF on A549 cells. The cells were 
incubated with the combination of D-LAK120-A and RIF at various concentrations for 24 h before 
MTT assay was carried out, data were presented as mean ± SD, (n=3).  Significant difference was 
determined by one-way ANOVA analysis Test followed by Dunnett’s Multiple Comparisons Test, 
**p<0.01, ***p<0.001, ****p<0.0001 compared with untreated control. 
 
Figure 4.5 Cytotoxicity study of combinations of D-LAK120-A and INH on A549 cells. The cells were 
incubated with the combination of D-LAK120-A and INH at various concentrations for 24 h before 
MTT assay was carried out, data were presented as mean ± SD, (n=3).  Significant difference was 
determined by one-way ANOVA analysis Test followed by Dunnett’s Multiple Comparisons Test, 





Figure 4.6 Cytotoxicity study of combinations of D-LAK120-HP13 and RIF on A549 cells. The cells 
were incubated with the combination of D-LAK120-HP13 and RIF at various concentrations for 24 h 
before MTT assay was carried out, data were presented as mean ± SD, (n=3).   
 
 
Figure 4.7 Cytotoxicity study of combinations of D-LAK120-HP13 and INH on A549 cells. The cells 
were incubated with the combination of D-LAK120-HP13 and INH at various concentrations for 24 h 
before MTT assay was carried out, data were presented as mean ± SD, (n=3).    
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4.2.2 In vitro bacterial inhibitory assay of D-LAK peptides and anti-TB agents alone or in 
combinations against MDR clinical isolates, virulent Mtb H37Rv and Mtb Bleupan  
Resazurin microtiter assays (REMA) were performed to understand the in vitro bacterial 
inhibitory capacity of six different antimicrobial agents (two D-LAK peptides and four 
existing anti-TB drugs) on five Mtb strains (four MDR strains and the drug susceptible 
H37Rv) (Table 4.1). In addition, bioluminescence measurement was performed to evaluate 
the activity of these antimicrobial agents and delamanid on Mtb Bleupan. The minimum 
inhibitory concentration (MIC) of each anti-TB agent was defined either by the lowest 
concentration remained in blue in the REMA or 1-log reduction in bioluminescence as 
compared with untreated controls. Both D-LAK peptides did not show antimicrobial effect on 
any of the Mtb strain, even at their highest tested concentration of 128 μM. Higher 
concentration was not used due to the solubility issue in 7H9O medium.  As compared with 
the drug susceptible Mtb strain H37Rv, all the four MDR clinical isolates clearly 
demonstrated resistance towards the two first-line anti-TB drugs, rifampicin and isoniazid, as 
reflected by their much higher MICs. Potent bacterial inhibitory effect was shown by both 
first-line anti-TB agents against H37Rv. Their MIC values against H37Rv were found to be 
at least 25 times lower than that of MDR clinical isolates. Susceptibility of H37Rv towards 
both first-line drugs was significantly higher than that of Mtb Bleupan (p < 0.01) by student’s 
t-test.  
Capreomycin, a second-line anti-TB agent, demonstrated satisfactory inhibitory effect against 
all mycobacterial strains tested. The MICs of capreomycin ranged from 2.71 to 4.69 µM on 
different Mtb strains. On the contrary, colistin did not show any inhibitory effect on any of 
the Mtb strains, even at the highest studied concentrations. This observation was reasoned by 
the absence of lipooligosaccharides (LOS) target in Mtb for the action of the drug, therefore it 
was not studied further. In addition, Mtb Bleupan was shown to be susceptible to delamanid, 
a new FDA-approved MDR-TB drug, which was included as reference for its reported mode 




Table 4.1 MIC of anti-TB agents against drug-susceptible Mtb H37Rv and Mtb Bleupan strain and MDR clinical isolates 03M, 08M, 08MB and GB2.  MIC is the 
minimum inhibitory concentration defined by the lowest concentration remained in blue in the Resazurin microtiter assays or 1-log reduction in 
bioluminescence* as compared with untreated controls, expressed as mean ± SD, (n=3). 
Anti-TB agent 
MDR clinical isolates Drug-susceptible strains 
MIC (μM) 
03M 08M 08MB GB2 H37Rv Bleupan* 
D-LAK120-A >128 >128 >128 >128 >128 >128 
D-LAK120-HP13 >128 >128 >128 >128 >128 >128 
RIF >121 >121 14.2 ± 1.5 5.1 ± 2.2 0.190 0.5 ± 0.2 
INH 20.1 ± 2.6 >730 >730 >730 0.8 ± 0.3 6.9 ± 2.3 
CAP 4.7 ± 2.9 3.1 ± 1.2 3.3 ± 1.3 2.7 ± 1.8 4.1 ± 1.2 2.6 ± 0.9 
CST >86 >86 >86 >86 >86 >1730 
DLM -- -- -- -- -- 0.2 ± 0.1 
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The bacterial inhibitory efficiency of first-line anti-TB drugs and their combinations with 
D-LAK peptides were evaluated using chequerboard assay. Interactions between anti-TB 
agents were assessed and represented by the fractional inhibitory concentration index (FICI); 
it has been well-established that a FICI of < 0.5, indicative of a 4-fold reduction of MIC of 
each agent in the combination, is considered as synergistic interaction between two agents257. 
When D-LAK peptides were used in combination with rifampicin or isoniazid against 
MDR-TB strains, the FICIs were all < 1 (Table 4.2). The result suggested that D-LAK 
peptides exert at least additive effect with the two first-line drugs.  
D-LAK peptides in combination with rifampicin was shown to have a broader efficacy as 
indicated by their antimicrobial activity against all the studied MDR clinical isolates. Except 
the combination of rifampicin and D-LAK120-HP13 on the 08M strain, FICIs of D-LAK 
peptide in combination with rifampicin were all < 0.5, demonstrating their synergistic 
interaction on the MDR strains. This synergy of combinations also resulted in a drastic 
reduction of effective concentration of rifampicin, which was 2.5 to 40 times lower than 
when it was used alone. Moreover, being the most impervious strain, 08M strain was not 
susceptible to any single agent at the highest tested concentrations: D-LAK peptides at 128 
µM; rifampicin at 121 µM; or isoniazid at 730 µM. The growth of 08M strain was 
successfully inhibited by combining D-LAK120-A peptide (32 µM) and rifampicin 
(12.2 µM), showing the synergistic interaction of the two agents.  
D-LAK peptides in combinations with isoniazid were effective against 03M strain and 08MB 
strain in a synergistic manner, with a more potent effect on 08MB strain. In the combinations 
with either D-LAK peptides, effective concentration of isoniazid was reduced by 40 times 
and 4 times against 08MB and 03M respectively when compared with using isoniazid alone. 
FICI of D-LAK peptides in combination with isoniazid was not determined on 08M and GB2 
strains, as an inhibitory effect was not observed at their highest tested concentrations, i.e. D-
LAK peptide at 32 µM and isoniazid at 146 µM. Through understanding the nature of 
interaction of the combinations, this antibacterial assay has clearly demonstrated that 
combining D-LAK peptides with first-line anti-TB drugs, rifampicin and isoniazid, is a 




Table 4.2 Effect of D-LAK peptides in combination with RIF or INH against MDR clinical isolates. MIC is the minimum inhibitory concentration defined by the 
lowest concentration remained in blue in the resazurin microtiter assays, (n=3).   
 MIC in combination (μM) 
FICI Interaction 
Combination MDR strain D-LAK120-A D-LAK120-HP13 RIF INH 
D-LAK120-A + RIF 
03M 32  3.04  <0.28 synergistic 
08M 32  12.2  <0.35 synergistic 
08MB 32  3.04  <0.46 synergistic 
GB2 16  0.76  <0.28 synergistic 
D-LAK120-HP13 + RIF 
03M  32 3.04  <0.28 synergistic 
08M  32 48.7  <0.65 additive 
08MB  32 3.04  <0.46 synergistic 
GB2  32 0.76  <0.26 synergistic 
D-LAK120-A + INH 
03M 32   4.60 <0.48 synergistic 
08M >32   >146 ND1 -- 
08MB 16   18.25 <0.15 synergistic 
GB2 >32   >146 ND -- 
D-LAK120-HP13 + INH 
03M  32  4.60 <0.48 synergistic 
08M  >32  >146 ND -- 
08MB  8  18.3 <0.09 synergistic 
GB2  >32  >146 ND -- 




For Mtb Bleupan, bacterial inhibitory activity of combinations of D-LAK peptides with either 
rifampicin, isoniazid or capreomycin was determined by bioluminescence measurement 
(Table 4.3). The MIC50 of each anti-TB agent was determined using sigmoidal-response 
(variable slope) algorithm.  D-LAK peptides were ineffective against Mtb Bleupan when they 
were used alone. However, combinations of D-LAK peptides with anti-TB agents reduced 
the MICs of all the agents compared to that when they were used alone. Notably, the 
concentration of D-LAK peptides used in combination was reduced by 30-fold compared to 
the highest concentration tested for single peptides. With a small amount of D-LAK peptides, 
substantial reductions in effective concentration of the first-line anti-TB drugs were achieved; 
with a four-fold and two-fold reduction for rifampicin and isoniazid, respectively. Conversely, 
the reduction in capreomycin concentration when used in combinations with the D-LAK 
peptides was not evident. Combinations of D-LAK peptides with rifampicin displayed a 
highly synergistic relationship represented by an FICI of < 0.043 with D-LAK120-A, and < 
0.087 with D-LAK120-HP13 (Table 4.4). Comparing with the results observed in MDR-TB 
isolates, this high-level of synergy might be attributed to the intrinsic drug susceptibility of 
Mtb Bleupan. Modest synergy was observed when D-LAK peptides were used in 
combination with isoniazid, of which D-LAK120-HP13 demonstrated a better effect with a 
FICI of < 0.5. On the other hand, the interaction of D-LAK peptides with capreomycin was 
additive, which suggests that the D-LAK peptides were not as useful in assisting the action of 




Table 4.3 MIC50 of anti-TB agents alone and in combination against Mtb Bleupan strain. MIC50 was determined using sigmoidal-response (variable slope) 
algorithm, expressed as mean ± SD, (n=3). 
Anti-TB agent  MIC50 alone (µM) 
MIC50 in combination (µM) 
D-LAK120-A D-LAK120-HP13 RIF INH CAP 
D-LAK120-A >128   0.27 ± 0.11 0.67 ± 0.29 0.31 ± 0.06 
D-LAK120-HP13 >128   0.57 ± 0.10 3.91 ± 3.01 0.66 ± 0.34 
RIF 0.09 ± 0.01 0.02 ± 0.01 0.02 ± 0.01    
INH 3.72 ± 0.95 1.46 ± 0.58 1.67 ± 0.07    
CAP 0.41 ± 0.09 0.40 ± 0.11 0.38 ± 0.25    
CST >1730      
DLM 0.09 ± 0.02      
 
Table 4.4 FIC index of D-LAK peptides in combination with various antibiotics against Mtb Bleupan strain. 
Anti-TB agent  RIF INH CAP 
D-LAK 120-A <0.043 ± 0.016 <0.58 ± 0.04 <0.82 ± 0.03 




4.2.3 In vitro and ex vivo mycobactericidal activity of D-LAK peptides, rifampicin or 
isoniazid alone or in combinations against Mtb clinical isolates 
In the previous section, combinations of D-LAK peptides with rifampicin and isoniazid 
demonstrated significant inhibitory effect on the growth of MDR-TB strains in vitro using the 
REMA colorimetric assay. In particular, a potent antimicrobial activity was observed on 03M 
and 08MB strains, as reflected in their respective FIC indices. As a result, these combinations 
were subjected to further studies to evaluate their mycobactericidal ability in vitro and ex vivo. 
When D-LAK peptides were used in combination with rifampicin or isoniazid, their effective 
concentration was reduced to 16 to 32 μM. However, at these concentrations, the peptides 
were cytotoxic in mammalian cells. In order to reduce toxicity, concentration of peptides 
used in the combination in the mycobactericidal assay was conducted at 8 μM or below.  
Both 03M and 08MB strains were incubated with different concentrations of D-LAK 
peptides, rifampicin or isoniazid, either alone or their combinations, for seven days. Since 
03M demonstrated a higher sensitivity towards isoniazid and 08MB demonstrated higher 
sensitivity towards rifampicin, the mycobactericidal activity of combinations of D-LAK 
peptides with isoniazid and rifampicin were evaluated on 03M and 08MB, respectively. The 
growth of challenged bacteria was then evaluated on the agar plates by counting the colony-
forming unit (CFU), a test to determine any bactericidal activity of the combination. For 03M 
strain, both D-LAK peptides and isoniazid demonstrated in vitro bactericidal effect in a 
concentration-dependent manner when they were used alone (Fig. 4.8). Significant reduction 
of bacterial load was shown in D-LAK120-A at 256 μM, D-LAK120-HP13 at 128 μM or 
above, and isoniazid at 22 μM (1x MIC) or above.  When isoniazid was used alone at 1x MIC, 
almost 1-log reduction of bacteria load was achieved. At 2x MIC, a complete eradication of 
the bacteria was almost attained. Bactericidal effect was also seen in the combination of D-
LAK peptides and isoniazid, in which both agents were used at a lower concentration than 
when they were used alone. Prominent killing effect was observed when the combination 
contained 18 μM of isoniazid, regardless of the concentration of D-LAK peptides. 
Specifically, the combinations of isoniazid with either D-LAK120-A (at 2 μM) and D-
LAK120-HP13 (at 4 μM) were more effective than isoniazid alone at 1x MIC, leading to 1-
log reduction in bacterial load comparing with the untreated control. Moreover, the 
combinations with D-LAK120-HP13 at 4 μM achieved the greatest reduction of bacterial 
load without exhibiting any cytotoxicity. This supports that D-LAK peptides have an 
assisting character that enhances the action of isoniazid; when used in combination, they 
98 
 
result in the same synergistic interaction deduced from the chequerboard assay. Nonetheless, 
the two other combinations where isoniazid concentration was reduced to half and D-LAK 
peptides concentrations were increased to 32 μM, the killing mechanism was completely 
ineffective. These findings suggest that isoniazid serves as the active agent in the 
combination.  
 
Figure 4.8 In vitro mycobactericidal study of anti-TB agents against MDR-TB 03M strain. The 
bacteria were challenged with D-LAK peptides or INH alone or their combinations at various 
concentrations for 7 days before plating was carried out, data were presented as mean ± SD, (n=3). 
Concentrations for INH are shown in boldface. Significant difference was determined by one-way 
ANOVA analysis test followed by Tukey’s Comparisons Test, *p<0.05, **p<0.01, compared to the 
untreated control.  
 
In vitro mycobactericidal efficiency of D-LAK peptides and rifampicin, either alone or in 
combination, were studied on MDR-TB strain 08MB (Fig. 4.9). Concentration-dependent 
killing effect was observed when the anti-TB agents were used alone. Compared with the 
untreated control, significant reduction (p < 0.0001) in bacterial growth resulted at all 
treatments. Since rifampicin at ½ x MIC (7.3 μM) achieved significant mycobactericidal 
efficiency, lower rifampicin concentrations at 3 μM and 6 μM were employed in 
combinations with D-LAK peptides.  
Amongst all the combinations with D-LAK peptides, those with higher concentration of 
D-LAK peptides or rifampicin displayed a higher mycobactericidal ability than those with 
lower concentration of both agents. In particular, D-LAK120-HP13 combined with 6 μM of 
rifampicin displayed significantly higher Mtb killing capacity than when combined with 3 
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μM of rifampicin (p < 0.01), and this also observed when D-LAK120-HP13 was increased to 
8 μM. D-LAK120-A at 8 μM with rifampicin at 6 μM achieved the highest mycobactericidal 
ability, reducing almost 1-log of bacterial load as compared with rifampicin when used alone 
at ½ x MIC, although the difference was not statistically significant. This shows that with the 
addition of D-LAK peptide, similar or higher Mtb killing ability can be achieved with a 
reduced amount of rifampicin concentration. This indicates the possible assisting role of D-
LAK peptides in potentiating mycobactericidal activity of rifampicin.  
Overall, the studies of D-LAK peptides in combination with isoniazid against 03M and D-
LAK peptides in combination with rifampicin against 08MB, demonstrated the ability of D-
LAK peptides to further potentiate the potency of rifampicin and isoniazid against the more 
sensitive MDR Mtb strains. 
  
  
Figure 4.9 In vitro mycobactericidal study of anti-TB agents against MDR-TB 08MB strain. The cells 
were challenged with D-LAK peptides or RIF in alone or their combinations at various concentrations 
for 7 days before plating was carried out, data were presented as mean ± SD, (n=3). Concentrations 
for RIF are shown in boldface. Significant difference was determined by one-way ANOVA analysis 
Test followed by Tukey’s Comparisons Test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, 




Ex vivo studies were carried out using combinations of D-LAK peptides with isoniazid 
against 03M strains (Fig. 4.10). After the infection of differentiated THP-1 cells by 03M 
strain, the combination was added to the infected cells and incubated for seven days. 
Mycobactericidal capacity of combinations was then assessed by CFU counting method. D-
LAK peptides in combination with isoniazid demonstrated higher mycobactericidal 
efficiency than when each anti-TB agent was used alone. Treatment with isoniazid alone at 
18 μM, or combinations with D-LAK120-A or D-LAK120-HP13 at 1 μM, 2 μM and 4 μM 
resulted in significant reduction of bacterial load when compared with the untreated control. 
Albeit modestly, combining 4 μM of D-LAK120-A or D-LAK120-HP13 with isoniazid 
attained a lower bacterial load in which the latter achieved 1-log bacterial reduction as 
compared with isoniazid alone at the same concentration. However, the difference was not 
statistically significant. Furthermore, to understand the role of anti-TB agents in the 
combination, a high peptide concentration of 32 μM was combined with a low isoniazid 
concentration at 9 μM. This combination did not demonstrate mycobactericidal activity. 
Overall, combinations of D-LAK peptide at 4 μM with isoniazid were shown to exhibit the 
best mycobactericidal capabilities.   
 
Figure 4.10 Ex vivo mycobactericidal study of anti-TB agents against MDR strain 03M-infected 
differentiated THP-1 cells.  The infected cells were challenged with D-LAK120-A or its combinations 
with INH or D-LAK120-HP13 or its combinations with INH at various concentrations for 7 days 
before plating was carried out, data were presented as mean ± SD, (n=3). Concentrations for INH are 
shown in boldface. Significant difference was determined by one-way ANOVA analysis Test followed 




4.2.4 In vitro time-kill assay against Mtb Bleupan 
To determine the bactericidal activity of each of the anti-TB agents (D-LAK120-A, 
D-LAK120-HP13, rifampicin, isoniazid, capreomycin, delamanid and colistin), time-kill 
assays against Mtb Bleupan were performed at their respective 0.5x, 1x, 2x or 4x MICs 
(Fig. 4.11). Rifampicin, isoniazid and capreomycin showed a concentration-dependent effect 
against Mtb Bleupan). The rapid killing effect of capreomycin and rifampicin could already 
be observed on day 1. More than 1-log reduction in bacterial load (≥ 99% killing) was 
achieved by 2x and 4x MICs of rifampicin or capreomycin on day 7, which was the end-point 
of the study. Rifampicin was more effective than isoniazid in killing Mtb Blueplan at all 
tested concentrations. Delamanid had the highest bacterial killing efficacy, reducing 1.5-log 
of Mtb Blueplan on the first day at 1x, 2x and 4x MIC but did not result in eradication of Mtb 
Bleupan at the end point of the study. D-LAK120-A demonstrated a higher killing capacity 
relative to D-LAK120-HP13 at their highest tested concentrations. 
Furthermore, the killing assays were carried out to evaluate the efficiency of the 
combinations between D-LAK peptides and rifampicin or isoniazid (Fig. 4.12). When used 
alone at 4x MIC, both rifampicin and isoniazid can effectively eliminate almost 1-log of 
bacterial population of Mtb Bleupan by day 7. Interestingly, the addition of D-LAK peptides 
could reduce the amount of rifampicin or isoniazid in order to achieve a similar killing 
efficacy at the end of the study. The concentration of rifampicin required was reduced by 
two- to four-fold whereas that of isoniazid was reduced by two-fold. The combination of D-
LAK peptides and rifampicin was capable of achieving more consistent and rapid killing 
effect than D-LAK peptides with isoniazid; this combination may also be considered as more 
beneficial for treatment as both the peptide and rifampicin were used at lower concentrations. 
The result agrees with the highly synergistic interaction of D-LAK peptides and rifampicin 




Figure 4.11 Time-kill curves of anti-TB agents when used alone against Mtb Bleupan.  (A) D-LAK120-
A, (B) D-LAK120-HP13, (C) rifampicin, (D) isoniazid, (E) capreomycin, (F) delamanid and (G) 
colistin at various concentrations (0.5x, 1x, 2x and 4x MIC) were incubated over 7 days with Mtb 




Figure 4.12 Time-kill curves of combinations between D-LAK peptides and RIF or INH against Mtb 
Bleupan.  D-LAK120-A or D-LAK120-HP13 in combination with RIF or 4x MIC RIF alone (A), D-
LAK120-A or D-LAK120-HP13 in combination with INH or 4x MIC INH alone (B) were incubated 





Previous studies on D-LAK peptides showed that they possessed a de-clumping effect on 
mycobacteria. They were also able to inhibit the growth of various Mtb strains including 
drug-susceptible H37Rv strain, MDR clinical isolates GB2 and XDR clinical isolate WYC-
11 at a concentration-dependent manner259. Other studies using various biophysical 
techniques such as fluorescence spectroscopy and atomic force microscopy have also shown 
that high concentration of AMPs is generally required to cause bacterial death via membrane 
disruption mechanism285. D-LAK peptides induced toxicity in mammalian cells at high 
concentration while the non-toxic concentration was ineffective against Mtb clinical 
isolates259. However, D-LAK peptides were able to potentiate the activity of isoniazid against 
MDR clinical isolate when they were used in combination259. The potential synergistic 
interaction of the combination can reduce the effective concentration of both D-LAK 
peptides and the first-line anti-TB drug.  The aim of this chapter was to investigate the 
potential of combining D-LAK peptides with first-line anti-TB agents, rifampicin or isoniazid, 
by evaluating the cytotoxicity of the combinations in mammalian cells, and understanding the 
nature of interaction of the combinations against a series of MDR-TB clinical isolates and the 
severely attenuated Mtb Bleupan strain.  
Here, a number of key findings from the evaluation of antimicrobial activity of anti-TB drugs, 
D-LAK peptide and their combinations are highlighted. D-LAK peptides alone were not 
effective in inhibiting the growth of MDR clinical isolates or Mtb Bleupan but they were 
shown to be highly synergistic with rifampicin when used in combinations. Moderate synergy 
was also shown against Mtb Bleupan when D-LAK peptides were used in combinations 
isoniazid, and additive effect was shown in combination with capreomycin. In the CFU 
counting assays, the combinations of D-LAK peptides with isoniazid and rifampicin 
demonstrated mycobactericidal activity against MDR Mtb 03M and 08MB strains, 
respectively. The use of combinations also resulted in a reduced effective concentration of 
both the peptides and rifampicin or isoniazid in vitro and ex vivo. Time-kill assay revealed 
that high killing efficacy on Mtb Bleupan was achieved using at least two-fold reduced 
concentration of rifampicin or isoniazid when they were combined with D-LAK peptides.  
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MDR-TB clinical isolates exhibit high tolerance towards D-LAK peptides and anti-TB drugs 
whereas both Mtb Bleupan and drug-susceptible H37Rv displayed susceptibility towards first-
line anti-TB drugs 
Rifampicin and isoniazid are potent antibiotics against Mtb. Rifampicin inhibits the activity 
of the essential DNA-dependent RNA polymerase by binding to the ß-subunit (rpoB). This 
leads to the physical blockage of RNA chain growth, suppressing bacterial protein 
synthesis286. Isoniazid is a prodrug that requires the activation by intracellular catalase-
peroxidase which is expressed by katG. The catalase-peroxidase plays a critical role in Mtb to 
counteract the oxidative stress experienced by the bacteria. Isoniazid is designed to be 
oxidized via the action of this peroxidase to produce the active mycobactericidal isonicotinic 
acid under aerobic conditions. It inhibits the synthesis of mycolic acid through targeting the 
inhA carrier protein involving in fatty acid synthesis287. Therefore, genetic mutation at the 
rpoB, katG and inhA genes are commonly responsible for the resistance of Mtb towards 
rifampicin and isoniazid. In addition to the genetic mutations reported in resistant Mtb strains, 
alteration in mycobacterial membrane is another way which resistance is developed288. This 
resistance mechanism might also account for the multidrug-resistant phenotype towards first-
line anti-TB drugs rifampicin and isoniazid since both drugs act on the intracellular targets of 
mycobacteria.  It is hypothesized that the surface activity of the D-LAK peptides could 
intervene with the cell wall of drug-resistant Mtb strains potentially causing bacterial damage, 
thereby facilitating drug permeation.  
To test this hypothesis, in vitro and ex vivo mycobactericidal assays were previously 
performed against Mtb clinical isolates using D-LAK120-A, D-LAK120-HP13, rifampicin 
and isoniazid, either alone or in combinations. By evaluating the growth and morphology of 
Mtb colonies using light microscopy, it was reported that the de-clumping effect of D-LAK 
peptides was observed at a concentration-dependent manner. However, none of the D-LAK 
peptides managed to achieve complete eradication of Mtb clinical isolates at the highest 
tested concentration of 100 µM259. In the present study, bacterial inhibitory activity 
determined by a colorimetric resazurin assay also revealed the high tolerance of Mtb strains 
towards D-LAK120-A and D-LAK120-HP13 up to the concentration of 128 μM. This shows 
that although the action of D-LAK peptides on the mycomembrane has led to the de-
clumping effect on Mtb strains, the concentration might not be high enough to cause 
membrane disruption289 and induce mycobacterial lysis. It was suggested that a threshold 
concentration is critical for AMPs to exert detrimental actions on bacterial membrane290. This 
threshold concentration is determined by the intrinsic ability of the peptide to induce self-
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assembly as well as the extrinsic factors such as bacterial membrane composition and fluidity. 
The distinct feature of high-mycolic acid content in Mtb cell envelope renders its 
comparatively low membrane fluidity than Gram-positive and Gram-negative bacteria291. 
This may explain the high tolerance of Mtb strains towards the D-LAK peptides, unlike the 
high efficacy of these peptides against Pseudomonas aeruginosa and Escherichia coli. The 
membrane permeabilization activities of AMPs have been extensively reported19, 292. They 
typically act on the membrane through mechanisms such as thinning, pore formation or 
complete disintegration. The binding between cationic AMPs with the negatively charged 
components on Mtb leads to membrane disruption194. Besides, AMPs can interact with 
membrane surface cell-wall protein such as ATPase and inhibit mycobacterial growth200. 
Apart from destabilization of bacterial membrane, AMPs can also adopt different strategies to 
interact with lipid membrane293. Therefore, the mechanism of D-LAK peptide might not be 
entirely depending on direct disruption but rather to interact with membrane components and 
alter its permeability.   
Notably, the phenotypic resistance towards either isoniazid or rifampicin varies among the 
MDR-TB strains; 03M and 08M strains demonstrated high-level resistance towards 
rifampicin, whereas 08M, 08MB and GB2 strains demonstrated high-level resistance towards 
isoniazid. Target gene mutation associated with the mode of action of these drugs have been 
regarded as the main resistance mechanism. However, alternative mechanisms such as 
overexpression of efflux pump genes has shown increased resistance level in MDR-TB 
clinical isolates119. Moreover, some of the efflux pumps were found to express at higher 
levels in the presence of antibiotic stress112. A better understanding of the expression of efflux 
pump in the MDR-TB clinical isolates can be gained through sequencing of mycobacterial 
RNA. All the MDR-TB clinical isolates in this study were susceptible to the capreomycin, a 
second-line anti-TB agent. Capreomycin, a cyclic peptide antibiotic, targets the intracellular 
ribosomal subunit blocking protein synthesis in mycobacteria294. Capreomycin possesses 
multiple targets which interacts with tlyA-encoded methylations on riboses of both 16S and 
23S rRNA, giving rise to its high potency against MDR-TB strains123. Another cationic cyclic 
AMP colistin, a powerful antibiotic against Gram-negative bacteria, has shown to have 
inhibitory activities towards mycobacteria295, 296 but its clinical use is limited by the high MIC 
and systematic toxicity concerns. Concentration up to 512 μg/ml was reported for colistin to 
exert its effect on Mtb strain while sterilization was not achieved297. Colistin targets primarily 
the lipopolysaccharide (LPS) in bacterial outer membrane. It is an antibiotic primarily active 
against infection caused by Gram-negative bacteria including Pseudomonas aeruginosa, 
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Escherichia coli and Acinetobacter baumannii298. Since LPS is not present in cell envelope of 
Mtb strains299, treatment with colistin on Mtb did not result in any inhibitory effect at the 
highest tested concentration of 86 μM in this study.   
 
Synergy detected in combinations of first-line anti-TB drugs with D-LAK peptides 
Although the D-LAK peptides were not efficient against MDR-TB clinical isolates as a single 
agent, it could be used to potentiate the anti-TB efficacy of conventional antibiotics. Similar 
strategies have been demonstrated by various groups using other AMPs222, 261. Thus, 
combinations of D-LAK peptides and rifampicin or isoniazid were evaluated for their 
efficacy against MDR-TB clinical isolates using chequerboard assay. It was previously 
shown in a CFU counting assay that D-LAK120-A and D-LAK120-HP13 could increase the 
potency of isoniazid against MDR-TB strain GB2 in vitro as compared with isoniazid when 
used alone259. The results of the present study showed the efficacy of the combinations 
towards three additional MDR-TB clinical isolates, 03M, 08M and 08MB strains.  
The interaction between two agents in combinations fundamentally denotes by the FICI in 
which ≤ 1.0 is “synergy” and > 2.0 “antagonism”. However, taken into account the possible 
dilution error, it is later defined that “synergy” is < 0.5, “antagonism” is > 4.0 and “additive” 
is between 0.5-4.0300. Strong synergistic interaction was detected in the combinations of 
D-LAK peptides with rifampicin against all MDR-TB strains. D-LAK peptides in 
combination with isoniazid also displayed similar synergistic effect against MDR-TB strains 
03M and 08MB, denoted by FICI < 0.5. No antagonism was resulted in any of the 
combinations. Synergistic effect of AMPs and conventional antibiotics is suggested to be 
associated with the strong membrane-peptide interaction, leading to the increase in 
membrane permeability and thereby improving the accessibility of drug molecules19. Khara et 
al. has shown that a novel peptide M(LLKK)2M acts synergistically with rifampicin against 
rifampicin-resistant Mtb strain, possibly as a consequence of peptide-mediated action on the 
mycobacterial membrane261. Similar findings using combination treatment of AMPs, hbD-1 
or PG-1, with isoniazid also resulted in the reduced growth of MDR-TB strain RM22 when 
compared with individual drug treatment222. The de-clumping effect exhibited by the D-LAK 
peptides against Mtb clinical isolates indicates that their interaction with mycobacterial cell 
wall might be an important mechanism which led to the reduction in bacterial load. Since 
MDR-TB strain can develop resistance by decreasing cell wall permeability to antibiotics, the 
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synergy of the present combinations suggests that the D-LAK peptides possibly exert a 
membrane active action on the mycobacterial cell envelope as demonstrated through its de-
clumping ability, resulting in the entry of higher amount of rifampicin or isoniazid into the 
intracellular environment, facilitating them to reach their target sites of action.  
Interestingly, combinations of D-LAK120-A or D-LAK120-HP13 with isoniazid was 
effective against 03M and 08MB strains but not against 08M or GB2 strains. As reference to 
the antibiogram (shown in Chapter 3), the MDR-TB strains 08M and GB2 strains are 
streptomycin-susceptible whereas 03M and 08MB strains are streptomycin-resistant. Drug 
resistance acquired by mycobacteria is believed to be associated with a reduction in their 
fitness17. Studies have demonstrated a marked decrease in virulence or growth yield/rate of 
certain mycobacterial strains harboring resistance towards rifampicin, isoniazid, 
aminoglycosides and fluoroquinolones301, 302. Mutations leading to significant effect on 
fitness in streptomycin-resistant strains have been reported previously303. It was shown that 
the rpsL gene (Lys42→Asn) mutation significantly reduced fitness and virulence in 
streptomycin-resistant strains in vitro304, 305. Consequently, the increase in susceptibility of 
03M and 08MB strains towards D-LAK peptide and isoniazid combinations might possibly 
be explained by their reduced fitness due to the acquired streptomycin resistance. 
Furthermore, the fact that 08M and GB2 displayed high MICs towards isoniazid might 
suggest multiple mutations306, 307 acquired by these strains such as abrogation of drug 
activation or mutation of drug target which might inactivate isoniazid molecules that have 
gained entry into the bacteria.  
More importantly, by combining D-LAK peptides with antibiotics, the effective 
concentrations of both agents could be drastically reduced, as much as 40-fold.  This could 
lead to a reduction in overall cytotoxicity and enhanced bacterial inhibitory activity. 
Altogether, these results suggest that D-LAK peptides effectively enhanced the action of 
rifampicin and isoniazid towards the resistant Mtb strains potentially through their 
membrane-active action.  
 
Combinations of anti-TB drugs with D-LAK peptides at non-toxic concentration demonstrated 
in vitro and ex vivo mycobactericidal effect  
Following the demonstration of inhibitory effect of the combinations on Mtb, their 
mycobactericidal efficiency was also assessed. D-LAK peptides revealed the significant 
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mycobactericidal effect in vitro on two MDR-TB clinical isolates, 03M and 08MB, at high 
concentrations (≥ 128 μM). In vitro mycobactericidal assay revealed that rifampicin and 
isoniazid at 1x MIC could achieve almost 1-log reduction of both MDR-TB strains. This 
indicated the bactericidal effect of the first-line anti-TB drugs against replicating Mtb42. 
D-LAK peptides in combinations with rifampicin or isoniazid demonstrated effective 
mycobactericidal activity against MDR-TB, 03M and 08MB strains, in vitro. The results 
provided further evidence for the assisting role of D-LAK peptides. D-LAK peptides at low, 
non-toxic concentrations facilitated the action of isoniazid and rifampicin to eliminate the 
MDR-TB strains at higher efficiency than when either drug was used alone. Moreover, the 
increase in concentration of D-LAK peptides enhanced the bactericidal effect of the 
combinations, suggested that an optimal peptide concentration is a crucial factor to obtain an 
effective combination. Besides, these findings demonstrated the antibiotics acts as the active 
agent in the combinations to target the survival of bacteria. D-LAK peptides work within a 
narrow window, because of its toxic effect when used at high concentration. Therefore, the 
concentration of isoniazid has become critical and it determines whether the combinations 
work efficiently and exhibit mycobactericidal effect. This suggests the positive cooperativity 
of D-LAK peptides to promote the action of antibiotics while reducing their effective 
concentration, potentially delaying the development of drug resistance. 
On the other hand, as observed from the ability of D-LAK peptides to break down the 
clumping  Mtb, another possible mechanism of action of the peptides may be ascribed to their 
interaction with the mycobacterial cell surface components such as trehalose dimycolate 
(TDM). Mtb possess cyclopropanated TDM, enables the aggregation of mycobacterial cells 
in a tight and definite order, forming structures known as cords69. This cording is considered 
as a virulence factor in Mtb. The inability to form cords impaired virulence of Mtb in mice308 
and increased sensitivity to rifampicin309. Interaction of D-LAK peptides with cell surface 
component might intervene with the cord structure of Mtb, affecting the packing of 
mycomembrane and in turn alters membrane permeability to antibiotics.  
Also, different performances of D-LAK120-A and D-LAK120-HP13 peptides in enhancing 
bactericidal efficacy in combinations observed in this study suggests the association between 
the potency of D-LAK peptide and the distinct cell wall properties that are known to exist in 
different Mtb strains. Overall, D-LAK120-HP13 displayed a better safety profile and better 
bacterial inhibitory performance in combination with isoniazid against MDR-TB. This might 
be due to the incorporation of proline residue, as reported to reduce hemolytic potential310 on 
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one hand, while on the other it increased the peptide conformation flexibility to facilitate 
penetration and disruption action185. The importance of proline hinge on cell penetration 
efficiency and antimicrobial potency was also shown in the structure-activity analysis of 
buforin II186. 
With the effective concentration obtained for both D-LAK peptides and isoniazid against 
MDR-TB 03M strain, ex vivo mycobactericidal assay was performed to assess the 
intracellular anti-TB capacity of the combinations. Differentiated THP-1 cells have been 
shown as a good model for the study of intracellular residing Mtb311. THP-1 cells infected 
with MDR-TB 03M strain was treated with D-LAK120-A, D-LAK120HP13 and isoniazid, 
either alone or in combinations. Among all the treatments, D-LAK peptides in combination 
with isoniazid were found to demonstrate the highest potency, achieving a much greater 
reduction in drug-resistant bacterial load, when compared with isoniazid used alone. This 
demonstrated the ability of D-LAK peptides to facilitate drug action intracellularly at non-
toxic concentrations. In addition, this inefficiency of isoniazid alone can be due to the action 
of efflux pumps in MDR-TB clinical isolates. Jaiswal et al.312 investigated the effect of efflux 
pumps in Mtb clinical isolates and reported a reduced in MIC towards isoniazid in the 
presence of efflux pump inhibitors (verapamil, chlorpromazine and reserpine). Further, an 
increased expression of efflux candidate genes such as Rv0194, Rv2688c and Rv1634 were 
found in XDR-TB as compared with drug-susceptible clinical isolates, indicating the 
contributing role of efflux pump to drug resistance313. Since MDR-TB strains have been 
shown to express efflux pump genes constitutively through chromosomal mutations118, 
addition of D-LAK peptides might provide a route to overcome the efflux of isoniazid by 
increasing membrane permeability to promote drug influx or disrupting the electron transport 
chain314 which could in turn affect the function of efflux pumps, therefore sustaining the 
killing action of the drug.  
 
D-LAK peptides combination with rifampicin reveals the highest potency against Mtb Bleupan  
Combination drug treatment, as the cornerstone of anti-TB therapy, delays the emergence of 
drug resistance315 and also reduce effective concentration of each agent to lower the overall 
toxic effects. The combinations of D-LAK peptides with rifampicin or isoniazid 
demonstrated higher potency than combination with capreomycin against Mtb Bleupan. As 
reflected in the FICI, highly synergistic interaction was observed between both D-LAK 
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peptides and rifampicin, followed by D-LAK120-HP13 with isoniazid. Combinations of D-
LAK120-A with isoniazid and the two D-LAK peptides with capreomycin were shown to 
have additive effect. This is primarily ascribed to the high sensitivity of H37Rv towards 
rifampicin and isoniazid than capreomycin. Comparing between isoniazid and rifampicin, 
when they were used in combination with D-LAK peptides, their effective concentration was 
reduced by two and four folds, respectively. Yuan et al.316 reported the association of 
increased antibiotics susceptibility with the changes in the cell wall composition of Mtb. 
Complete replacement of keto-mycolate with methoxy-mycolate in a recombinant Mtb strain 
was found to be hypersensitive towards the hydrophobic rifampicin and the moderately 
hydrophobic ampicillin but not the hydrophilic isoniazid. This suggests the disturbance on 
mycomembrane affects the permeability of hydrophobic drugs preferably. AMPs have been 
demonstrated to improve the action of rifampicin through their membrane active actions, 
promoting entry of rifampicin and therefore their accessibility to intracellular targets317, 318. 
Anantharaman et al.319 reported the synergism between rifampicin and de novo-designed 
AMPs, namely ΔFm, ΔFmscr, and Ud, promoting drug access into E. coli via the aid of the 
AMPs’ membrane active action. Slama et al.309 demonstrated the inhibition of the formation 
of a fourth cyclopropanated segment in a Mtb mutant leading to reduced cord forming ability 
and lower tolerance to rifampicin. The lipophilic nature of rifampicin enables the drug to 
transverse across the lipid rich mycomembrane into the intracellular environment. On the 
contrary, isoniazid is a hydrophilic drug which is reported to gain access into the cell through 
the porin channels on Mtb17. Possible membrane active action of D-LAK peptides could 
increase the membrane permeability, reducing the resistance for the entry of rifampicin, 
whereas isoniazid and capreomycin could not gain the benefit to the same extent. On the 
other hand, Jackson et al.80 also suggested that isoniazid, with its small and non-ionized 
character at pH between 6-9, is plausible to diffuse through lipid membranes as shown in a 
liposome swelling experiment. It is however anticipated that mycolic acid layer would render 
higher resistance for the passive diffusion of isoniazid and therefore the synergy with D-LAK 
peptides was modest. Moreover, action of capreomycin was not promoted in the combination 
with D-LAK peptides, which might be due to its different uptake mechanism from isoniazid. 
Although the explicit role of each type of mycobacterial porins is yet to be verified, uptake of 
hydrophilic molecules of different sizes is believed to be mediated using different channels320. 
The existence of a cationic-selective porin with a main conductance of 0.7 nS was reported to 
have transport properties on Mtb and is permeable to large, hydrophilic antibiotics such as 
capreomycin321. These findings revealed that D-LAK peptides are highly likely to increase 
112 
 
mycomembrane permeability facilitating the diffusion of hydrophobic and possibly small 
hydrophilic drug into Mtb Bleupan whereas complete membrane disruption was not attained.  
In addition, isoniazid displayed concentration-dependent rapid killing of actively growing 
bacteria while the residual non-replicating bacteria remain unaffected322. Combination of 
D-LAK peptide to isoniazid achieved similar killing effect at a reduced concentration of 
isoniazid (two-fold reduction), this suggested the action of D-LAK peptide to improve the 
drug performance perhaps through the enhancement of drug entry to active bacteria and also 
possible by interacting with the non-replicating bacteria leading to re-sensitization. Unlike 
isoniazid, the concentration- and time- dependent killing effect of rifampicin was reported in 
previous a pharmacokinetic study323. This effect was also demonstrated in the killing 
efficiency assay. The combination with D-LAK peptide at non-toxic level effectively reduced 
effective concentration of rifampicin by at least two-fold. Towanda et al.324 studied the 
relationship between rifampicin exposure and microbial killing using a pharmacokinetic-
pharmacodynamic model of Mtb. The results indicated that dosage of rifampicin higher than 
the current regimen (600 mg/day) could optimize the effect of rifampicin although it might 
not be tolerable by all patients. This reveals that D-LAK peptides have the potential to 
enhance the effect of rifampicin through maximizing the tolerable range of concentration. 
More importantly, since higher concentration of rifampicin is also likely to suppress the 
selection of resistance, the combination with D-LAK could possibly delay the emergence of 
rifampicin resistance. Delayed rifampicin resistance was also demonstrated in the synergistic 
AMP combination against M. smegmatis324. Future work to investigate the ability of D-LAK 
peptides in lowering the chance of drug resistance emergence can further unmask its potency 
in combating Mtb and MDR-TB clinical isolates. 
 
Higher tolerance of Mtb Bleupan towards rifampicin and isoniazid due to disparate culture 
conditions 
Compare with the virulent H37Rv, Mtb Bleupan displayed higher MICs towards rifampicin 
and isoniazid. This might be due to the differences in growth conditions between solid and 
broth medium as well as the treatment procedure to prepare for the inoculum. The use of 
glass beads for the de-aggregation of virulent H37Rv colonies from solid medium possibly 
induced mechanical disturbance to the outermost capsule layer of the bacteria, leading to the 
higher permeability of the drugs. Notably, the MICs of rifampicin and capreomycin against 
Mtb Bleupan are comparable to the reported in vitro MIC values in other studies on H37Rv42 
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while that of isoniazid was found to be much higher. This is very likely attributed to the static 
culture condition of Mtb Bleupan and the prolonged incubation time of six weeks. Mtb 
Bleupan was grown in broth medium without agitation, this might limit the availability of 
oxygen for a sub-population of bacteria albeit the additional aeration and vortexing 
performed twice-weekly throughout the incubation period. Mtb is known to possess 
numerous response and resistance mechanisms to adapt to changes or stress in the 
surroundings17. This poses the chance for a subset of bacteria to develop phenotypic-derived 
drug resistance conferring higher tolerance to anti-TB drugs325. This might explain the 
isoniazid tolerance demonstrated by Mtb Bleupan. Since isoniazid has a high efficacy 
towards the replicating bacteria rather than the non-replicating Mtb322, the limited availability 
of oxygen may drive a sub-population towards persistent state326, resulting in the increased 
MIC. Furthermore, peroxidase activity is significantly lowered under anaerobiosis leading to 
reduced isoniazid oxidation, therefore the decreased production of intracellular active 
isonicotinic acid327.  
The present study has shown the D-LAK peptides potentially facilitate the action of 
rifampicin and isoniazid against MDR-TB strains when used in combination in vitro and ex 
vivo. Since the current MDR-TB regimens consist of highly toxic second- and third-line 
drugs; the long duration of therapy brings huge impact on patients’ compliance. These 
findings suggest the possibility of re-sensitization of MDR-TB strains towards rifampicin and 
isoniazid by the aid of D-LAK peptides at non-toxic level. Moreover, the reduced effective 
concentration of rifampicin and isoniazid through the positive cooperativity of D-LAK 
peptides could shorten the therapy duration thereby potentially delay the emergence of drug 
resistance. The remarkable ability of the D-LAK peptides in combination first-line drugs 
against MDR-TB indicated the prospect for clinical applications. Inhalable spray-dried 
powder of both D-LAK peptides have been evaluated and revealed a good aerosol 
performance without substantial effect on their secondary structures328. This shows the 
outstanding physiochemical properties of the peptides to be delivered via pulmonary routes. 
Hence, in vivo studies of the D-LAK peptides with rifampicin or isoniazid combinations to 
evaluate their bioefficacy, pharmacokinetics and host immune responses would be crucial.  
Given the diverse proposed mechanisms of D-LAK peptides, the next step of this study aims 
to further elucidate their mode of action. Mtb Bleupan demonstrated similar behaviors to its 
parent virulent H37Rv strain in terms of responses towards antibiotic activity and 
combination synergy, indicating its applicability to be used as a Mtb model. In the following 
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chapters, mechanistic studies employing Mtb Bleupan and a fast-growing species 
Mycobacterium smegmatis are described. Using different microscopic and biophysical 
techniques, peptide-induced direct action on mycomembrane, changes in membrane 
properties and interaction with membrane components would be demonstrated. This valuable 
information would inform the next stage development of D-LAK peptides into formulations 
against MDR-TB. The continuous investigation on the D-LAK peptide and first-line drug 
combinations could be promising, pathing the development of a novel, safe and efficient 
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In the previous chapter, D-LAK peptides were found to enhance the antimicrobial activity of 
two first-line anti-tuberculosis (anti-TB) drugs, rifampicin and isoniazid, against MDR Mtb 
clinical isolates, suggesting that the antimicrobial peptides (AMPs) work synergistically with 
these two first-line anti-TB drugs. The waxy lipid-rich mycomembrane of Mtb is known to be 
one of the major barriers impeding drug entry. It is also reported to contribute to the drug 
resistance of Mtb255. The demonstrated synergy between AMPs and rifampicin or isoniazid 
may be attributed to the surface activity of the D-LAK peptides on MDR-TB clinical isolates 
shown in previous studies259. The peptides were shown to effectively break down the heavy 
clumping of mycobacteria and prevent bacterial cell aggregation. It is therefore hypothesized 
that this action of D-LAK peptides can modify the surface properties of the Mtb cell envelope, 
enhancing the efficacy of anti-TB drugs.  
The first objective of this study was to investigate the surface-active action of D-LAK 
peptides on mycobacteria using transmission electron microscopy and confocal microscopy. 
The second objective of this study was to understand the effect of D-LAK peptides and 
various antibiotics on mycobacterial membrane properties and metabolism, thereby gaining 
insights to the synergy between the anti-TB agents in combinations. To investigate how M. 
smegmatis responds to the challenge of D-LAK peptides and antibiotics, three different 
techniques were employed. Changes in bacterial membrane properties were measured with 
two fluorescent probes, Laurdan and trans-1,6-diphenyl-1,3,5-hexatriene (DPH). High-
resolution magic angle spinning (HR-MAS) and liquid-state nuclear magnetic resonance 
(NMR) metabolomics were exploited to elucidate the induced metabolic changes in the 
bacteria. Furthermore, D-LAK120-A and D-LAK120-HP13 exhibited different levels of 
synergy with rifampicin and isoniazid. The proline residue was demonstrated to enhance the 
antimicrobial activity of peptide against Gram-negative bacteria but this was not always the 
case when applied against Mtb H37Ra188. This suggests that structural differences between 
the proline-containing D-LAK120-HP13 and the proline-free D-LAK120-A could possibly 
affect their mode of action. This work also aimed to compare the mechanisms between the 
proline-containing and proline-free analogues against mycobacteria. 
M. smegmatis has been a popular model for mycobacterial studies and it was also shown to 
possess the closest profile to MDR-TB strains as compared to other fast-growing 
mycobacterial species329. M. smegmatis is chosen as a model bacterium in this study also due 
to its fast-growing nature compared to Mtb, testing time could be reduced from two months 
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to a week. Besides, the non-pathogenic nature of M. smegmatis allows experiments to be 
carried out in an environment with less safety constraints, so more assays were possible.  
DPH and Laurdan fluorescent probes were employed to study the changes of mycobacterial 
membrane in response to the challenge of D-LAK peptides and antibiotics. DPH is a rigid 
hydrophobic rod-like fluorescent probe, with an all-trans polyene structure that aligns along 
the lipid acyl chains in the phospholipid bilayer330, 331. DPH anisotropy allows the estimation 
of acyl chain mobility and is commonly used to determine structural and dynamic properties 
of lipid bilayers. During the measurement, vertically polarized light excites the probes 
embedded in the membrane, resulting in the fluorescence emission which is detected in the 
movable polarizer (Fig. 5.1). The measurement of the rotational diffusion of the probe in the 
restricted region is denoted by the anisotropy (r) (calculation as shown in Chapter 3). Since 
this estimation reflects the packing order of the acyl chain, the notion of anisotropy is also 
considered as an interpretation of membrane rigidity, in which a more rigid membrane 
displays a higher value of anisotropy. Laurdan is another fluorescent probe which is 
amphipathic in nature with a high sensitivity of excitation and emission spectra in terms of 
the physical state of the membrane332. The fluorescent moiety of Laurdan probe lies within 
the shallow region of the bilayer, predominantly reporting the stiffening or dehydration of the 
lipid carbonyls333 (Fig. 5.2). Laurdan fluorescence at different wavelengths is quantified by 
general polarization (GP) in which higher value of GP represents more dehydration and 
reduced order of the membrane. The application of Laurdan probe was also reported in other 
similar studies. The effect of a cyclic hexapeptide, cWFW, was studied with Laurdan probe 
on the membrane of Bacillus subtilis334. Also, Laurdan was employed to measure the 
difference in the organization of bacterial membrane through the challenge of membrane-






Figure 5.1 Schematic diagram of DPH anisotropy principle.  Membrane fluidity can be monitored 
using DPH fluorescent probe. The hydrophobic probe aligned parallel to the lipid acyl chains in the 
bacteria membrane. Vertically polarized light is generated and excites the embedded probes resulting 
in the fluorescence emission detected in the movable polarizer. The intensity of vertical (IVV) and 
horizontal (IVH) polarized light are measured relative to the excitation beam. Membrane with higher 
fluidity allows tumbling rotation of embedded probes resulting in depolarized emission denoted by 
lower anisotropy (r).  On the contrary, rigid membrane restricts rotation movement of DPH probes 





Figure 5.2 Schematic diagram of Laurdan fluorescent probes. Laurdan probes reside at the interfacial 
region of the membrane with the Naphthalene moiety situating towards the aqueous environment. 
Disordered membrane experiences more hydration by water molecules (black dot) while an ordered 
membrane experiences less hydration as the probes are restricted by the tight arrangement of lipid 
molecules. General polarization (GP) denotes the order of the membrane such that an increasing GP 
value corresponds to a more ordered membrane.  
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NMR metabolomics can be used to detect perturbations of metabolome of cell extracts to 
monitor disease progression and drug response. The 1H NMR spectra collection is followed 
by multivariate data analysis. Principal component analysis (PCA) is done through reducing 
each NMR spectrum into a single point in a two-dimensional scores-plot. The generation of 
score plot allows the inspection of clusters and the identification of general trends and 
outliers. Further, orthogonal projections to latent structures discriminant analysis (OPLS-DA) 
is performed by maximizing the separation between control and each treatment condition. 
This provides further useful information such as the metabolic resonances that have the most 
discriminatory importance in the data and the reliability and predictability of statistical 
models. Through comparing the metabolite profile of mycobacteria subjected to different 
treatment conditions, it is possible to discern the respective influence of anti-TB agents, thus 
reasoning the synergy mechanisms of the drug combinations. In order to avoid addition effect 
on the erosion of bacterial capsule, the culture condition adopted in this study was employed 
without any detergent or agitation. This is different from usual broth culturing practice of 
mycobacteria215, 261, but was essential to this study to minimize manipulation of bacterial 
morphology.  
HR-MAS is a NMR technique that has been applied in TB studies. It is an effective means to 
study biological matrixes and the cell structure of intact bacteria in order to elucidate the 
actions of antibiotics. Hanoulle et al. discovered the unidentified ‘ethionamide*’ as the active 
antimycobacterial ethionamide derivative by studying ethionamide activity in M. smegmatis 
using HR-MAS337. Inhibition of cyclopropanation in mycolic acids of Mycobacterium bovis 
Bacillus Calmette-Guérin by another anti-TB agent, thiacetazone, was also detected by 
HR-MAS338. This demonstrated the potential of the technique to explore drug action 
associated with the unique lipid-rich cell envelope of mycobacteria. HR-MAS enables a non-
destructive analysis which minimizes the interference to the samples as well as the possible 
spontaneous modification/oxidation of metabolites that may be resulted in assays which 
require extraction/purification processes339. Together with the application of DPH and 
Laurdan membrane probe assays, HR-MAS was demonstrated to be useful to investigate the 






5.2.1 In vitro bacterial inhibitory activity against M. smegmatis 
The antimicrobial activity of six anti-TB agents were evaluated by resazurin assay either 
alone or in combination with D-LAK peptides against M. smegmatis mc2 155 (Table 5.1). 
This bacterial inhibitory assay was performed both in the presence and absence of tyloxapol. 
Notably, both D-LAK peptides, rifampicin and isoniazid showed a more potent anti-TB 
effect in the presence of tyloxapol while the activity of colistin and capreomycin were not 
affected. This might be the result of the capsule-shedding effect of tyloxapol which removed 
the outermost barrier for the passage of anti-TB agent340.  
The fractional inhibitory concentration indices (FICI) of combination of rifampicin, isoniazid, 
colistin or capreomycin with each of the D-LAK peptides were calculated (Table 5.2). The 
FICI is widely used for the interpretation of antimicrobial interaction assessment of such that 
FICI for “synergy” is < 0.5, “antagonism” is > 4.0 and “additive” is between 0.5-4.0300.  
Overall, the effect of the combinations was additive. Only combinations of capreomycin and 
the D-LAK peptides were modestly synergistic against M. smegmatis. In the absence of 
tyloxapol, the minimum inhibitory concentration (MIC) of each agent in these combinations 
was reduced to more than half when it was used in combination, as compared to when it was 
used alone.  The synergistic effect was more pronounced when the combination was used in 
the presence of tyloxapol. 
Interestingly, the two D-LAK peptides demonstrated very different behaviours when used in 
combination with rifampicin. Without tyloxapol, D-LAK120-A showed no synergy with 
rifampicin but approached an antagonistic effect, with a FICI of 2.5 which was the highest 
among all combinations. In contrast, though modestly, the combination of D-LAK120-HP13 
with rifampicin was able to reduce MIC of both agents to half of that required when they 
were used alone. Similar effect was observed when D-LAK120-HP13 was used in 
combination with colistin but not in the combination with D-LAK120-A. The difference in 
assisting ability of the two D-LAK peptides towards different drugs suggests their disparate 
mechanism of action. The same experiments were performed with isoniazid but no synergy 
effect with either peptide was observed. Besides, isoniazid showed a high MIC against M. 
smegmatis which might be due to the inefficient activation of the prodrug in addition to the 
intrinsic resistance of the bacteria.  
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Based on the above observation, combinations of D-LAK peptides with rifampicin and 
capreomycin were chosen for the further investigation of their underlying mechanisms in the 
mycobacterial growth response assay.   
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Table 5.1 MIC50 of anti-TB agents alone and in combination against M. smegmatis mc2 155. The MIC50 of the D-LAK peptides and antibiotics rifampicin (RIF), 
isoniazid (INH), capreomycin (CAP) and colistin (CST) when used alone and in combinations are listed for comparison. 
Anti-TB agent MIC50 alone (μM) 
MIC50 in combination (μM) 
D-LAK120-A D-LAK120-HP13 RIF INH CST CAP 
D-LAK120-A 1.68 ± 0.43 
  
1.56 ± 0.17 0.39 ± 0.17 1.73 ± 0.49 0.62 ± 0.07 
D-LAK120-HP13 1.80 ± 0.39 
  
0.77 ± 0.08 0.78 ± 0.01 0.66 ± 0.08 0.85 ± 0.15 
RIF 38.1 ± 5.83 59.8 ± 1.39 14.6 ± 2.91 
    
INH 203 ± 92.3 197 ± 12.3 228 ± 18.2 
    
CST 4.44 ± 0.72 3.31 ± 0.90 2.96 ± 1.29 
    
CAP 1.35 ± 0.25 0.46 ± 0.18 0.67 ± 0.28 
    
D-LAK120-A* 0.82 ± 0.07 
  
0.91 ± 0.05 0.53 ± 0.09 0.39 ± 0.12 0.09 ± 0.01 
D-LAK120-HP13* 0.63 ± 0.03 
  
0.75 ± 0.22 0.70 ± 0.10 0.19 ± 0.09 0.14 ± 0.01 
RIF* 19.9 ± 3.04 9.33 ± 4.38 8.88 ± 1.44 
    
INH* 199 ± 46.9 228 ± 82.6 179 ± 31.0 
    
CST* 5.44 ± 1.66 4.25 ± 3.32 2.64 ± 0.70 
    
CAP* 1.72 ± 0.43 0.58 ± 0.24 0.52 ± 0.28 
    
*With tyloxapol 
Table 5.2 FIC index of D-LAK peptides in combination with various antibiotics against M. smegmatis mc2 155. 
Anti-TB agent RIF INH CST CAP 
D-LAK120-A 2.50 ± 0.14 1.19 ± 0.30 1.77 ± 0.13 0.71 ± 0.04 
D-LAK120-HP13 0.81 ± 0.02 1.55 ± 0.11 1.03 ± 0.32 0.97 ± 0.20 
D-LAK120-A* 1.58 ± 0.10 1.55 ± 0.18 1.26 ± 0.16 0.45 ± 0.13 




5.2.2 Assessment of action of D-LAK peptides by transmission electron microscopy 
The action of D-LAK peptides on M. smegmatis was first investigated to verify, as suggested 
from their activity on Mtb MDR clinical isolates, their action on the mycobacterial cell wall 
using microscopic techniques. Transmission electron microscopy (TEM) was exploited to 
visualize the effect of D-LAK peptides on the ultrastructural changes of M. smegmatis 
(Fig. 5.3). Untreated cells had lipid inclusions, regular rod shape cell body with well-defined 
intact cell membranes and homogeneous cytoplasm (Fig. 5.3A). A distinct cell envelope was 
visible with the cytosol surrounded by the plasma membrane, additionally bound by an 
internal and an outer electron dense layer65, 341. Slight displacement of cell content in some 
untreated cells was ascribed to the sample preparation process. After the bacteria were treated 
with D-LAK120-A (Fig. 5.3B) and D-LAK120-HP13 (Fig. 5.3D) at 1x MIC of for 5 mins, 
ruffling of the membrane was observed. Detachment of inner cell membrane from the outer 
cell wall indicated observable cytoplasmic retraction. This phenomenon was also reported 
when Escherichia coli and Bacillus subtilis were exposed to a tick defensin derived AMP342. 
Ernst et al. presented similar findings in which granulysin demonstrated membrane active 
action towards Mtb (Erdman strain) leading to inner cell membrane detachment as observed 
in osmotic lysis343. The reduction in membrane uniformity suggests a cell penetrating action 
of D-LAK peptides. Notable intracellular changes including clumped cytosol and increased 
amount of mesosome formation were also caused by the action of D-LAK peptides. This 
observation is similar to other studies in which intracellular membranous mesosome 
structures were found in Gram-negative and Gram-positive bacteria when exposed to cationic 
antimicrobial peptides170, 344. The formation of mesosomes was suggested to be a repair 
mechanism adopted by bacteria to combat cell lysis345. Prolonged treatment by D-LAK 
peptides for 30 min resulted in large scale of cell lysis and cell debris could be seen 
(Fig. 5.3C and 5.3E). This suggests that D-LAK peptides were able to disturb cell membrane 






Figure 5.3 TEM images of M. smegmatis mc2 155 exposed to D-LAK peptide treatment. As compared 
with control (A), ultrastructure morphological changes can be observed when M. smegmatis mc2 155 
was treated with 1x MIC D-LAK120-A (B,C) or D-LAK120-HP13(D,E)  for 5 min and 30 min 




5.2.3 Assessment of action of D-LAK peptides by confocal microscopy 
Confocal microscopy study was performed to examine the membrane activity of D-LAK 
peptides in the potentiation of drug entry or interaction with the bacteria. M. smegmatis was 
treated with sub- or supra- MIC of D-LAK120-A, D-LAK120-HP13, isoniazid or rifampicin 
(Fig. 5.4).  Rifampicin and isoniazid were used as negative controls given that they do not 
target mycobacterial membrane directly. Only cells treated with D-LAK peptides (Fig. 
5.4B-E), but not rifampicin nor isoniazid (Fig. 5.4F/G), were stained with 150 kDa 
fluorescein isothiocyanate (FITC) dextran. FITC-dextran has been employed to investigate 
the membrane permeabilization activity of different antimicrobial peptides346, 347. Ladokhin et 
al. 348 reported the escape of 4 kDa dextran loaded in lipid unilamellar vesicles after the 
exposure to antimicrobial peptide melittin while the release of the 50 kDa analogue was 
much less. This suggested the ability of melittin to form pores on membrane with a defined 
size of 25-30 Å  in diameter. On the contrary, other antimicrobial peptides were found to 
facilitate the release of dextran at a range of different sizes, yet complete leakage was never 
attained346, 347. Due to the resolution of the image and the large size of dextran used in this 
study, it is difficult to distinguish whether the signal observed was inside or on the surface of 
the bacteria. Nonetheless, this shows that the D-LAK peptides could potentially enhance 
dextran adsorption on the membrane and/or increase dextran diffusion into the intracellular 
compartment. It is possible that the same functionality of D-LAK peptide, which caused the 
de-clumping of Mtb259, enabled the dextran to adsorb to the surface of M. smegmatis. 
Moreover, Khara et al.261 reported similar results after the exposure of M. smegmatis to 
cationic peptide M(LLKK)2M with 150 kDa FITC-dextran. They concluded that the peptide 
action resulted in the promotion of passive diffusion of FITC-dextran into the intracellular 
environment, and this uptake of FITC-dextran increases with duration of exposure. Taken 
together with the results from TEM, the membrane activity of D-LAK increased the 
permeability of the bacterial membrane thereby potentially facilitating the interaction of 
molecules with the bacteria. The mechanism of this peptide action was further explored in the 




Figure 5.4 Confocal images of M. smegmatis mc2 155 exposed to D-LAK peptide and FITC-dextran. M. 
smegmatis mc2 155 either unchallenged (A) or challenged with 2x MIC isoniazid (F) or rifampicin (G), 
½  MIC (B/C) or 2x MIC (D/E), D-LAK120-A (B/D) or D-LAK120-HP13 (C/E). In contrast to 





5.2.4 Determination of media effect on membrane properties by Laurdan fluorescence 
assay  
To gain better understanding of the effect of media composition on the growth of M. 
smegmatis, changes in bacterial membrane property was determined using Laurdan 
fluorescent probes. M. smegmatis grown in different media exhibited differing membrane 
property as detected by changes in Laurdan fluorescence, revealing the effect of media 
supplementation with 0.025% tyloxapol or oleic acid-albumin-dextrose-catalase (OADC) 
(Fig. 5.5). The general polarization (GP) value reflects the local polarity around the 
fluorophore and is commonly influenced by the penetration of water molecules into the lipid 
layer. This is taken as a proxy for membrane order in which a higher GP value denotes a 
higher membrane order. M. smegmatis grown in 7H9 broth media supplemented with OADC 
without tyloxapol were found to have the highest GP values. Moreover, the membrane order 
of mycobacteria grown in media without tyloxapol was significantly higher than those grown 
in 7H9 broth media with tyloxapol. Membrane order of bacteria grown in RPMI 1640 was 
similar to those grown in 7H9 broth media with tyloxapol. These results showed that M. 
smegmatis grown in media with tyloxapol generally demonstrate a lower membrane order 






Figure 5.5 Media effect on membrane properties of M. smegmatis mc2 155 by Laurdan fluorescence 
assay. 7H9 denotes the basic broth medium, 7H9 w tyloxapol denotes the additional 0.025% tyloxapol, 
7H9O denotes the additional OADC supplement. Data were presented as mean ± SD (n=3). 
Significant difference was assessed using one-way ANOVA analysis followed by Tukey’s post-hoc test, 
*<0.05, **<0.01, ***<0.001 
. 
5.2.5 Mycobacterial growth response assays  
 
Fluorescence assays 
DPH fluorescence polarization or anisotropy is commonly employed to determine alteration 
in bacterial membrane fluidity in response to environmental stimulus or stress349. Since the 
DPH probes lie within the hydrophobic core aligning with the acyl chains in the membrane, 
increase in r represent the reduction in degree of rotation of the probes, therefore increased 
rigidity of the mycomembrane. Significant increases (p < 0.01) in fluorescence anisotropy, r, 
were resulted when M. smegmatis was challenged with D-LAK120-HP13, capreomycin or its 
combinations with D-LAK peptides. The same effect was also observed in the presence of 
0.025 % tyloxapol (Fig. 5.6A). Small and nonsignificant increase in membrane rigidity were 
detected when bacteria were challenged by D-LAK120-A, colistin, isoniazid, rifampicin and 
D-LAK peptides with rifampicin. The change in fluorescence anisotropy indicated that 
131 
 
M. smegmatis responded in particular to the challenge of capreomycin and its combinations 
by a substantial increase in membrane rigidity.  
As mentioned previously, Laurdan fluorescence polarization has been used as a measurement 
of membrane order in bacterial studies. Due to the nature of the Laurdan probe giving rise to 
its positioning in membrane interfacial region, the measurement represents the effect of 
solvent surrounding the probe and thereby the increase in polarity, denoted by the reduction 
of GP, reflecting the more disordered in regions of the membrane. As a result, any reduction 
of GP in the samples compared to the control indicated that the local environment around the 
probe become more polar, suggesting that there was a reduction of membrane order of M. 
smegmatis when they are subjected to these challenges. Significant reductions (p < 0.001) in 
Laurdan GP were observed in M. smegmatis when challenged with capreomycin, its 
combinations with D-LAK peptides or in the presence of tyloxapol (Fig. 5.6B). All the other 
treatments did not induce significant changes as compared to untreated control. When the 
bacteria were challenged with capreomycin alone, the GP reduction was significantly greater 
than when it was used in combination with D-LAK120-A but not that with D-LAK120-HP13.  
Notably, an opposite trend was demonstrated using Laurdan fluorescent probe and DPH 
probe. Since the increase in DPH anisotropy is associated with the increase in membrane 
rigidity, this trend depicting a less-ordered (an increase of GP in Laurdan fluorescence) but 
more rigid membrane was surprising. Consequently, the correlation between Laurdan 
polarization and DPH anisotropy was assessed by the application of Spearman’s rank 
correlation method (Fig. 5.6C). Interestingly, the result showed a strong negative correlation 
(Spearman’s rho = -0.742) between Laurdan and DPH data which suggests the two 
techniques have a monotonic relationship and are reporting on the same event. Although the 
precise locations of where the two probes reside are yet to be determined, these results have 
revealed that the physical properties of the mycobacterial envelope are substantially altered in 
response to the challenge by capreomycin and perhaps D-LAK120-HP13 but to a lesser 
extent. On the contrary, other anti-TB agents and D-LAK120-A did not seem to have a 





Figure 5.6 Fluorescence spectroscopic perspective of the response of M. smegmatis mc2 155 to 
challenge with antibiotics. DPH fluorescence anisotropy (A), Laurdan GP fluorescence (B) and 
correlation (Spearman R = -0.742, p < 0.0001) of DPH and Laurdan (C). Data were presented as 
mean ± SD (n=9). Significant difference was assessed using one-way ANOVA analysis followed by 





Metabolite assignment of M. smegmatis mc2 155 
HR-MAS 1H NMR metabolomics elucidated the metabolites in the whole cell sample of 
M. smegmatis. 1H NMR spectra were obtained from HR-MAS and liquid state NMR 
spectrometer. Assignments of metabolites associated with peaks are shown as a reference for 
the backscaled loadings and NMR spectra. The unchallenged whole M. smegmatis cell 
spectrum (Fig. 5.7) was dominated by the lipid resonance including various kinds of saturated 
and unsaturated carbon functional groups. This could be explained by the lipid rich 
mycomembrane structure consisting mainly of non-oxygenated α-mycolic acids in 
M. smegmatis. Amino acids and sugars without overlapping with lipids were also identifiable, 
namely trehalose, sucrose, alanine, lysine, glycerate, serine, valine and glutamate. The NMR 
spectrum of spent media of unchallenged M. smegmatis (Fig. 5.8) contained sharper peaks 
without the influence of broad lipid resonance compared to the spectrum of the whole cell 
sample (Fig. 5.7). By comparing the spectra of challenged bacteria with control, spectra of 
HR-MAS and spent media could provide information of substantial changes in various 






Figure 5.7 1D 1H HR-MAS spectrum of whole cell M. smegmatis mc2 155. 
 
 




Multivariate analysis  
PCA is an unbiased and important preliminary evaluation of differences between different 
treatment groups. The PCA scores plots (Appendix B, Fig. 7.4 and 7.5) derived from the 1H 
NMR spectra of whole cell M. smegmatis samples upon treatment in the presence of 
tyloxapol or challenges with anti-TB agents alone, D-LAK peptides alone or their 
combination revealed clear clustering by plotting along principle component 1 and 2 (PC 1 
and 2), indicating significant changes in different challenged conditions. The challenge with 
D-LAK peptides (2.0 and 3.0) cluster more closely together with the unchallenged control 
(0.0) while capreomycin and its combinations with D-LAK peptides (7.0, 8.0 and 9.0) cluster 
on the other side of the coordinate plane. This marks the distinct differences in metabolic 
changes of M. smegmatis while subjected to the respective challenges.  
The specific metabolites that distinguished the treatments (Appendix B, Fig. 7.4 and 7.5) 
indicated that the highest variance (98.1%) which was explained by PC 1 were attributed to 
the reduction in lipid components (1.29 ppm) and trehalose (3.86 ppm). At the same time, PC 
2 accounted for the remaining variance (1.7%) found in the data set and indicated this 
variance was ascribed to production of trehalose.  
PCA plots for spent media of M. smegmatis upon different challenges revealed clustering of 
spectra from rifampicin challenged cultures and also its combinations with D-LAK peptides 
while similar clustering was observed for cultures challenged with isoniazid and its 
combinations with D-LAK peptides. The highest variance (PC 1, 87.8%) was shown to be 
attributed to the reduction of glycerol (3.58 ppm) and PC 2 indicated influence by the 
production of pyruvate (2.38 ppm) accounting for 11.6% of the variance. This suggests that 
the challenged cultures grew slower than the untreated controls.   
Cross-validated orthogonal projections to latent structures discriminant analysis (OPLS-DA) 
was done to identify significant changes in 1H HR-MAS spectra acquired for M. smegmatis 
upon various challenges as indicated (Appendix B, Fig. 7.6-7.28). The key metabolites 
responsible for the differentiation between classes were further verified by OPLS-DA model 
as it can demonstrate significantly improved discrimination compared to PCA models, model 
predictability, as assessed by Q2 (Table 5.3). It also indicates the level of significance in the 
separation between each challenge condition and the untreated control.  
A hierarchical clustered heatmap was generated based on the degree of similarity of 
metabolite abundance profiles to give an overview of all the individual metabolite detected in 
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1H HR-MAS (Fig. 5.9) and liquid-state (Fig. 5.10) NMR. Volcano plots allows the individual 
comparisons of unchallenged control with each challenged condition. Fold changes of these 
metabolites were generated according to their relative peak intensities compared with the pre-
processed data of the 1H NMR spectra. This facilitates the identification of the magnitude and 
significance of changes in key metabolites as compared across challenges in the univariate 
analysis plots to reveal individual impact.  
Heatmap generated from the whole cell HR-MAS analysis gives a general trend of changes in 
metabolites in M. smegmatis subjected to different treatments (Fig. 5.9).  An overall 
reduction in lipid resonances was induced by all treatments except for D-LAK120-A as 
compared with the untreated control. Production of trehalose was only resulted in treatment 
with capreomycin and combinations of capreomycin with D-LAK peptides. On the other 
hand, liquid state NMR indicated the production of tartrate and consumption of glycerol by 
rifampicin and its combination with D-LAK peptides or colistin alone (Fig. 5.10). Opposite 
changes in these two metabolites were demonstrated in all the other treatments in addition to 
the reduction of succinate, pyruvate and citrate. Significance of these changes are illustrated 




Figure 5.9 Hierarchical clustered heatmap comparing loadings obtained from cross-validated OPLS-




Figure 5.10 Hierarchical clustered heatmap comparing loadings obtained from cross-validated OPLS-
DA of liquid-state NMR spectra of M. smegmatis mc2 155 challenged with indicated conditions. 
 
In the presence of 0.025% tyloxapol, M. smegmatis showed significant and substantial 
changes in a number of metabolites involving components of the mycobacterial membrane 
(Fig. 5.11A). The increase in the amount of glutamate was the greatest change while there 
was a modest increase in lysine, serine, alanine and glycerate. Highly significant reduction in 
lipid resonances including the R2CH-COOH, R2CH-OH groups as well as saturated alkyl 
chains -(CH2)n– were detected which are associated with mycolic acid. Notably, tyloxapol 
treatment did not affect the resonance of unsaturated alkyl groups –CH=CH– 
or -CH2-CH=CH–. Mycolic acids of mycobacteria comprise of two branches: a short α-chain 
consists of saturated alkyl carbon and a long mero-chain of 40-60 carbon atoms with two 
functional moieties at the distal and proximal positions. Mycomembrane of M. smegmatis 
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consists of mostly non-oxygenated α’ mycolic acids which possess cis-alkene functional 
groups in the mero-chains. In addition to the capsule-shedding effect of tyloxapol, it was also 
reported to reduce the amount of surface lipids of mycomembrane, especially 
trehalose 6,6’ -dimycolate (TDM) on M. bovis BCG350. This reduction of only saturated alkyl 
chains might suggest the effect of tyloxapol on the short α-chains of TDM of M. smegmatis. 
It is also worth-noting that the fold changes of all the four saturated hydrocarbon lipid 
resonance were similar, showing the consistent reduction in the number of saturated α-chains, 
while the mero-chains containing unsaturated alkene were unaffected.  
On the other hand, it was observed that both the saturated and unsaturated hydrocarbon lipid 
resonances were affected when the bacteria were challenged with rifampicin or capreomycin 
(Fig. 5.11D/G). Although the magnitudes of responses observed have substantial variations 
and qualitative differences, the common effect brought about by these challenges were the 
reduction of unsaturated lipid resonances. More importantly, the fold changes of all lipid 
resonances were similar. This might imply the reduction of the amount of intact mycolic 
acids instead of shortening the alkyl chains in mycolic acids. In addition to the reduction of 
both saturated and unsaturated lipid resonances, R2CH-COOH and R2CH-OH groups also 
followed the same trend with the similar negative fold changes, further explaining the general 
decrease in mycolic acid content. Mycolic acids are essential component of the 
mycomembrane and they play a major role in membrane permeability. With the inner leaflet 
covalently bonded to arabinogalactan, the outer leaflet of the mycomembrane consists of 
extractable free trehalose mycolates, trehalose 6-monomycolates (TMM) and TDM. In this 
study, an increase in signal intensity of trehalose resonance was only found when M. 
smegmatis was challenged with capreomycin (Fig. 5.11G). This increase was of similar 
magnitude as the decrease in mycolic acid resonances, revealing the ratio of mycolic acid to 
trehalose was substantially influenced when the bacteria was challenged by capreomycin. 
This would be consistent with a shift in the balance between TDM and TMM, leading to the 
predominance of the latter in mycomembrane. Significant increase in sucrose, serine and 




Figure 5.11A-F ¾  MIC Challenges induce changes in various metabolites in whole cell M. smegmatis 
mc2 155. Volcano plots are shown for individual comparisons of unchallenged bacteria and those 
challenged with 0.025% tyloxapol (A), D-LAK120-A (B), D-LAK120-HP13 (C), rifampicin (D), 
rifampicin in combination with D-LAK120-A (E) or D-LAK120-HP13 (F). Volcano plots are of PQN 
normalized data and allow comparison of fold changes and significance of each metabolite; blue –





    
Figure 5.11G-K ¾  MIC Challenges induce changes in various metabolites in whole cell M. smegmatis 
mc2 155. Volcano plots are shown for individual comparisons of unchallenged bacteria and those 
challenged with capreomycin (G), capreomycin in combination with D-LAK120-A (H) or 
D-LAK120-HP13 (I), isoniazid (J) or colistin (K). Volcano plots are of PQN normalized data and 
allow comparison of fold changes and significance of each metabolite; blue – significant reductions, 
red – significant increases and grey – non-significant changes in the indicated metabolites. 
142 
 
The decrease in the amount of mycolic acid caused by capreomycin is much greater as 
compared to that of rifampicin and tyloxapol. Across different challenges, it is clear that 
capreomycin triggered the strongest and the most significant (p < 0.05) impact on both 
saturated and unsaturated hydrocarbons (Fig. 5.12G-L). On the contrary, rifampicin induced a 
modest reduction in the lipid resonances, while tyloxapol only resulted in changes in 
saturated hydrocarbons (Fig. 5.12G-J) but not unsaturated lipids (Fig. 5.12K-L). Again, 
neither rifampicin nor tyloxapol triggered significant changes in trehalose that was seen in 
capreomycin challenge (Fig. 5.12F). It can be concluded that the membrane remodeling 
effect, brought about by rifampicin, was much subtler than that induced by capreomycin 
which is probably the reason behind the lack of changes in membrane properties observed in 
the fluorescence assays. Treatment of M. smegmatis by isoniazid induced significant 
reduction in trehalose, glutamate, glycerate and lipid R2CH-COOH. Colistin did not induce 
significant changes of any metabolites.  
The challenge of the two D-LAK peptides resulted in quantitatively and qualitatively 
different responses in M. smegmatis as compared with rifampicin and capreomycin. The 
assessment of OPLS-DA models of either peptide indicated a significant response when 
considering all metabolites (Table 5.3). However, changes in individual metabolites were 
subtle and did not pass the stringent significant threshold (Fig. 5.11B/C). Volcano plots 
showed that D-LAK120-HP13 peptides induced a significant increase in glutamate (p < 0.05), 
which was a similar phenomenon as observed in capreomycin but not rifampicin. Unlike 
capreomycin, the D-LAK peptides did not cause any changes in trehalose (Fig. 5.12F). The 
difference in certain metabolic responses distinguishes the two D-LAK peptides which might 
reflect their different mechanism of actions. Significant increase (p < 0.05) in both saturated 
and unsaturated lipids was found when the bacteria were challenged with D-LAK120-HP13 
but not D-LAK120-A peptide (Fig. 5.12G-L).  This is consistent with the membrane 
manipulation activity of D-LAK120-HP13 as detected in the DPH fluorescence assay. 
Besides, significant increase in lysine resonance was observed in D-LAK120-HP13.  
HR-MAS 1H NMR data were also obtained for combinations of capreomycin and rifampicin 
with D-LAK peptides. Notably, concentration of capreomycin and rifampicin used in 
combination with D-LAK peptides were much lower than when they were used alone. 
Combination of D-LAK120-A with capreomycin has shown modest synergism while the 
combination of D-LAK120-A with rifampicin was found to be indifferent or even 
antagonistic. D-LAK120-A dampened the decrease in lipid resonances (Fig. 5.12G-L) and 
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the increase in trehalose (Fig. 5.12F) caused by capreomycin (p < 0.05) but had no effect on 
the level of glutamate (Fig. 5.12E). The responses of M. smegmatis on rifampicin alone or in 
combination with D-LAK120-A were indistinguishable.  
There was modest synergism between D-LAK120-HP13 and rifampicin while only an 
additive effect was seen when the peptide was used in combination with capreomycin. As 
compared to proline-free D-LAK120-A peptide, the proline containing D-LAK120-HP13 
peptide showed a weaker influence on the metabolic changes caused by rifampicin or 
capreomycin. Despite the lower impact on the reduction of both saturated and unsaturated 
hydrocarbons than capreomycin alone, the mitigation induced by the combination of D-
LAK120-HP13 with capreomycin was not significant. On the other hand, combination of 
rifampicin with D-LAK120-HP13 did not cause great impact on changes in metabolites 
except -CH3, in which a significant (p < 0.05) mitigation was recorded, (Fig. 5.12J). 
 
Table 5.3 Test and permutated Q2 scores for cross-validated OPLS-DA models from 1H HR-MAS and 
liquid-state NMR spectra of M. smegmatis mc2 155. Comparison of unchallenged bacteria with those 
obtained from bacteria treated by the indicated conditions.   
1H HR-MAS Liquid-state 
 Q2 permutated Q2  Q2 permutated Q2 
0.025% Tyloxapol 0.866 -0.377 0.025% Tyloxapol 0.820 -0.491 
D-LAK120-A 0.769 -0.423 D-LAK120-A 0.222 -0.539 
D-LAK120-HP13 0.729 -0.360 D-LAK120-HP13 0.632 -0.351 


























Colistin 0.700 -0.363 Colistin 0.526 -0.341 
Isoniazid 0.859 -0.429 Isoniazid 0.900 -0.453 





Figure 5.12A-F Univariate analysis of relative metabolite levels in M. smegmatis mc2 155. Significant 
differences with respect to unchallenged bacteria, as determined by one-way ANOVA with Tukey 




Figure 5.12G-L Univariate analysis of relative metabolite levels in M. smegmatis mc2 155. Significant 
differences with respect to unchallenged bacteria, as determined by one-way ANOVA with Tukey 




To gain a better understanding of the relationship between the changes in metabolite 
concentration and the physical properties of mycomembrane, Spearman correlation was used 
to assess the samples challenged by capreomycin and/or D-LAK peptides or growth in the 
presence of tyloxapol. The changes of magnitude of individual metabolites and fluorescence 
anisotropy were evaluated using partial least square regression model (Fig. 5.13). Highly 
significant correlations (p< 0.0001) were demonstrated between the metabolites, which 
showed substantial changes upon aforementioned challenges, and their corresponding 
fluorescence anisotropy. Saturated hydrocarbons resulted in the strongest negative correlation 
with fluorescence anisotropy, with the Spearman constant of -0.733 for –(CH2)n– (Fig. 
5.13A) and -0.708 for -CH3 (Fig. 5.13E), whereas slightly weaker correlations were found 
with unsaturated hydrocarbons at -0.631 for –CH=CH– (Fig. 5.13C) and -0.543 for –CH2-
CH=CH– (Fig. 5.13D). Positive correlation (R = 0.564) was detected between trehalose and 
fluorescence anisotropy. These correlations support the reasoning behind the observations in 
which capreomycin triggered responses in all lipids and trehalose, while D-LAK120-HP13 
only triggered changes in most lipid resonances except –CH2-CH=CH–. Tyloxapol triggered 
changes solely in saturated hydrocarbons. Moreover, the strength of these correlations may 
reveal the influence of each of these mycomembrane components on membrane rigidity. It 
could be deduced that the increase in rigidity of mycomembrane appears to be the direct 
result of the changes in membrane components, as indicated by the increase in trehalose and 





Figure 5.13 Correlation between membrane rigidity and the altered composition of the 
mycomembrane of M. smegmatis mc2 155. Spearman correlations are shown between DPH anisotropy 
(r) and 1H HR-MAS NMR resonance intensities obtained for M. smegmatis mc2 155 grown without 
challenge or with 0.025% Tyloxapol or ¾  MIC of D-LAK120-A, D-LAK120-HP13, capreomycin, 
capreomycin with D-LAK120-A or capreomycin with D-LAK120-HP13. Data is shown for lipid –




Changes in metabolites in spent bacterial culture media were also analyzed by OPLS-DA 
(Appendix B). The results illustrated that qualitative change occurred in metabolism of M. 
smegmatis only when it was challenged with rifampicin alone, its combinations with D-LAK 
peptides, as well as isoniazid alone (Fig. 5.14D-F/J). A binary comparison of spent media of 
unchallenged bacteria with fresh media indicates that M. smegmatis consumed glucose and 
produced glycerol, 2-hydroxyisobutyrate and tartrate (Fig. 5.14L). The changes in these 
metabolites indicate normal cell metabolism of bacteria which can denote the relative rate of 
bacterial growth. Upon challenging with rifampicin, there was a slight increase in 
consumption of citrate and glucose, and a more pronounced reduction of valine, alanine and 
lactate.  An increase in pyruvate production and more modest decrease in malate and tartrate 
production were also observed (Fig. 5.14D). Since citrate and succinate are the key 
components of the carbon metabolic pathways, the reduction of both metabolites may be due 
to the increase lipid catabolism351. Although reduction in succinate in rifampicin treatment 
was just below the significant threshold, these changes in spent media together with the 
reduction in lipid resonances revealed in HR-MAS have demonstrated the effect of 
rifampicin on bacterial lipid metabolism. The changes in pyruvate, alanine, malate, tartrate, 
glucose and citrate were preserved when rifampicin was used in combination with D-
LAK120-A but mostly muted when used in combination with D-LAK120-HP13 (Fig. 
5.14E/F). Challenge with isoniazid also resulted in increased consumption of citrate in 
addition to the significant reduction in succinate, acetate and acetoacetate (Fig. 5.14J). De 
Carvalho et al. reported that the decrease in acetate may also be attributed to its metabolism 
through glyoxylate shunt258. This indicated the action of isoniazid on lipid biosynthesis 
associated with one of its mechanisms of action to inhibit anabolism of fatty acid352. The 
changes in lipid resonances in HR-MAS were found to be just below the significant threshold, 
possibly due to the inefficient amount of activated isoniazid to exert a significant effect on 
mycomembrane lipids. Apart from these conditions, no other challenges induced any 





Figure 5.14A-F ¾  MIC Challenges induce changes in various metabolites in spent media of M. 
smegmatis mc2 155. Volcano plots are shown for individual comparisons of unchallenged bacteria and 
those challenged with 0.025% tyloxapol (A), D-LAK120-A (B), D-LAK120-HP13 (C), rifampicin (D), 
rifampicin in combination with D-LAK120-A (E) or D-LAK120-HP13 (F).Volcano plots are of PQN 
normalized data and allow comparison of fold changes and significance of each metabolite; blue –






Figure 5.14G-L ¾  MIC Challenges induce changes in various metabolites in spent media of M. 
smegmatis mc2 155. Volcano plots are shown for individual comparisons of unchallenged bacteria and 
those challenged with capreomycin (G), capreomycin in combination with D-LAK120-A (H) or 
D-LAK120-HP13 (I), isoniazid (J), colistin (K) or Fresh Media (L). Volcano plots are of PQN 
normalized data and allow comparison of fold changes and significance of each metabolite; blue –





M. smegmatis mc2 155 is a smooth morphotype strain isolated from the isogenic rough 
wild-type strain ATCC 607341. Owing to its non-pathogenic and fast-growing nature, this 
species is safe and practical to culture in the laboratory, making it an attractive model 
organism for the pathogenic Mtb353. Arguments have been raised to discuss the 
appropriateness of M. smegmatis as a Mtb surrogate due to its obvious differences of being a 
non-persistent and non-infectious saprophyte with a genome 1.7 times bigger than that of 
Mtb354. Surprisingly, a major portion of homologues virulence genes, and genes related to 
environmental sensing and response were detected in M. smegmatis355. Other similarities 
include the reaction to acid-fast staining, principal structure of cell wall, formation of biofilm 
and mycothiol synthesis. As a result, M. smegmatis is considered to serve as a useful system 
for studying stress responses250, 356, genetic analysis357 cell envelope characterization63, 
screening of anti-TB drugs358, 359, AMPs candidates193, 360 and metabolomic studies135, 253. 
Given the widespread usage of M. smegmatis as a surrogate model to study the common 
biological aspects of mycobacteria, this species was employed in this study as a model to 
demonstrate various techniques to investigate the mode of action of anti-TB drugs and the 
novel D-LAK peptides, pathing the exploitation of those techniques in the study of Mtb.  
Using the HR-MAS 1H NMR metabolomic and fluorescent probes that are sensitive to 
membrane order and rigidity, dramatic changes in mycomembrane of M. smegmatis mc2 155 
were found in response to the challenge with capreomycin. In contrast, only modest changes 
in the mycomembrane were induced by the challenge with rifampicin, and challenge with 
isoniazid and colistin resulted in the least changes. D-LAK120-A and D-LAK120-HP13 
peptides cannot be clearly distinguished from each other as there was not enough evidence 
based on the changes in physical properties of the mycomembrane. However, the different 
metabolic responses triggered in M. smegmatis have reflected distinct mechanism of action of 
these two peptide analogues.  In the presence of tyloxapol, synergy was detected in the 
combinations of capreomycin with either peptide. However, this effect was attenuated in the 
absence of tyloxapol, leaving only modest synergy between capreomycin with D-LAK120-A 
but not with D-LAK120-HP13. D-LAK120-HP13 acted modestly beneficial with rifampicin 
in the absence of tyloxapol. These findings may provide insights to understand how the D-





In vitro antimycobacterial activities of anti-TB agents 
 
In vitro bacterial inhibitory assays were performed on M. smegmatis to evaluate the 
inhibitory efficacy of the anti-TB agents alone or in combinations with D-LAK peptides. M. 
smegmatis was susceptible to all the agents to a different extent. D-LAK peptides affected the 
growth of the bacteria with an MIC50 of < 2 µM in contrast to their inefficiency against Mtb 
strains shown in Chapter 4. This difference could be due to the substantial structural 
variations of cell wall bound mycolic acids between the two mycobacteria species, in 
particular the cyclopropanated mycolic acids in Mtb versus the olefinic ones in M. 
smegmatis361. On the other hand, M. smegmatis revealed its high tolerance towards both first-
line anti-TB drugs, rifampicin and isoniazid, which is consistent with previous studies by 
other groups362, 363. Resistance to rifampicin was related to its possession of the ADP-
ribosyltransferase (encoded by arr gene) which enables the inactivation of rifampicin through 
ribosylation106. Rifampicin susceptibility of M. smegmatis was reported to be similar to that 
of drug susceptible Mtb H37Rv via downregulation of the corresponding gene364. The alkyl 
hydroperoxide reductase C (ahpC) gene encodes the subunit C of alkyl hydroperoxide 
reductase, an enzyme that counteracts organic peroxides365. ahpC gene which was found in M. 
smegmatis but not in Mtb H37Rv366 might partly account for the low isoniazid susceptibility. 
Nonetheless, the exceptionally high MIC of isoniazid displayed in this study might be 
reasoned by additional factors induced in the static-culturing condition.  Isoniazid is a 
prodrug that requires the activation by the mycobacterial catalase-peroxidase in the presence 
of molecular oxygen42. Static-culturing condition reduces the availability of oxygen and 
therefore limits the transformation of isoniazid into the active isonicotinic acid in the 
mycobacterial cells. Gillespie et al.367 reported that the decrease in catalase production by M. 
smegmatis grown in oxygen-depleted condition might be another factor of reduced isoniazid 
activation. This reduced oxygen availability might trigger dormancy responses in 
M. smegmatis similar to those of Mtb356, leading to increased tolerance to isoniazid326.  
The entry pathway of capreomycin is still yet to be elucidated though it was suggested that 
the hydrophilic drug is likely to enter the bacteria through the porin channels17. Interaction of 
D-LAK peptides with membrane surface enhanced the permeability of capreomycin resulting 
in the lowest FICI among other peptides and drug combinations. Unlike the inefficacy on Mtb 
strains, colistin was effective against M. smegmatis. M. smegmatis possesses  
lipooligosaccharides (LOS)368, an analogue of LPS369, which is the target of colistin. The 
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effect of tyloxapol was also studied in this assay. Presence of tyloxapol reduced the MIC of 
D-LAK peptides and rifampicin while its effect on isoniazid, capreomycin and colistin was 
modest. This is mostly attributed to the capsule-shedding effect of surfactants such as Tween 
80 and tyloxapol340. Since the D-LAK peptides act on the mycomembrane of M. smegmatis, 
the removal of bacterial capsule by tyloxapol eliminates the barrier to the peptides, thereby 
lowering their effective concentration. In addition to the removal of bacterial capsule, 
tyloxapol was also reported to reduce the amount of TDM on M. bovis BCG strain350. This 
potentially induces alteration in the mycomembrane permeability, reducing the resistance for 
the transverse of rifampicin across the cell envelope. Given the effect of morphological 
manipulation on mycobacteria, tyloxapol was not employed as a de-clumping agent in the 
culture of this study. Rather, it was included as a treatment condition for comparison with 
D-LAK peptides and other anti-TB drugs.  
 
Membrane-destabilization activity of D-LAK peptides  
 
The antimicrobial activity of AMPs was reported to be mediated by different mechanisms 
including targeting intracellular sites and/or cell membrane as described in Chapter 1. 
Cationic AMPs adopting the amphipathic structure is known to interact with bacterial 
membranes via a non-specific membrane-destabilization mechanism, which induces the 
formation of pore, membrane disruption, depolarization, and eventually disintegration 
following the leakage of cell content194. Treatment with D-LAK peptides leads to observable 
membrane ruffling, mesosomes formation and membrane destabilization in M. smegmatis. 
This revealed the rapid activity and direct membrane interaction of the D-LAK peptides. 
Similar results with the formation of mesosomes have also been shown when avirulent Mtb 
H37Ra strain was exposed to treatment by other AMPs345.  
Reflecting on the synergy demonstrated against MDR-TB strains, D-LAK peptides alone did 
not affect bacterial survival while combination with rifampicin or isoniazid resulted in 
synergy. One of the resistance mechanisms acquired by MDR-TB strain is the alteration in 
mycobacterial membrane. It was reported that the cell wall of MDR-TB strains is generally 
thicker than drug-susceptible strains370. This might suggest the MDR-TB strains possess 
mutations conferring resistance on cell envelope would be likely be affected by the action of 
D-LAK peptide resulted in enhanced accessibility of anti-TB drugs and consequently their 
intracellular action. To further investigate this argument, M. smegmatis incubated with 
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D-LAK peptides and fluorescein isothiocyanate labelled dextran was visualized by confocal 
microscopy. Neither rifampicin nor isoniazid treatment induced staining of M. smegmatis, 
implying the integrity of mycomembrane remained largely intact. Conversely, M. smegmatis 
treated with D-LAK peptides at various concentrations were stained with intense green signal. 
This revealed the ability of D-LAK peptide in altering the surface properties of bacterial 
membrane, potentially enhancing the access of small molecules into M. smegmatis. Similar 
study has also been done which showed the action of cationic peptide promoting passive 
diffusion of FITC-labelled dextran of the similar size261. Although the 2-dimentional images 
shown in this study render the impossibility to differentiate surface-absorbed from 
intracellular signal, provided the membrane lytic action of D-LAK peptide obtained from 
TEM assessment, the results clearly suggested the membrane destabilization or alteration 
bring forth by the action of D-LAK peptides.  
 
Changes in membrane properties by tyloxapol and anti-TB agents 
 
Given that D-LAK peptide act on M. smegmatis via membrane-active actions, the structure of 
mycomembrane would expect to be altered. The studies of membrane rigidity and membrane 
order provide additional clues to the changes in organization of the cell wall lipids brought 
about by the peptides’ action. Rodriguez-Rivera et al.371 revealed the highest membrane 
rigidity of mycobacteria using M. smegmatis as the model species as compared with the other 
actinobacteria included in the study. The finding suggested membrane rigidity as a function 
of length hydrocarbon chains and presence of functional group in mycolic acids. 
Fluorescence steady-state anisotropy of DPH and Laurdan general polarization were 
employed to measure the effect of different treatment conditions to mycomembrane. Due to 
the complexity of the mycobacterial cell envelope, the exact location of DPH or Laurdan 
probe is still yet to be elucidated. However, taken together with the HR-MAS metabolomics 
studies which indicated the changes in components of mycolic acids as a result of exposure to 
anti-TB agents, the fluorescent probe is likely to be reporting the properties of 
mycomembrane in the mycobacterial envelope. Also, the high correlation shown between GP 
and DPH anisotropy supports the findings in which membrane rigidity has an inverse 
relationship with membrane order on M. smegmatis and the changes in membrane rigidity is 




Significant difference was observed when M. smegmatis was grown in the presence of 
tyloxapol, with a higher membrane rigidity and lower membrane order when compared with 
the growth control without tyloxapol (7H9O). The established capsule shedding effect of 
tyloxapol might be one explanation. The extractable and loosely bound lipids removed from 
the bacterial surface might lead to the enhanced hydration of the Laurdan fluorescent moiety 
or facilitate the penetration of DPH probe in the mycomembrane which resulted in a lowered 
GP value and an increased DPH anisotropy r. Metabolic studies revealed the reduction of 
saturated lipid resonances in the presence of tyloxapol which suggests its effect on the 
mitigation of membrane surface lipid components. This further indicates the mycomembrane 
structure was altered in response to the action of the surfactant. In essence, tyloxapol is a 
lipase inhibitor which has been reported to exert metabolic effects350.  
Interestingly, capreomycin without the capsule washing action, caused the same effect of 
increasing rigidity whereas reducing the order of mycomembrane. Although the exact 
mechanism of the action of capreomycin is not fully understood, its antimicrobial activity 
against mycobacteria is thought to be the influence on the function of ribosomes leading to 
the inhibition of protein translation110. Specifically, it involves the tlyA gene coding an rRNA 
methyltransferase for the methylation of the ribosomal interface in 16S and 23S rRNAs372. A 
transcriptomic study on Mtb confirmed this essential mechanism while uncovered substantial 
changes in an additional range of gene classes including cell wall processes, lipid and 
intermediary metabolism as well as cell respiration373. Notably capreomycin was shown to 
affect the preference of carbon source, through the upregulation of icl, glcB and acaAa genes. 
The glyoxylate shunt, an anaplerotic pathway of tricarboxylic acid (TCA) cycle which 
utilizes fatty acid and acetate for carbohydrates biosynthesis, was stimulated. Meanwhile, the 
expression of a series of genes associated with electron transport chain, including those 
encoding for NADH dehydrogenase or NADH-ubiquinone oxidoreductase, was reduced. The 
present study on M. smegmatis is consistent with these findings in which the substantial 
reduction in mycolic acid corresponds to the fatty acid being diverted for use as a carbon 
source. Otherwise, the accumulation of glutamate and trehalose, following the challenge with 
capreomycin, might be a result of stress-induced response. It was reported that glutamate may 
serve as an energy reserve when bacteria were stressed. M. bovis BCG were shown to use 
glutamate as carbon source under acidic and nitrosative stress374. Cowley et al.375 have also 
proposed the increased level in glutamate and glutamine may act as a source of amine for the 
synthesis of reducing buffers such as mycothiol by Mtb to deal with oxidative stress. Boots et 
al.376 identified the concomitant release of free trehalose as a signal for cell envelope stress in 
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mycobacteria. Therefore, the action of capreomycin led to the alteration of cell wall integrity, 
in turn triggered the redox stress response, resulted in the increase in glutamate and trehalose 
production. The decrease in fatty acid and accumulation of glutamate were also shown in a M. 
smegmatis mutant with a Mce4- knockdown351. Mce proteins are involved in the transport of 
cell wall lipid and their absence alters cell wall structure and architecture. This suggests 
capreomycin might induce the same downstream responses through the induction of cell wall 
remodeling. When compared with challenge by rifampicin, no significant change was 
detected in individual metabolite levels in spent culture media with capreomycin. Overall, 
these findings indicate that a substantial shift in metabolism was initiated by the challenge of 
capreomycin causing a greater consumption of fatty acids, depletion of mycolic acid and 
mycomembrane rigidification as ratio of trehalose dimycolates to trehalose monomycolates 
was shifted favoring the latter. Consequently, this alteration of membrane caused by 
capreomycin may influence the ability of other antimicrobials to cross the barrier and reach 
their intracellular targets.  
Alternatively, rifampicin induced a comparatively less intense reduction in saturated and 
unsaturated lipid resonances than capreomycin and induced modest changes in 
mycomembrane properties. Rifampicin targets the DNA-dependent RNA polymerase of 
mycobacteria, exerting a greater antimicrobial effect on Mtb than M. smegmatis due to the 
intrinsic resistance of the latter. Nonetheless, challenge with rifampicin against Mtb was 
reported to alter expression in genes of the same functional classes as that affected by 
capreomycin377. Moreover, activation of isocitrate lyases in Mtb challenged by rifampicin and 
isoniazid indicates the upregulation of glyoxylate shunt bypassing the TCA cycle to reduce 
the production of reactive oxygen species (ROS), therefore increasing the resistance towards 
oxidative stress378.  The changes in mycolic acid induced by rifampicin alone or D-LAK120-
A in combination with rifampicin might be an indication of oxidative stress and reflected the 
penetration into the bacterium. Notably, combination of rifampicin with D-LAK120-HP13 
did not have the same effect. This again revealed the different mechanism of action of the 
two D-LAK peptides and therefore the difference in the level of potentiation when combining 
with various first and second-line anti-TB drugs.  
Trehalose also plays a role as mycolate carrier379. Surprisingly, significant decrease in 
trehalose was shown in isoniazid treatment.  This observation is unexpected as isoniazid acts 
by inhibiting mycolic acid synthesis and therefore accumulation of trehalose was reported as 
a result of the influence of isoniazid380. Isoniazid-treated M. smegmatis and Mtb were also 
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reported to accumulate free trehalose381. This discrepancy might be attributed to the effect of 
anaerobiosis as aforementioned, which reduces the amount of active isoniazid molecules 
rendering their ineffectiveness towards the bacteria. The absence of significance in most of 
the lipid resonances might also support the lack of isoniazid activity.  Furthermore, it was 
reported that trehalose was used as a carbohydrate source by M. smegmatis under anaerobic 
conditions367. The dissimilar response of M. smegmatis to the challenge of rifampicin 
compared with that to capreomycin, both quantitatively in HR-MAS and also qualitatively in 
spent culture media proposes evidence that the bacteria resist against oxidative stress by 
adopting different strategies. This counteracting mechanism towards rifampicin is likely to be 
facilitated by the alteration in metabolism of fatty acid in M. smegmatis but to a lesser extent 
than when challenge by capreomycin.  
 
Differing mechanism of action of D-LAK120-A and D-LAK120-HP13 
 
The difference in response in the combinations with capreomycin and the induced changes in 
bacterial metabolism showed that the two D-LAK peptides have distinct mechanism of action. 
The presence of proline residue in D-LAK120-HP13 gives rise to its flexible conformation to 
facilitate its penetration into mycomembrane. Consequently, significant changes in 
mycomembrane rigidity and induced reduction in lipid resonances were triggered by 
D-LAK120-HP13 but not the proline-free D-LAK120-A. The increase in flexibility of the 
peptide may allow a more intimate interaction between the peptide and the anionic lipid 
components, leading to lipid reorganization in the mcyomembrane. Other study shows that 
segregation of lipids were demonstrated in model multilamellar vesicles by membrane active 
cationic AMPs in vitro382. The selective lipid interaction with peptide was suggested to relate 
to the changes in membrane fluidity. Moreover, Scheinpflug et al.383 reported the membrane 
rigidification in live Bacillus subtilis induced by a synthetic cyclic hexapeptide cWFW. 
Adaptive response in the bacteria was also triggered on the level of membrane fatty acid 
composition upon cWFW stress. In addition to the changes in membrane property, stress 
response in M. smegmatis indicated by accumulation of glutamate was only observed when 
the bacteria were exposed to D-LAK120-HP13. This indicates D-LAK120-HP13 exert a 
membrane active effect inducing mycomembrane remodeling. On the contrary, D-LAK120-A 
inhibited the growth of M. smegmatis but did not induce the similar remodeling response at 
sub-MIC. The exact mode of action of this peptide cannot be clearly elucidated in the present 
study though the absence of induced membrane remodeling might shed light on other 
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mechanisms. For instance, the stronger synergy with capreomycin mediated by D-LAK120-A 
reveals its possible intracellular targeting ability. Overall, the results obtained using the 
combination of HR-MAS metabolomics and fluorescent probes have provided further 
information demonstrating distinct mechanism exhibited by the proline-free and 
proline-containing analogues.  
 
Action on mycomembrane underpins synergy in combinations 
 
In general, a synergistic combination requires two agents to work complementarily with each 
other by acting on different target sites or distinct effect on the same target, without 
counteracting each other’s activities. The combination of HR-MAS 1H NMR and 
fluorescence techniques allow the investigation of the different actions of antibiotics on the 
mycomembrane. This is attained by gaining the perspective of bacteria towards the exposure 
to antibiotics and thereby inferring the drug activity according to the corresponding bacterial 
responses. Using these quantitative and qualitative responses of M. smegmatis, the distinct 
membrane activity of antibiotics was proposed which underpins the synergistic effect in 
different combinations.  
Potency of D-LAK peptides or rifampicin in isolation against M. smegmatis was improved in 
the presence of tyloxapol but the effect of their combination was indifferent. Since rifampicin 
and tyloxapol both triggered a certain extent of remodeling in mycomembrane, it is 
postulated that the membrane active effect of D-LAK peptides might be inhibited in the 
combination with rifampicin in the presence of tyloxapol. In the absence of tyloxapol, action 
of D-LAK120-HP13 was more prominent and thereby showing a better antimicrobial 
efficacy than D-LAK120-A when combined with rifampicin. This result may reflect the 
different effect on the activity of the two D-LAK peptides caused by changes in membrane 
properties induced by rifampicin. In contrast to the antagonistic D-LAK120-A and rifampicin 
combination, it could be suggested that D-LAK120-HP13, with the proline modification, is 
more effective in facilitating the penetration of rifampicin through the mycomembrane. On 
the other hand, modest synergistic interaction occurs in combination of capreomycin with 
either of the D-LAK peptide. Nonetheless, this interaction was promoted in the presence of 
tyloxapol. Since tyloxapol enhanced the action of both D-LAK peptides and rifampicin but 
not capreomycin against M. smegmatis when used alone, this promotion of synergy is more 
likely due to the improved access of either D-LAK peptide in the combination instead of 
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capreomycin. Although difference in the performance of both combinations was not 
significant, D-LAK120-A outperformed D-LAK120-HP13.  The poorer synergy in D-
LAK120-HP13 combination with capreomycin might be due to the similar mechanism of 
action of both agents on the mycomembrane. Also, this action of D-LAK120-HP13 could 
possibly affect the structure or functioning of porin channels on the mycomembrane 
hindering the diffusion of hydrophilic capreomycin to a certain extent. Despite the difference 
in magnitude of bacterial responses, the induction of changes in mycomembrane by both 
capreomycin and rifampicin suggest membrane interaction as one of the important 
determinants for synergistic interaction against M. smegmatis. The distinct physicochemical 
properties of the drugs might be a possible explanation. Capreomycin and rifampicin are both 
cationic molecules with the molecular weight of 668 Da and 823 Da respectively, but the net 
positive charge at physiological pH of capreomycin is +4, higher than +1 of rifampicin. 
D-LAK peptides, possessing a net charge of +9, have a high affinity for the negatively 
charged mycomembrane, therefore may serve as a screen for the membrane to interact with 
either rifampicin or capreomycin. The higher positively charged capreomycin would render it 
easier to overcome this screen and this may explain the observed synergy of the combinations.  
In conclusion, the action of the two D-LAK peptide analogues can be distinguished based on 
the corresponding response of M. smegmatis and their different abilities in facilitating the 
antimicrobial activities of other antibiotics. Besides, the combination of fluorescence 
spectroscopy and HR-MAS 1H NMR technique revealed that combining with anti-TB agent, 
in particular those that trigger mycomembrane remodeling, may affect the effectiveness of 
peptides in combinations. In addition to the mode of action of each anti-TB agents, 
understanding their mutual interactions would be crucial for the design of prominent 
antibiotic combinations. This study demonstrated the use of these techniques on M. 
smegmatis, which pathed the way to apply to the investigation on Mtb. In the next chapter, a 
severely attenuated Mtb Bleupan strain would be exploited to bring a step closer to the 
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In the previous chapter, a better understanding of the effect of the anti-tuberculosis (anti-TB) 
agents on mycobacterial membrane was gained using Mycobacterium smegmatis as model, 
HR-MAS metabolomics studies revealed the changes in the bacterial metabolites were 
mainly associated with the changes in the physical properties of the mycomembrane as well 
as an induced stress-response. The correlation of membrane rigidity with 
mycomembrane-dominated mycolic acids content identified the action of anti-TB agents, 
notably capreomycin and rifampicin, to trigger membrane remodeling in mycobacteria. These 
findings establish the basis for these techniques to be exploited to study the biological 
activity and mode of action of antibiotics on mycobacteria.  
In most of the early drug screening processes, different mycobacterial models have been 
employed as surrogate384 to avoid the use of slow growing, highly pathogenic Mtb. One of the 
most popular models, Mycobacterium bovis Bacillus Calmette-Guérin (BCG), is derived 
from the species M. bovis in the Mtb complex. M. bovis BCG was initially used for screening 
of 50 analogues of Para-aminosalicylic acid385. It has then become a popular model for TB 
research as it demonstrates high level of similarity to Mtb in terms of sensitivity towards drug 
candidates386, 387. Nonetheless, the differences between BCG and pathogenic Mtb, especially 
due to the result of region of difference 1 (RD1) deletion, rendering the use of BCG 
undesirable due to different host pathogen interactions. Although the doubling time of BCG 
(~16 hours) is shorter than that of Mtb (~24 hour), this remains a major limitation for 
efficient drug discovery studies. Instead, the fast-growing Mycobacterium aurum, bearing 
low pathogenicity but the ability to survive inside macrophage, serves as an alternative model 
of high throughput TB drug screening research388. In addition, the possession of mycolic acid 
analogues and similar antibiotic susceptibility profile to Mtb encourage the use of M. aurum 
as a surrogate to study anti-TB agents389. Despite the merits suggested, this non-tuberculous 
species also demonstrated highly deviated stress responses as compared to Mtb and did not 
show non-replicating persistence390. As the induced-stress response can be one of the possible 
mechanisms of drug action, it is necessary to take this into consideration and therefore the 
choice of M. smegmatis in the preceding study was made for its similarity to Mtb in this 
aspect390.  
Other model mycobacteria employed in TB studies include M. fortuitum, M. phlei, M. 
abcessus, M. marinum, all with varying strengths and weaknesses in serving as Mtb model388. 
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The shorter doubling time and requirement of lower biosafety facility render M. smegmatis 
an attractive model for the study of TB biology353. However, much of the controversy 
involving the use of M. smegmatis has also stemmed from its low pathogenicity and different 
cell wall structure354 while studies to verify their applicability are rare. To address this issue, 
the response between Mtb Bleupan and M. smegmatis were compared to deduce whether M. 
smegmatis is a reliable surrogate model. The severely attenuated Mtb Bleupan strain was 
demonstrated in Chapter 4 as a useful model for studying virulent Mtb strains due to their 
similar susceptibility towards antibiotics and D-LAK peptide combinations. Thus, 
corresponding drug-induced mechanistic responses of Mtb Bleupan were evaluated here 
using the combination of biophysical techniques established in the preceding chapter. 
Through comparison with the data generated from Mtb Bleupan, the level of translatability of 
findings in M. smegmatis can be deduced, allowing evaluation of the continued applicability 
of the latter for further antibiotic studies. 
Since the high potency of combinations of D-LAK peptides with rifampicin or isoniazid 
against MDR-TB clinical isolates was not shown on M. smegmatis, a more relevant Mtb 
model was used to look for possible explanations. Therefore, this study aimed to use Mtb 
Bleupan as the model to investigate the action of anti-TB agents and the underlying 
mechanism of synergy between the D-LAK peptides and rifampicin or isoniazid observed in 
MDR-TB. This would enable a more in-depth understanding of the effect of anti-TB agents 
on Mtb metabolism and growth responses, in particular concerning components consisting 
the mycomembrane. More information could then be gathered to postulate the mechanism of 
interaction between D-LAK peptides and rifampicin or isoniazid. 
In this study, the culture of Mtb Bleupan strain was incubated with sub-inhibitory 
concentration of antibiotics or D-LAK peptide combinations in liquid medium without 
agitation nor detergent. Owing to the slow-growth rate, two different conditions were 
selected for the sub-MIC challenge assay, i) six weeks challenge of 1% inoculum with ¼  
MIC of anti-TB agents and ii) 72 hours challenge of six-week cultured bacteria with ½  MIC 
of anti-TB agents. Membrane properties were examined by DPH fluorescent probe. HR-MAS 
and liquid-state NMR metabolomics were performed to study metabolic changes induced by 
each of the challenge conditions. These experiments were designed to test how the antibiotics 
and their combinations with D-LAK peptides may act on Mtb and provide valuable insights 
regarding the suitability of the mycobacterial models in the study of antibiotics actions using 
a variety of biophysical techniques. 
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6.2 RESULTS  
6.2.1 Determination of media effect on membrane properties by DPH and Laurdan 
fluorescence assays 
Laurdan and DPH fluorescence assays were used to study how different culture media 
composition affected the membrane properties of Mtb Bleupan (Fig. 6.1). The aim of this 
preliminary experiment is to understand the effect of OADC-supplement (denoted by the 
“O”) and tyloxapol on the growth of Mtb Bleupan. OADC-supplement is considered 
necessary for the normal growth of mycobacteria in vitro, whereas tyloxapol acts as an anti-
clumping agent but also induced changes in mycobacterial membrane morphology as 
described for M. smegmatis in the preceding chapter. GP values and anisotropy (r) denote the 
membrane order and rigidity, respectively. Significant differences were found between the 
GP values of Laurdan dyed Mtb Bleupan cultured in 7H9 with tyloxapol and cultured in 7H9 
alone (p < 0.05) as well as between Mtb Bleupan cultured in 7H9O with tyloxapol and 7H9O 
(p < 0.01). The membrane order, as inferred from Laurdan GP, was found to be higher in the 
presence of tyloxapol in both cases. The presence of OADC-supplement also resulted in 
significantly higher membrane order when compared with those conditions without 
supplement. The measurement of membrane rigidity using DPH fluorescence assay did not 
show any significant changes in different conditions. Albeit modestly, Mtb Bleupan grown in 
7H9 medium with OADC supplement showed to have the highest membrane rigidity which 
suggests the possession of an intact mycomembrane with tight packing of mycolates. 
Danilchanka et al.391 also demonstrated OADC maintained healthy growth and thriving of 
Mtb as compared with other carbon sources such as 1% glucose, 0.5 % glucose with glycerol 
or 1 % tween 80 in 7H9 medium. Mtb Bleupan cultured in 7H9O was then used as untreated 






Figure 6.1 Media effect on membrane properties of Mtb Bleupan by Laurdan and DPH fluorescence 
assay. The left y-axis shows the GP values from Laurdan probe; the right y-axis shows the DPH 
anisotropy r. Significant difference in GP values between conditions was assessed using one-way 
ANOVA analysis followed by Tukey's Multiple Comparisons Test, *<0.05, **<0.01, ***<0.001. No 




6.2.2 Mycobacterial growth response assays 
 
Fluorescence assays 
In order to study the mechanism of action of different anti-TB agents and their combinations, 
Mtb Bleupan was challenged with various anti-TB agents and their combination with D-LAK 
peptides. Two conditions were performed in this study: i) six weeks challenge of 1% 
inoculum with ¼  MIC of anti-TB agents and ii) 72 hours challenge of six-week cultured 
bacteria with ½  MIC of anti-TB agents. Due to the complexity of Mtb cell envelope, the 
distribution of interfacial Laurdan probe would be anticipated to vary in a greater extent than 
DPH probes which mainly reside in the hydrophobic regions. Therefore, only DPH probe was 
selected to perform this study. Anisotropy of the DPH fluorescent probe was measured for 
bacteria grown in both conditions (Fig. 6.2). Notably, the membrane rigidity of untreated Mtb 
Bleupan was generally higher than that of M. smegmatis (r < 0.1). This might reflect the 
differences in the structure of mycolic acids consisting the respective mycobacterial 
membrane. For the six-week challenge (Fig. 6.2A), a significant decrease in membrane 
rigidity was observed when the bacteria were cultured in the presence of 0.025 % tyloxapol. 
This contrasts with the analogous experiment performed for M. smegmatis mc2 155 in the 
previous chapter where the fluorescence anisotropy was observed to decrease for the same 
treatment. Growth of Mtb Bleupan with D-LAK peptides at ¼  MICs induced slight increase 
in membrane rigidity and this effect is also observed when they were used in combination 
with rifampicin or isoniazid while capreomycin induced similar level of changes in 
membrane rigidity. However, none of these changes was significant when a one-way 
ANOVA was performed across all samples. Since it was speculated that the modest changes 
in membrane property might be due to the degradation of anti-TB agents through the long 
incubation time, another study condition was performed in which six-week cultured bacteria 
were challenged with ½  MIC of anti-TB agents for 72 hours. 
Challenge of Mtb Bleupan with ½  MIC for 72-hour resulted in slightly different observations 
in some of the conditions (Fig. 6.2B). Again, the general trend was that each treatment led to 
a modest increase in fluorescence anisotropy, and hence membrane rigidity. However, the 
differences were found to be non-significant when a one-way ANOVA was performed across 
all samples. Exceptions were treatment with isoniazid alone, which resulted in highly 
significant (p < 0.001) increase in membrane rigidity denoted by r at 0.19 ± 0.02 comparing 
to 0.13 ± 0.02 of untreated control (7H9O), and the combination of isoniazid with D-
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LAK120-A which led to more modest increase in r. Combination with D-LAK120-HP13 was 
shown to mitigate the action of isoniazid itself resulting in negligible changes in membrane 
rigidity. These results are consistent with manipulation of the membrane physical properties 
by sub-inhibitory isoniazid challenge, possibly through the drug action of interfering the 
synthesis of mycolic acid. Neither of the D-LAK peptides induced similar responses 
indicating that the mechanisms of response to the D-LAK peptides are different to those 
found for isoniazid. This may be essential for the synergistic interaction of these different 
antibiotics as seen in the previous FIC studies (Chapter 4, Table 4.4). The mitigation of the 
isoniazid induced increase in rigidity may therefore be a hallmark of synergism but may also 
be related to the fact the concentration of both D-LAK peptide and isoniazid used here in the 
combination were much lower than when they were applied alone. Again, capreomycin 
challenge brought about a modest but non-significant increase in membrane rigidity. 
Delamanid, another anti-TB drug acts by inhibition of mycolic acid synthesis, caused an 
increase in membrane rigidity of the same magnitude as that induced by capreomycin but this 
was found to be significant (p < 0.05).  Colistin, targeting cytoplasmic membrane of Gram-
negative bacteria, on the contrary, did not induce any changes in mycobacterial membrane in 







Figure 6.2 DPH fluorescence anisotropy of Mtb Bleupan response to challenge with anti-TB agents 
and combinations. Mtb Bleupan subjected to challenge at ¼  MIC for 6 weeks (A) or ½  MIC for 72 
hours (B). Data were presented as mean ± SD (n=9). Significant difference was assessed using one-





Metabolite assignment of Mycobacterium tuberculosis Bleupan  
HR-MAS 1H NMR metabolomics was used to elucidate the metabolites in the whole cell 
sample of unchallenged Mtb Bleupan. Comparison of the 1H NMR spectra obtained from 
HR-MAS (Fig. 6.3) and liquid state NMR (Fig. 6.4) show the dominance of broad lipid peaks 
in whole cell sample of Mtb Bleupan in the HR-MAS spectra. As compared with spectra of 
M. smegmatis, some of the lipid resonances were less intense in the whole cell analysis 
whereas more metabolites were detected in the spent culture media of Mtb Bleupan. 
Assignments of metabolites associated with peaks are shown as a reference for the 
backscaled loadings and NMR spectra shown in this section.  Lipid resonances were assigned 
according to the general mycolic acid structure. Distinct mycolic acid signals were identified 
to consist of the different saturated and unsaturated lipid resonances and trehalose. A low 
intensity resonance assigned to unsaturated -CH=CH- lipid (2.03 ppm) arising from the 
meromycolate chains of mycolic acids was detectable. Signals from the integration of 
cyclopropyl proton resonances (- 0.33 ppm), however, were not detected. This may be a 
result of the low sensitivity of HR-MAS in addition to the low diffusion rate of mycolates in 
the mycomembrane. Insufficient hydration by D2O leads to very weak signals from certain 
protons and although the bacteria samples were allowed to hydrate for at least 2 h before 
being analyzed by HR-MAS, rehydration in 10 x volume of D2O may be required239. Alahari 
et al. also proposed the addition of 5 μl of chloroform to disrupt the mycobacterial cell wall 
which allowed the observation of the protons of the cyclopropyl-ring by HR-MAS338. 
Alternatively, proton NMR analysis of lipid extract of Mtb enabled the detection of 
cyclopropane structure in mycolic acids255.  Assignment of resonance without overlapping 
signal from lipids, was possible for valine, alanine, lysine, glutamate, serine, trehalose, 
sucrose and glycerate (Fig. 6.3). Spectra of spent culture media of Mtb Bleupan showed 
relatively higher resolution without the interference of broad peaks (Fig. 6.4). Binary 
comparison of metabolism of Mtb using spent media versus fresh media revealed the bacteria 
consumes pyruvate and glutamate but not glucose unlike M. smegmatis and, they produced 
mainly succinate, acetate and another metabolite cadaverine which was not detected in M. 
smegmatis culture (Fig. 6.5). Metabolites assigned with their corresponding ppm are 





Figure 6.3 1D 1H HR-MAS spectrum of whole cell Mtb Bleupan grown in 7H9O media. Spectrum was 
obtained at 600 MHz for 1H at a sample spinning speed of 5 kHz with the sample maintained at 310 K.  
 
 
Figure 6.4 1D 1H CPMG NMR spectrum of spent 7H9O culture media after 6 weeks growth of Mtb 




Figure 6.5 Volcano plot depicting changes in various metabolites in spent media of Mtb Bleupan 
incubated for 6 weeks as compared with Fresh Media 7H9O. Volcano plots are of PQN normalized 
data and allow comparison of fold changes and significance of each metabolite; blue – significant 
reductions, red – significant increases and grey – non-significant changes in the indicated metabolites. 





In order to evaluate how each treatment affects the growth of Mtb Bleupan, the metabolic 
profile of whole cell bacteria and their spent media were analysed using a non-targeted NMR 
metabolomics approach. All reduced data matrices from 1H NMR spectra after pre-processing 
were subjected to multivariate analysis. PCA plots were constructed initially to obtain an 
overview of the dataset (Appendix C, Fig. 7.30-7.33). For both six-week and 72-hour 
challenge, PC 1 accounted for over 90 % of the variation. The loading plots indicate that 
these variations are associated with the saturated lipid components at 1.29 ppm and trehalose 
at 3.8 ppm. PC 2 explained less than 1 % of the variation in both conditions. Nonetheless, no 
obvious clustering was resulted by projecting the dataset through PC1 and PC2. This 
phenomenon might arise as PCA is limited to a linear model which does not readily 
distinguish variations between within-class and between-class392. The most influential 
metabolites in sample variation were denoted, -(CH2)n- and trehalose. On the other hand, 
analysis of spent culture media was also similar at both conditions in which PC 1 explained 
the majority of the variance found in the dataset at 96.2 % and 92.9 % for six-week and 72-
hour incubation, respectively. The key metabolites responsible for the variations were ethanol, 
pyruvate and tartrate. Fresh media samples were found to be clustering in both conditions, 
while samples with tyloxapol only clustered in the analysis of 72-hour challenged samples.  
OPLS-DA was used to extract further information relevant to the growth response of Mtb 
Bleupan under each treatment to identify significant metabolites that contributed to their 
differences from the untreated control. The Q2 and permutated Q2 indicate the predictability 
of the proportion of variance in the data by machine-generated models using assigned and 
random class labeling respectively.  (Table 6.1 and 6.2). The calculated Q2 of assigned 
classes in most conditions are close to 1 or have a greater value than permutated Q2. Value of 
Q2 above zero is useful for the determination of significance of certain treatment. The greater 
the value of Q2 than permutated Q2, the more reliable the model is in illustrating the 
significant difference between each assigned class and the untreated control. These 
treatments with high Q2 were marked in bold which resulted in significant changes illustrated 
by the succeeding volcano plots and univariate analysis. While in some cases such as the 1H 
HR-MAS data of D-LAK120-A with rifampicin and D-LAK120-HP13 with rifampicin at six-
week incubation, a negative Q2 was produced. This reflects the assigned classes did not show 
significant difference from the untreated control, suggesting that these treatments did not 
trigger detectable difference in terms of metabolic responses.  
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Results from the 72-hour challenge reflected a generally better separation in each treatment 
from the untreated control where the higher drug concentration and/or shorter incubation time 
contribute to a more prominent effect. The best separation in the 72-hour treatment was the 
combination of D-LAK120-A with capreomycin and it is also the treatment that induced the 




Table 6.1 Test and permutated Q2 scores for cross-validated OPLS-DA models of 1H HR-MAS or 
liquid-state NMR spectra of Mtb Bleupan challenged for 6 weeks. Comparison of unchallenged 
bacteria with those obtained from bacteria treated by the indicated conditions. Those conditions where 
significant changes are also seen in individual metabolites were highlighted in bold (univariate 
analysis with Mann-Whitney U test and Benjamini-Hochberg false discovery rate adjustment). 
 
Table 6.2 As above but for cross-validated OPLS-DA models of 1H HR-MAS or liquid-state NMR 




 Q2 permutated Q2  Q2 permutation Q2 
0.025%Tyloxapol 0.788 -0.394 0.025%Tyloxapol 0.808 -0.200 
D-LAK120-A 0.084 -0.337 D-LAK120-A 0.361 -0.206 
D-LAK120-HP13 0.162 -0.304 D-LAK120-HP13 0.407 -0.204 


























Capreomycin 0.594 -0.334 Capreomycin 0.705 -0.211 
Colistin 0.248 -0.293 Colistin 0.832 -0.238 
Delamanid 0.643 -0.393 Delamanid 0.865 -0.306 
   Fresh media 0.931 -0.188 
HR-MAS Liquid-state 
 Q2 permutated Q2  Q2 permutation Q2 
0.025%Tyloxapol 0.631 -0.404 0.025%Tyloxapol 0.886 -0.262 
D-LAK120-A 0.503 -0.271 D-LAK120-A 0.630 -0.267 
D-LAK120-HP13 0.426 -0.337 D-LAK120-HP13 0.824 -0.413 
Rifampicin 0.593 -0.267 Rifampicin 0.331 -0.277 







Isoniazid 0.185 -0.275 Isoniazid 0.497 -0.303 
























Colistin 0.702 -0.348 Colistin 0.816 -0.399 
Delamanid 0.624 -0.310 Delamanid 0.643 -0.291 
   Fresh Media 0.983 -0.175 
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A hierarchical clustered heatmap compares the loadings for each model calculated from the 
analysis (Appendix C, Fig. 7.34 and 7.35). On a relative scale, intense changes were mostly 
found in saturated and unsaturated lipid resonances, trehalose and glutamate for 1H HR-MAS 
dataset. Although the two study conditions gave quite a different response in terms of 
changes in these metabolites, it is probably originating from the difference in duration of drug 
challenges. This shows that Mtb Bleupan adopts alternative mechanisms when exposed to 
different stimuli or hostile environment as well as the length of exposure time. In the case of 
the changes in spent media across all treatments, accumulation and depletion of metabolites 
including 2-hydroxyisobutyrate, isovalerate, glycerol, ethanol, succinate, valine, pyruvate, 
acetate, glutamate, citrate, glucose and tartrate were more pronounced. 
To further verify the magnitude and significance of changes in certain key metabolites in 
HR-MAS, volcano plots were constructed for individual comparison of each condition for 
six-week incubation (Fig. 6.6). The presence of tyloxapol induced a significant increase in 
both saturated and unsaturated lipid resonances: –(CH2)n-, -CH3, -CH=CH- and R2CH-OH, 
while a decrease in trehalose, glutamate, serine and lipid R2CH-COOH were detected (Fig. 
6.6A). This is markedly different from the observation in M. smegmatis in which a significant 
decrease in saturated lipid resonances was resulted whereas glutamate and serine were 
significantly increased without any significant changes in trehalose content. Capreomycin 
treated Mtb Bleupan was shown to reduce the level of glutamate, lysine, lipid R2CH-COOH 
and both unsaturated lipids (Fig. 6.6J). This result was similar to the capreomycin-treated M. 
smegmatis in which there was a significant reduction in lipid resonances but on the contrary, 
a significant production of glutamate was observed. Higher amount of saturated lipid alkyl 
groups –(CH2)n- and -CH3 resulted from delamanid treatment whereas a reduction in 
glutamate, lysine and trehalose was also observed (Fig. 6.6L). Reduction of glutamate was 
detected in all samples that were exposed to isoniazid, whether in combination with D-LAK 
peptides or not (Fig. 6.6G-I). Combining D-LAK peptides with isoniazid mitigated the 
reduction in glutamate but, as above, the concentration of each antibiotic used in 
combinations was substantially lower than when it was used alone. Changes in metabolites 
for other challenge conditions, including rifampicin and both D-LAK peptides, did not pass 




Figure 6.6A-D ¼  MIC Challenges induce changes in various metabolites in whole cell Mtb Bleupan 
incubated for 6 weeks. Volcano plots are shown for individual comparisons of unchallenged bacteria 
and those challenged with 0.025% tyloxapol (A), D-LAK120-A (B), D-LAK120-HP13 (C), rifampicin 
(D). Volcano plots are of PQN normalized data (n=9) and allow comparison of fold changes and 
significance of each metabolite; blue – significant reductions, red – significant increases and grey –





Figure 6.6E-H ¼  MIC Challenges induce changes in various metabolites in whole cell Mtb Bleupan 
incubated for 6 weeks.  Volcano plots are shown for individual comparisons of unchallenged bacteria 
and those challenged with rifampicin in combination with D-LAK120-A (E) or D-LAK120-HP13 (F), 
isoniazid (G), isoniazid in combination with D-LAK120-A (H). Volcano plots are of PQN normalized 
data (n=9) and allow comparison of fold changes and significance of each metabolite; blue – 





Figure 6.6I-L ¼  MIC Challenges induce changes in various metabolites in whole cell Mtb Bleupan 
incubated for 6 weeks. Volcano plots are shown for individual comparisons of unchallenged bacteria 
and those challenged with isoniazid in combination with D-LAK120-HP13 (I), capreomycin (J), 
colistin (K) or delamanid (L). Volcano plots are of PQN normalized data (n=9) and allow comparison 
of fold changes and significance of each metabolite; blue – significant reductions, red – significant 




Univariate analysis allows the observation of significant changes in certain major metabolites 
across the treatments. Univariate plots (Fig. 6.7) depicting the changes in the key metabolites 
across treatments showed reduction in glutamate level when Mtb Bleupan was challenged 
with capreomycin and delamanid but not rifampicin (Fig. 6.7A). Delamanid also showed 
significant increase in saturated alkyl -CH3 group and –(CH2)n– chains (Fig. 6.7C/D). The 
presence of 0.025% tyloxapol resulted in the significant reduction of trehalose and increase in 
saturated alkyl -CH3 groups (Fig. 6.7B/D). Albeit modestly, increase in the saturated alkyl 
chains – (CH2)n– and both unsaturated alkyl groups –CH=CH– and –CH2-CH=CH– was 
observed in the presence of tyloxapol as compared with the untreated control (Fig. 6.7C/E/F). 
Results from binary comparisons illustrated in volcano plots and univariate analysis 





Figure 6.7 Univariate analysis of relative metabolite levels in whole-cell Mtb Bleupan challenged with 
indicated conditions for 6 weeks. Data were PQN normalized and presented as mean ± SD (n=9). 
Significant differences with respect to unchallenged bacteria, as determined by one-way ANOVA with 




Using partial least squares (PLS) regression model, correlation between metabolites and 
fluorescence anisotropy, r, were assessed (Fig. 6.8). The correlation between trehalose and 
DPH anisotropy was found to have the highest Spearman R correlation at 0.073. Despite the 
modest correlation, six-week challenge data set indicated membrane rigidity tended to 
increase with the increasing amount of trehalose (Fig. 6.8A) while decrease with the level of 
lipid resonances (Fig. 6.8C/D/E). The very modest negative correlation between membrane 
rigidity and lipid metabolites could also be observed from the correlations. None of the 
correlations was found significant therefore no trend was identified from the Mtb dataset. As 
compared with the correlation observed in anti-TB agent challenge on M. smegmatis in which 
membrane rigidity was significantly correlated with increasing trehalose content and 
decreasing lipid resonances, this indicated none of the anti-TB agents had any effect on Mtb 
in both challenge conditions.  
 
 
Figure 6.8 Correlation between membrane rigidity and the altered composition of the mycomembrane 
of Mtb Bleupan. Spearman correlations are shown between DPH anisotropy (r) and 1H HR-MAS NMR 
resonance intensities obtained for Mtb Bleupan grown without challenge or with 0.025% Tyloxapol or 
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¼  MIC of indicated conditions in the legend (n=9). Data is shown for trehalose (A), lipid –(CH2)n- (B), 
lipid -CH3 (C) and lipid –CH=CH- (D). 
From the results of spent media at six-week challenge, changes in metabolites were found in 
a few conditions. Growth with 0.025% tyloxapol reduced acetoacetate, acetate and succinate 
production (Fig. 6.10A). Delamanid treatment reduced the production of these metabolites as 
well as 2-hydroxyisobutyrate. In addition, more glucose, glutamate and alanine were 
consumed (Fig. 6.10F). Interestingly, in contrast to delamanid, challenge with capreomycin 
increased production of 2-hydroxyisobutyrate, lactate, acetoacetate, acetone, valine (Fig. 
6.10D) and a significant amount of glucose was found accumulated in this treatment (Fig. 
6.9). Similarly, accumulation of glucose was seen in colistin treatment and there was also an 
increase production of citrate, methylmalonate, alanine and glutamate but not valine (Fig. 
6.10E). Exposure to isoniazid caused the reduced production of acetate only. Other 
treatments including both D-LAK peptides and their combinations with rifampicin or 
isoniazid did not show significant changes in any metabolites (Appendix C, Fig. 7.48.)  
 
 
Figure 6.9 Univariate analysis of glucose levels in spent media of Mtb Bleupan challenged with 
indicated conditions for 6 weeks. Data were PQN normalized and presented as mean ± SD (n=9). 
Significant differences with respect to unchallenged bacteria, as determined by one-way ANOVA with 





Figure 6.10A-F ¼  MIC Challenges induce changes in various metabolites in spent media of Mtb 
Bleupan incubated for 6 weeks. Volcano plots are shown for individual comparisons of unchallenged 
bacteria and those challenged with 0.025% tyloxapol (A), rifampicin (B), isoniazid (C), capreomycin 
(D), colistin (E), delamanid (F). Volcano plots are of PQN normalized data (n=9) and allow 
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comparison of fold changes and significance of each metabolite; blue – significant reductions, red – 
significant increases and grey – non-significant changes in the indicated metabolites. 
Considering 72-hour challenge of Mtb Bleupan, Volcano plots of 1H HR-MAS data of whole 
cell bacteria indicate changes in metabolites resulted in only a few conditions (Fig. 6.11). 
Compared with the combination of capreomycin with D-LAK120-HP13, combination with 
D-LAK120-A induced more changes in metabolites. Sucrose, lysine and both saturated and 
unsaturated lipid resonances were reduced with an increase of glycerate. Moreover, decrease 
in the amount of sucrose was also detected in colistin alone, and in combinations of 
D-LAK120-HP13 with capreomycin or D-LAK120-HP13 with isoniazid. On the other hand, 
significant changes were only detected in a few treatments after the analysis of spent media 
of Mtb Bleupan (Fig. 6.12). Reduction of isovalerate, 2-hydroxybutyrate, tartrate and lactate 
were found when the bacteria were grown in the presence of 0.025% tyloxapol. D-LAK120-
HP13 challenge resulted in an increase in the level of 2-hydroxyisobutyrate, lactate and 
cadaverine. D-LAK120-A challenge also increased the production of cadaverine. Notably, the 
production of cadaverine was detected in untreated Mtb culture (Fig. 6.5) but the production 
further increased in the treatment of D-LAK peptides. The changes in this antioxidative 
metabolite is particular interesting as it was not detected in M. smegmatis samples. Besides, 
isoniazid induced production of succinate whereas colistin increased the amount of 
methylmalonate and lactate found in the spent media. Nonetheless, other treatment did not 





Figure 6.11A-D ½  MIC Challenges induce changes in various metabolites in whole cell Mtb Bleupan 
incubated for 72 hours. Volcano plots are shown for individual comparisons of unchallenged bacteria 
and those challenged with capreomycin in combination with D-LAK120-A (A) or D-LAK120-HP13 (B), 
isoniazid in combination with D-LAK120-HP13 (C), colistin (D). Volcano plots are of PQN 
normalized data (n=9) and allow comparison of fold changes and significance of each metabolite; 
blue – significant reductions, red – significant increases and grey – non-significant changes in the 





Figure 6.12A-D ½  MIC Challenges induce changes in various metabolites in spent media of Mtb 
Bleupan incubated for 72 hours. Volcano plots are shown for individual comparisons of unchallenged 
bacteria and those challenged with 0.025% tyloxapol (A), D-LAK120-A (B), D-LAK120-HP13 (C), 
isoniazid (D). Volcano plots are of PQN normalized data (n=9) and allow comparison of fold changes 
and significance of each metabolite; blue – significant reductions, red – significant increases and grey 




Re-analysis of anti-TB agent data excluding D-LAK peptides and corresponding combinations 
As presented above no effect of D-LAK peptides or their combinations with anti-TB agents 
could be demonstrated on Mtb Bleupan using either the techniques of fluorescent probes and 
NMR metabolomics. Any observable changes were generally less significant and 
characterized by substantial variation when compared with the analogous study of M. 
smegmatis. Concern was raised that, in the six-week incubation the expected variable half-
life of the D-LAK peptides would increase the variability of the bacterial response and this 
would negatively impact on the ability to discern significant differences when considering the 
dataset as a whole. While accepting that more work is required to optimize the treatment 
conditions for Mtb, to allow evaluation of the techniques and discussion of the information 
they provide on the elucidation of the mechanism of action of existing antibiotics, the 
analysis was performed again with the conditions involving D-LAK peptides removed.  
For the six-week challenge, 0.025% tyloxapol increased membrane fluidity modestly while 
capreomycin triggered significant (p < 0.01) reduction of membrane fluidity in Mtb Bleupan 
(Fig. 6.13A). This observation was also shown in 72-hour challenge (Fig. 6.13B). In addition 
to capreomycin, isoniazid and delamanid both induced significant increase in membrane 
rigidity as compared to untreated control grown in 7H9O broth medium. Also, membrane 
property of Mtb Bleupan treated by these two agents was found to be significantly different 
from those grown in the presence of tyloxapol in which the latter demonstrate a higher 
membrane fluidity, consistent with the observation at the six-week challenge. Treatment with 
rifampicin did not result in any detectable changes in bacterial membrane properties as shown 




Figure 6.13 DPH fluorescence anisotropy of Mtb Bleupan response to challenge with antibiotics. Mtb 
Bleupan subjected to challenge at ¼  MIC for 6 weeks (A) or ½  MIC for 72 hours (B). Data were 
presented as mean ± SD (n=9). Significant difference was assessed using one-way ANOVA analysis 
followed by Dunnett's or Tukey’s Multiple Comparisons Test for comparison between conditions, 
*<0.05, **<0.01, ***<0.001, and by Multiple Comparisons Test to compare with untreated control 




Univariate analysis shows a clearer picture of the changes triggered by each condition at 
six-week incubation regarding six representative metabolites (Fig. 6.14). Four treatments 
including isoniazid, capreomycin, delamanid and the presence of tyloxapol resulted in the 
same significant reduction in glutamate with respect to the unchallenged bacteria (Fig. 
6.14A). Mtb Bleupan cultured in tyloxapol also demonstrated significant reduction of 
trehalose whereas capreomycin did not show an explicit effect on the level of trehalose (Fig. 
6.14B). Capreomycin triggered modest reduction in lipid resonances, in particular it induced 
a significant reduction in -CH2-CH=CH- which is similar to its effect on M. smegmatis. In 
contrast to delamanid and tyloxapol, none of the other three antibiotics triggered any changes 
in saturated carbon –(CH2)n- and CH3- groups (Fig. 6.14C/D). The increase in saturated lipids 
in delamanid treatment might be the direct result of its reported mechanism to inhibit the 
production of keto- and methoxy-mycolic acids393. In terms of unsaturated lipid metabolites, 
significant reduction was only shown in capreomycin treatment while other conditions did 
not cause an apparent effect as compared with 7H9O bacterial control (Fig. 6.14E/F). The 
corresponding analysis for 72-hour challenge identified no significant differences between 




Figure 6.14 Univariate analysis of relative metabolite levels in whole-cell Mtb Bleupan challenged for 
6 weeks with ¼  MIC antibiotics or in the presence of 0.025% tyloxapol. Data were PQN normalized 
and presented as mean ± SD (n=9). Significant differences with respect to unchallenged bacteria, as 




From the results of PLS regression model using the data of the five treatment conditions and 
the untreated control (Fig. 6.15), similar trends were observed as in Fig. 6.8 in which none of 
the correlations was significant.  
 
Figure 6.15 Correlation between membrane rigidity and the altered composition of the 
mycomembrane of Mtb Bleupan (Re-analysis). Spearman correlations are shown between DPH 
anisotropy (r) and 1H HR-MAS NMR resonance intensities obtained for Mtb Bleupan grown without 
challenge or with 0.025% Tyloxapol or ¼  MIC of antibiotics. Data is shown for trehalose (A), lipid –





In the previous chapter, action of antibiotics and D-LAK peptides was shown to trigger 
various responses in M. smegmatis in terms of membrane properties and cell metabolism. 
Bacterial metabolism was substantially altered when challenged with tyloxapol, rifampicin 
and capreomycin, specifically by the remodeling of mycobacterial membrane. The changes 
were consistent with the increase in mycobacterial membrane rigidity detected in 
capreomycin and tyloxapol treatment. M. smegmatis is an attractive model system for the 
study of antibiotic mechanisms of action due to the much shorter doubling time.  However, 
the susceptibility of M. smegmatis towards the combination of rifampicin or isoniazid with 
D-LAK peptides was quite different from that observed for the MDR-TB clinical isolates. 
Therefore, to better understand the extent to which M. smegmatis is a suitable model 
organism to study the mechanism of action of anti-TB agents against MDR Mtb, the 
NMR/fluorescence anisotropy approach was replicated with the severely attenuated 
Mycobacterium tuberculosis Bleupan strain here. 
In the present study, fluorescence assays and NMR metabolomics studies revealed different 
changes induced by the anti-TB agents in Mtb Bleupan. As compared with M. smegmatis, the 
use of carbon sources (the preference for glucose by M. smegmatis but mostly pyruvate and 
glutamate by Mtb Bleupan) and disparate response to treatments such as tyloxapol suggested 
that the two microorganisms may adopt different biological pathways and counteracting 
mechanisms upon challenges. The employment of 72 hours and 6 weeks duration of 
challenge on Mtb Bleupan resulted in various levels of changes in individual metabolites and 
membrane properties. This indicates the greater need to understand the reason for the absence 
of antibiotic effect which might suggest importance of determining the in vitro half-life of 
anti-TB agents. Besides, it is essential to optimize the treatment conditions when using Mtb 
Bleupan to obtain significant understanding of action of anti-TB agents; due to its slow 
growing nature it is suggested that variation in the in vitro half-life of each antibiotic has 
much greater impact on the outcome of the NMR metabolomics and fluorescence anisotropy 
measurements than when the analogous experiment was performed in M. smegmatis. Notably, 
no impact of the D-LAK peptides, when used alone, could be detected in either treatment 
condition, except for an acute response at 72 hours challenge, characterized by increased 
production of cadaverine, detected in the spent media. Combinations of D-LAK peptides with 
isoniazid did induce a response but this was not significant when considered across the data 
set. Rifampicin and its combinations with D-LAK peptides induced no significant response. 
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Nevertheless, despite the generally modest responses, significant metabolic changes were 
consistently observed following treatment with capreomycin and delamanid, and these can be 
related to their reported mechanism of action. This allows a detailed comparison of the 
responses of the two species and is important information in understanding the relative 
strengths and weaknesses of the two systems for the investigation of the mechanism of anti-
TB agents. 
Membrane changes and NMR metabolomic responses following challenge with delamanid are 
consistent with its known mechanism of action  
 
Since peptide treatments did not show a great effect on Mtb Bleupan but led to greater 
variability of the data, removing those conditions revealed responses towards other anti-TB 
drugs in terms of membrane manipulation and metabolic influence on Mtb Bleupan. 
Significant reduction of glutamate was found in bacteria treated with isoniazid, capreomycin, 
delamanid and 0.025% tyloxapol. These treatments all share the common influence on cell 
wall synthesis. It was proposed that glutamate and pyruvate can be converted to D-alanine 
and thereby the biosynthesis of peptidoglycan in mycobacteria394. This change in glutamate 
might be the result of cell wall remodeling in response to the drug action although the 
changes in pyruvate and alanine were not significant in most conditions. Notably, the 
responses triggered by delamanid correlate with its reported mode of action. Delamanid acts 
by inhibiting the production of keto- and methoxy- mycolic acids393. Therefore, the 
accumulation of acyl chains and reduction in trehalose as well as the significant membrane 
rigidification could be the direct consequences.  
 
Differences in response observed in Mtb Bleupan compared with M. smegmatis indicate 
appropriateness to apply for antibiotic mechanistic study 
 
Mtb and M. smegmatis differ fundamentally by their cell wall structure, virulence and rate of 
growth. Comparison of the two metabolomic studies reveals that M. smegmatis mainly 
consume glucose while Mtb Bleupan consumes pyruvate and glutamate. Utilization of 
difference carbon sources for the growth of M. smegmatis and Mtb was also reported395. The 
study showed that both species consumed pyruvate, glutamate and glucose but did not report 
the comparison of relative dependence of different carbon sources. Its non-pathogenic 
behaviour and fast-growing nature are the major attractions for M. smegmatis to be employed 
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over Mtb. The significance of this study is the elucidation of the translatability of findings of 
these two models for antibiotic efficacy and mechanistic study of Mtb. By comparing the 
responses of M. smegmatis and Mtb Bleupan towards different antibiotics, the strength and 
weakness of the corresponding models are revealed. These findings therefore facilitate the 
further investigation to elucidate mechanism of drug action on Mtb.  
Delamanid was reported to show similar concentration-dependent killing effect to rifampicin 
against drug-susceptible Mtb396. The bacterial inhibitory studies on Mtb Bleupan revealed its 
high potency and killing efficiency resembling rifampicin. D-LAK peptides interacted 
synergistically with rifampicin and modestly with isoniazid against Mtb Bleupan. This 
response is similar to the action of these combinations demonstrated on MDR-TB clinical 
isolates. However, this synergy was not observed on M. smegmatis but rather when D-LAK 
peptides in combination with capreomycin. This may be ascribed to the intrinsic resistance of 
M. smegmatis to rifampicin and isoniazid. Agrwal et al.364 generated M. smegmatis strains 
with arr gene deletion which was found to be susceptible to rifampicin at the same level as 
Mtb, therefore suggested its use as a surrogate for Mtb drug testing. Khara et al.261 reported 
the synergy of the cationic M(LLKK)2M peptide with rifampicin on M. smegmatis and M. 
bovis BCG but the effect was additive on Mtb H37Rv. Such substantial differences in 
behavior suggest that variation in cell envelope composition between Mtb and M. smegmatis 
could serve as a critical factor on the action of AMPs especially those that interact with the 
mycomembrane. One of the major differences between cell wall components of the two 
mycobacteria is the types of structural mycolic acid. This affects the physical properties such 
as the packing of mycolates and rigidity of mycomembrane397.  In terms of length, the 
oxygenated mycolic acids that only exist in Mtb contain around 84-88 carbon atoms which is 
four to six carbons longer than that of M. smegmatis398. In terms of structure, the occurrence 
of trans-cyclopropanes facilitates the folding of oxygenated mycolic acids into a W-
conformation with the four acyl chains in parallel, forming a tight packing of mycolates in 
Mtb Bleupan399. These two intrinsic properties of the mycolates were shown to give rise to a 
high transition temperature of the cell wall of Mtb which could be the major factor that 
reduces the fluidity of the cell wall397. Indeed, when measured with the DPH probe, Mtb 
Bleupan exhibits a higher membrane rigidity than M. smegmatis as revealed by the higher 
fluorescence anisotropy values. In addition, the amount and nature of mycolic acids were also 
shown to correlate with the permeability of mycobacteria18.  
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Tyloxapol treatment again demonstrated the composition difference of mycobacterial cell 
envelope in the two microorganisms. When Mtb Bleupan was grown in medium of different 
compositions, changes in membrane order were observed as denoted by the general 
polarization (GP) value. Membrane order was found to be higher in the presence of tyloxapol. 
An opposite trend was depicted by M. smegmatis on membrane GP as compared to Mtb 
Bleupan. This suggests the differences in mycolic acid structure comprising the 
mycomembrane confer different properties on the cell wall of mycobacterial species. Besides, 
0.025 % tyloxapol led to an increase in saturated and unsaturated carbons but a reduction in 
trehalose content in Mtb Bleupan while M. smegmatis had an opposite response. This 
indicates that tyloxapol has the direct opposite effect on membrane order and lipids and 
trehalose in the two species. The fact that Mtb possesses cord-forming TDM while M. 
smegmatis does not, might give a possible explanation to this observation255. Tyloxapol was 
reported to reduce the surface TDM content of mycobacteria350. During the long incubation 
time, Mtb might adapt to the reduction in TDM content on the surface of cell wall and 
undergo remodeling by reducing TDM production, and in turns the reduction of free 
trehalose production and accumulation of intracellular -CH=CH- containing meromycolates. 
This phenomenon can also be supported by the reduced in vitro biofilm (formed by free MAs 
from TDM hydrolysis400) formation, in the culture with tyloxapol compared with other 
treatment conditions.  
Furthermore, the different synergistic outcome brought about by the capreomycin 
combinations in the two microorganisms suggests a differing channel distribution on 
corresponding mycomembrane. M. smegmatis possesses channels mainly of > 2 nS single 
channel conductance401. Among all types of porins present in M. smegmatis, 70% of them are 
mspA porins which mediate the transport of small hydrophilic molecules while large 
hydrophilic substances such as aminoglycosides are thought to enter by self-promoted 
uptake320. In contrast, Mtb intrinsically possesses much lower amount of porin320, apart from 
the existence of a few unnamed channels321. Other than the existence of ompA porin which is 
not involved in drug transport320 and  the absence of mspA homologues44, transport systems 
in Mtb remain largely unknown. Nonetheless, these pieces of information are sufficient to 
conclude that the mode of entry for hydrophilic substances varies immensely between the two 
microorganisms.  
Not only does the susceptibility and/or accessibility of Mtb to capreomycin differ from 
M. smegmatis but also the metabolic response, albeit with some common themes. For Mtb, 
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six-week challenge with capreomycin alone resulted in a reduction in the intensity of 
unsaturated lipid and lysine resonances. Meromycolate chains with double bond is the 
precursor of the synthesis of cyclopropanated mycolic acids in Mtb255, the synthesis of 
meromycolate chains might be affected leading to the reduction in unsaturated carbon 
resonance. Also, reduction in lysine may correspond to the effect of drug treatment that 
affects the mycolic acid pathway253.  
Overall, the results illustrated the closer resemblance of Mtb Bleupan to Mtb and MDR-TB 
clinical isolate as compared with M. smegmatis in biological responses towards antibiotics or 
combinations with D-LAK peptides. The findings also deduced the higher similarity in terms 
of mycomembrane composition and properties of Mtb Bleupan to MDR-TB clinical isolates 
than M. smegmatis. This study addressed the marked differences in mycobacterial cell wall 
and metabolic responses between Mtb Bleupan and M. smegmatis, pointing out the important 
consideration when choosing to use M. smegmatis as model for the study of antibiotic 
susceptibility and/or mechanism of action.    
 
Mtb Bleupan as a valid model to assess antibiotic efficacy and potentially optimized for 
promising mechanistic study 
 
Modest changes in membrane rigidity of Mtb Bleupan were detected by the DPH probe upon 
challenges at various treatments and experimental conditions. A significant increase in 
membrane rigidity was observed in treatments with isoniazid, D-LAK120-A with isoniazid, 
delamanid for 72-hour incubation and with 0.025% tyloxapol but only for the six-week 
incubation. This insensitivity, when compared to the significant findings in M. smegmatis, 
might be attributed to the inadequate amount of drug used for challenges and the hydrolysis 
of drug molecules over the long incubation period; it is challenging to identify the optimum 
time point for assessing changes in membrane physical properties and/or metabolism. The 
drug concentration used in the study was determined on the basis that the growth of Mtb 
could be maintained since the initial inoculum was 1% for the six-week challenge. Further, 
due to the long incubation period without continuous agitation, formation of biofilm was 
observed in most of the treatment conditions. This biofilm is known to protect mycobacterial 
cells from the bactericidal activity of antibiotics402 and related to the harboring of drug-
tolerant population403. Vortexing was performed intermittently to impede the formation of 
biofilm, though this downstream effect of biofilm formation could not be completely avoided. 
197 
 
The drug concentration was increased at the 72-hour challenge of Mtb Bleupan at mid-log 
phase aiming to observe a more dramatic response in the membrane structure. The later 
challenge did induce significant membrane changes in more conditions which shows that a 
higher concentration could be employed to observe the immediate effects of anti-TB agents. 
The six-week challenge approach is easily affected by the half-life of drugs. In order to assess 
the growth response of Mtb Bleupan, additional challenges might be introduced during the 
six-week incubation to maintain the drug effect. One must also take into consideration the 
emergence of resistant population under continuous treatment of sub-MIC drug 
concentration30. Future experiments should include the evaluation of the metabolic stability 
and half-life of each antibiotic using quantification techniques such as liquid-chromatography 
mass spectrometry404. This will enable the challenges to be performed with optimal 
concentration as well as to be replenished at relevant condition, eliminating the lack of 
responses due to the absence of sufficient antibiotics.     
 
Biophysical techniques and NMR metabolomics provide insight to the function of D-LAK 
peptides  
 
Antimicrobial peptides such as pleurocidin and LL-37 have been reported to induce oxidative 
stress in Candida albicans405 and Escherichia coli406, respectively. There is evidence that 
D-LAK peptides are capable of inducing oxidative stress in mycobacteria, but this is 
manifested in different ways in M. smegmatis and Mtb. The significantly increased 
production of cadaverine in D-LAK120-A or D-LAK120-HP13 treatment after 72-hour 
challenge is a response observed in the metabolism of Mtb which was not observed in that of 
M. smegmatis; D-LAK120-HP13 but not D-LAK120-A was implicated as an enhancer of 
oxidative stress in M. smegmatis due to glyoxylate shunt associated reductions in lipids. 
Cadaverine is an antioxidant polyamine which is synthesized by bacteria to counter oxidative 
stress induced by free radicals. Loots407 demonstrated the increase production of cadaverine 
in INH-resistant Mtb strain to compensate for the reduced catalase-peroxidase synthesis due 
to katG downregulation. Tkachenko et al.408 also reported the upregulation of katG activity 
by a range of polyamine including cadaverine under the exposure to oxidative stress. This 
implies that the responses in Mtb, induced by the immediate action of D-LAK peptide, have 
highlighted a role for oxidative damage in the action of D-LAK peptides. Overall, these 
findings suggest the possible multifunctional properties of D-LAK peptides in particular 
against Mtb.  
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The NMR metabolomics study also provides evidence of metabolic changes in Mtb induced 
by particular treatments. D-LAK120-A in combination with capreomycin led to significant 
reduction of saturated and unsaturated lipid resonances after 72 hours of challenge. Since 
these changes were not found in either D-LAK120-A or capreomycin when they were used 
alone, the combination might exert an effect on the metabolism of Mtb Bleupan.  
 
Overall summary  
 
Differences in terms of membrane properties and metabolomic responses between 
M. smegmatis and Mtb Bleupan have highlighted the issue of applicability of the 
non-pathogenic model for direct extrapolation of findings. Comparing to the six-week 
culturing time of Mtb, M. smegmatis only needs 48-hour to attain mid-log phase. This highly 
desirable feature enables the acceleration of study on mycobacteria, it would therefore be 
recommended to employ as a preliminary model for establishment of methodology.  
Furthermore, this study showed that some notable differences in the biological responses, 
membrane physiology and metabolism of M. smegmatis and Mtb Bleupan meaning the latter 
is likely to more faithfully reproduce the behaviour of clinical Mtb strains. It can be 
concluded that, despite the practical challenges involved in the use of Mtb Bleupan, it 
represents as a more favorable model for Mycobacterium tuberculosis and can potentially 
generate more translatable data in the study the action of TB antibiotics. Due to the slow 
growth of Mtb Bleupan, further optimization in terms of the challenge time period and 
knowledge of the in vitro half-life for each antibiotic are essential to develop a reliable assay 






















Tuberculosis (TB) is a global disease that creates one of the most pressing worldwide 
medical emergencies; fueled by the emergence of multidrug-resistant (MDR) strains, TB is 
continuously endangering the gains that have already made in its control. Most of the drugs 
involved in TB treatment nowadays were developed four decades ago, the growing 
emergence of drug resistance renders these medications inefficient, creating an urgency to 
establish a novel, safe and effective treatments than those currently available.  
Antimicrobial peptides (AMPs) are capable of rapid killing through a variety of mechanisms. 
They have demonstrated potent antimicrobial activity against a broad spectrum of microbes. 
When combined with conventional anti-TB drugs, AMPs can serve as a promising strategy 
for TB therapy. The novel D-LAK peptides, have displayed a detergent-like effect which 
affected the survival of MDR and extensively drug-resistant (XDR) TB clinical isolates in 
vitro and ex vivo259. The ability of D-LAK120-A and D-LAK120-HP13 to potentiate the 
activity of isoniazid against MDR Mycobacterium tuberculosis (Mtb) strain suggested the 
potential synergy between D-LAK peptides and first-line anti-TB agents to re-sensitize 
drug-resistant Mtb strains.  
This work started with the investigation of the antimicrobial action of the combinations of 
D-LAK120-A or D-LAK120-HP13 with rifampicin or isoniazid and then the potential 
synergistic interaction of the combinations against Mtb strains was evaluated. The 
combinations were demonstrated to be effectively synergistic against MDR-TB clinical 
isolates 03M, 08MB, GB2 and 08M strains. Combination with either peptide re-sensitized all 
the four studied strains towards rifampicin, while the addition of either peptide also restored 
the sensitivity of 03M and 08MB towards isoniazid. In vitro studies revealed the 
mycobactericidal effect of D-LAK peptides in combination with isoniazid against 03M, and 
D-LAK peptides in combination with rifampicin against 08MB were comparable with 
rifampicin or isoniazid alone but at a reduced drug concentration. Moreover, combination of 
D-LAK120-HP13 with isoniazid achieved a log reduction of 03M in THP-1 macrophages as 
compared with isoniazid used alone. This synergy demonstrated by the combinations with D-
LAK peptides achieved at least two-fold reduction of rifampicin or isoniazid concentration, 
reflecting the possibility of these combinations to delay the emergence of drug resistance. 
Incorporation of D-LAK peptides at non-toxic concentration enhanced the efficacy of 
rifampicin and isoniazid, overcoming the resistant phenotype of MDR Mtb strains. This 
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indicates the potential of these combinations to be further developed as new therapeutics 
against drug-resistant TB.  
Based on the de-clumping action demonstrated by the D-LAK peptides in the previous 
studies259, 310, further investigation on the interaction of D-LAK peptides with mycobacterial 
membrane was performed using transmission electron microscopy and confocal microscopy. 
Treatment with D-LAK120-A and D-LAK120-HP13 revealed their instant influence leading 
to obvious morphological changes in Mycobacterium smegmatis while prolonged treatment 
led to bacterial lysis as indicated by the formation of mesosomes, cell content leakage and 
cell death. Besides, treatment by D-LAK peptides promoted the interaction of 150 kDa 
FTIC-dextran with the mycobacteria. These results suggested the D-LAK peptides interact 
with the bacteria to potentially manipulate or modify their membrane properties.  
After establishing the surface-active action of D-LAK peptides, the mechanism underlying 
the synergistic effect on MDR-TB clinical isolates was studied using a bacterial growth 
response assay. The growth response of M. smegmatis after incubating with subinhibitory 
concentrations of different treatments was determined. Significant increase in membrane 
rigidity and decrease in membrane order was resulted after treatment with tyloxapol, 
capreomycin or its combinations with D-LAK peptides. The study of whole cell metabolism 
by HR-MAS revealed the significant decrease in both saturated and unsaturated lipid 
resonances while an increase in trehalose content was caused by capreomycin and its 
combinations with D-LAK peptides. A much subtler reduction in saturated and unsaturated 
lipid resonances was induced by rifampicin while the presence of tyloxapol only induced 
reduction in saturated lipid resonances. Neither of the treatment caused changes in trehalose. 
This indicated the effect of capreomycin in triggering membrane remodeling in M. smegmatis, 
leading to a shift in ratio between mycomembrane components, trehalose monomycolate and 
trehalose dimycolates. The remodeling effect by rifampicin or tyloxapol was much subtler 
which is presumably the origin of the lower significance in membrane properties changes as 
detected by fluorescence techniques.  
Liquid state nuclear magnetic resonance (NMR) metabolomics identified induced oxidative 
stress in treatment with capreomycin or rifampicin. Using M. smegmatis as a model, the 
combination of fluorescence spectroscopy and NMR metabolomics is established as a useful 
tool for the elucidation of mode of actions of antibiotics against mycobacteria. Consequently, 
these techniques were further exploited to evaluate the action of first-line anti-TB drugs and 
their combinations against Mtb Bleupan. Two challenge conditions were performed to assess 
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the growth response of Mtb Bleupan in the presence of subinhibitory concentration of 
antibiotics and their combinations with D-LAK peptides. Significant increase in membrane 
rigidity was resulted in treatment with isoniazid, D-LAK120-A with isoniazid and delamanid 
at 72-hour incubation and only in the presence of tyloxapol at 6-week incubation. Only 
modest changes in individual metabolite and bacterial membrane rigidity were observed by 
other treatments at either condition. Despite subtle changes in Mtb metabolism or membrane 
properties, this study marked the first use of HR-MAS on the investigation of direct action of 
antibiotics on a Mtb strain. The modest changes induced by certain antibiotics, such as 
isoniazid and delamanid, is likely to resemble their known mechanisms.  
Due to the complication of sample preparation of virulent Mtb species, previous studies of 
drug action using HR-MAS were only demonstrated on surrogate models such as 
Mycobacterium bovis Bacillus Calmette-Guérin and M. smegmatis. Using this attenuated Mtb 
Bleupan strain, drug action studies can be performed on a more reliable basis and generate 
more translatable findings. Although two different challenge conditions were included in this 
study, the slow-growing nature of Mtb is still rendered a main constraint for the detection of 
significant changes. Further optimizations on concentration and challenge duration could 
likely increase the significance of growth responses, enriching the basis for the elucidation of 
antimicrobial action on Mtb.  
Finally, this study addressed the translatability of findings using one of the most commonly 
employed M. smegmatis model to compare with the results of Mtb strains. The findings 
revealed apparent differences in terms of the responses to antibiotics by M. smegmatis as 
compared to Mtb. In contrast to M. smegmatis, synergy of D-LAK peptides combinations 
with rifampicin or isoniazid was observed when used against the severely attenuated Mtb 
Bleupan and MDR Mtb strains. However, the synergy between D-LAK peptides and 
capreomycin against M. smegmatis was not observed against Mtb Bleupan. Fluorescence 
spectroscopy revealed that generally, Mtb Bleupan has a higher membrane rigidity than M. 
smegmatis due to their possession of differing mycolic acids. Besides, culturing in the 
presence of tyloxapol showed a completely opposite effect on the membrane rigidity between 
M. smegmatis and Mtb Bleupan. Furthermore, significant membrane remodeling action 
triggered by capreomycin treatments in M. smegmatis was not observed in Mtb Bleupan. 
Thus, it may be concluded that cautious interpretation should be carried out when using M. 
smegmatis to study and develop anti-TB therapy. Nonetheless, the fast-growing nature of M. 
smegmatis makes it a highly desirable organism for the establishment of TB studying 
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techniques. Finally, this study also demonstrated the higher resemblance of Mtb Bleupan to 
Mtb clinical isolates, suggesting that this category 2 Mtb strain is applicable and useful for 
the production of translatable findings on TB antibiotic studies.  
 
7.2 LIMITATIONS  
The study of MDR-TB strain poses various limitations. The doubling time of a drug 
susceptible Mtb strain is around 24 hours and takes three to four weeks to reach mid-log 
phase. Due to the fitness-cost of mutant strains, MDR-TB takes an even longer period for 
optimal growth. All experiments are confined to a containment level 3 laboratory, rendering 
restricted use in times of emergencies such as malfunctioning of controlled pressure system 
and spillage accidents leading to laboratory suspension for disinfection. These unpredictable 
scenarios occurred randomly, leading to delay of data collection and unretrievable 
experimental data.  
On the other hand, due to safety concerns, experiments with Mtb strains may only be 
performed within the area of the cabinet. In this circumstance, no measurement involving 
external instruments, such as fluorescence reading of resazurin dye, was possible and largely 
limited the studies that could be performed on the bacteria. Moreover, resazurin is also used 
as a redox indicator409 which might affect the interpretation of results as some antibiotics 
induces the production of reactive oxygen species. Alternatively, measurement of metabolic 
activity via ATP level with the BacTiter-GloTM Microbial Cell Viability Assay410 or 
quenched-fluorescence oxygen sensing411 are two methods that can provide informative 
insights of cell viability in in vitro assays.  
Using as a surrogate, the findings from M. smegmatis must be interpreted carefully and 
should not be directly extrapolate to Mtb. The differences in the action of D-LAK peptides on 
M. smegmatis and MDR-TB strains have demonstrated a good example in this regard. M. 
smegmatis is undoubtedly a convenient and useful model for the preliminary study of 
experimental assays and techniques, nevertheless, Mtb strains would be the best choice to aim 
for translatable findings. Concerning the use of fluorescent probe, uneven nature of annular 
labelling observed in mycobacteria introduces obscurity in data interpretation412. The 
substantial differences in mycomembrane composition or in the physical state of lipid 
components lead to possible uneven distribution, exclusion or differing affinities of 
fluorescent probes, resulting in uneven annular labelling. This poses further challenges in 
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data interpretation, as fluorescent probe assay only provides an average value for the lipid 
order but does not indicate by scale whether a more rigid region is segregated from a more 
fluid region on the same membrane. Therefore, future investigation in the labelling 
characteristics on mycobacteria would be beneficial to further TB research. 
Studies on Mtb has been a challenge owing to the physiology of the bacteria; on one hand the 
slow growth rate implies long incubation time, and therefore, unpredictable morphological 
changes and induced metabolomic adaptations. On the other hand, disease complexity 
increases the difficulty of interpreting clinical outcome based on results of in vitro assays. As 
a result, a consensus regarding culture conditions such as medium composition and pH, 
carbon source and time of incubation has to be reached within the field.  
 
7.3 FUTURE WORK 
This study has further demonstrated the synergy of D-LAK peptides and rifampicin or 
isoniazid combinations on MDR Mtb clinical isolates. It has also established biophysical and 
membrane sensitive techniques for detecting the action of antibiotics and addressed the 
applicability of M. smegmatis model while proposed a Mtb Bleupan model with higher 
translatability. Study findings creates a foundation for subsequent questions which initiate the 
need of more research work. 
The combination of fluorescence spectroscopy and NMR metabolomics techniques was 
demonstrated to be useful in elucidating the mode of action of antibiotics on M. smegmatis. 
However, no definitive mechanistic explanations of antibiotics or synergy of D-LAK peptide 
combinations against Mtb strains were determined in this work. Thus, further work could 
focus on the optimization of the mechanistic studies of anti-TB agents on Mtb Bleupan. 
Challenges at various conditions with different concentrations can trigger disparate growth 
responses in Mtb, enabling the determination of suitable protocol for the observation of 
action of anti-TB agents as demonstrated in M. smegmatis.   
The fluorescent probes used in this work were deduced to label predominantly the 
mycomembrane layer of the mycobacteria. Nonetheless, due to the complexity of 
mycobacterial cell envelope, the distribution or location of membrane fluorescent probes can 
be more precisely determined. Some preliminary work has been attempted to observe the 
distribution of Laurdan probe on M. bovis BCG using fluorescence microscopy (Fig. 7.1). 
The resolution of the images, however, was insufficient for the determination of their exact 
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locations. Thus, future work would exploit confocal microscopy to obtain higher resolution 
images and to produce Z-stack images to visualize the exact location of probes in the 
mycobacteria.  On the other hand, to further evaluate peptide internalization in mycobacteria, 
studies can be performed by treating mycobacteria with fluorescence-labelled D-LAK 
peptides and observe the localization using fluorescence microscopy215 or making use of 
radiolabeled peptides413. 
 
Figure 7.1 M. bovis BCG labelled with Laurdan fluorescent probes. Fixed bacteria were re-suspended 
in PBS and stained by 2.5 µM Laurdan fluorescent probe. Samples were imaged with a 
65x oil-immersion objective lens using a Zeiss LSM-510 inverted confocal microscope (Carl Zeiss Inc., 
Germany).  
 
Synergistic studies were conducted to evaluate the mycobactericidal activity of D-LAK 
peptides and rifampicin against 03M and D-LAK peptides and isoniazid against 08MB in 
vitro and ex vivo. However, the assay was irretrievable due to an unexpected BSL 3 
laboratory incident occurred simultaneous to the present studies. Since 03M and 08MB 
displayed resistance towards rifampicin and isoniazid respectively when the drug was used 
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alone, potential synergistic interaction in the combinations with D-LAK peptide would be 
anticipated to be more beneficial in terms of overcoming the resistant phenotype. It would 
therefore, be essential to obtain these results again. In addition to RIF and INH, synergy 
between D-LAK peptides and fluoroquinolones or current second-line anti-TB agents could 
also be investigated as the combinations might be beneficial to reduce the effective 
concentration of these highly toxic agents. Besides, conducting cell viability assay using a 
wider range of macrophage models for Mtb such as murine J744 and primary human or 
murine macrophages would be beneficial to obtain a more comprehensive picture of the 
biocompatibility of the combinations.414 
Moreover, this study revealed the potential of combination with D-LAK peptides to reduce 
the effective dosage of rifampicin and isoniazid by at least two-fold, indicating the positive 
cooperativity of the peptides to potentiate the action of the drug. More importantly, this 
synergy may also prevent or delay the development of drug resistance in bacteria261, 415. It will 
be interesting to decipher the capability of D-LAK peptide combinations in supressing the 
selection of resistant Mtb mutants through conducting the drug resistance stimulation study.  
Synergy was demonstrated in D-LAK peptides in combination with rifampicin against all the 
four MDR isolates, while combinations with isoniazid only showed synergistic effect against 
particular strains. This indicates that there might be possible sequence specificity exhibited 
by the D-LAK peptides combinations, and therefore, genomic sequencing of the MDR-TB 
clinical isolates is a logical step to gain better understanding of this aspect. Genome-wide 
techniques are useful to identify drug target, mode of action and resistance mechanism416, 417. 
Through sequencing the MDR-TB isolates, corresponding genes that are biochemically or 
physiologically relevant to the peptides’ mode of action can be unveiled, therefore enriching 

















Appendix A: Notes on metabolite assignment 























Table 7.2 Assignments used for 1H HR-MAS NMR experiments. 
Metabolite ppm 
Lipids CH3- 0.89 
Lipids -(CH2)n- 1.29 
Alanine 1.47 
Lipids -CH2-OH 1.59 
Lysine 1.91 
Lipids -CH2-CH=CH- 2.03 










Figure 7.2 Representative 2D COSY 1H HR-MAS NMR spectrum of M. smegmatis mc2 155. A partial 
assignment is shown of identified metabolites. the spectrum was obtained on a 600 MHz Bruker 
spectrometer. General formula of mycolic acid (MA) is shown for the identification of cross-peaks 
between carbon groups.  
 
 
Figure 7.3 Representative metabolite assignment of a 1D 1H HR-MAS NMR spectrum of M. smegmatis 
mc2 155 with Chenomx software. Chenomx allows the overlaying of standard NMR spectra of 
compounds (coloured) with the NMR spectrum of sample under study (black).   
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Appendix B: Supplementary figures for multivariate analysis of mycobacterial 
growth response assay on M. smegmatis  
 
 
Figure 7.4 PCA of whole cell M. smegmatis mc2 155 subjected to different challenges. PCA score plot 
(Left) as shown for unchallenged bacteria (1.0), in the presence of 0.025% tyloxapol (1.0) or those 
challenged with ¾  MIC of D-LAK120-A (2.0), D-LAK120-HP13 (3.0), rifampicin (4.0), rifampicin in 
combination with D-LAK120-A (5.0) or D-LAK120-HP13 (6.0), capreomycin (7.0), capreomycin in 
combination with D-LAK120-A (8.0) or D-LAK120-HP13 (9.0), colistin (10.0), isoniazid (11.0). PCA 
loadings (Right) denoted the major metabolite responsible for the clustering in the score plot.  
 
 
Figure 7.5 PCA of spent culture media of M. smegmatis mc2 155 subjected to different challenges. 
PCA score plot (Left) as shown for unchallenged bacteria (1.0), in the presence of 0.025% tyloxapol 
(1.0) or those challenged with ¾  MIC of D-LAK120-A (2.0), D-LAK120-HP13 (3.0), rifampicin (4.0), 
rifampicin in combination with D-LAK120-A (5.0) or D-LAK120-HP13 (6.0), capreomycin (7.0), 
capreomycin in combination with D-LAK120-A (8.0) or D-LAK120-HP13 (9.0), colistin (10.0), 
isoniazid (11.0). PCA loadings (Right) denoted the major metabolite responsible for the clustering in 




Figure 7.6 OPLS-DA cross-validation data of whole cell M. smegmatis mc2 155 in the presence of 






Figure 7.7 OPLS-DA cross-validation data of whole cell M. smegmatis mc2 155 in the presence of 




Figure 7.8 OPLS-DA cross-validation data of whole cell M. smegmatis mc2 155 in the presence of 






Figure 7.9 OPLS-DA cross-validation data of whole cell M. smegmatis mc2 155 in the presence of 




Figure 7.10 OPLS-DA cross-validation data of whole cell M. smegmatis mc2 155 in the presence of 






Figure 7.11 OPLS-DA cross-validation data of whole cell M. smegmatis mc2 155 in the presence of 




Figure 7.12 OPLS-DA cross-validation data of whole cell M. smegmatis mc2 155 in the presence of 






Figure 7.13 OPLS-DA cross-validation data of whole cell M. smegmatis mc2 155 in the presence of 




Figure 7.14 OPLS-DA cross-validation data of whole cell M. smegmatis mc2 155 in the presence of 







Figure 7.15 OPLS-DA cross-validation data of whole cell M. smegmatis mc2 155 in the presence of 




Figure 7.16 OPLS-DA cross-validation data of whole cell M. smegmatis mc2 155 in the presence of 






Figure 7.17 OPLS-DA cross-validation data of spent culture media of M. smegmatis mc2 155 in the 




Figure 7.18 OPLS-DA cross-validation data of spent culture media M. smegmatis mc2 155in the 






Figure 7.19 OPLS-DA cross-validation data of spent culture media M. smegmatis mc2 155 in the 




Figure 7.20 OPLS-DA cross-validation data of spent culture media M. smegmatis mc2 155in the 






Figure 7.21 OPLS-DA cross-validation data of spent culture media of M. smegmatis mc2 155 in the 






Figure 7.22 OPLS-DA cross-validation data of spent culture media of M. smegmatis mc2 155 in the 







Figure 7.23 OPLS-DA cross-validation data of spent culture media of M. smegmatis mc2 155 in the 




Figure 7.24 OPLS-DA cross-validation data of spent culture media of M. smegmatis mc2 155 in the 







Figure 7.25 OPLS-DA cross-validation data of spent culture media of M. smegmatis mc2 155 in the 





Figure 7.26 OPLS-DA cross-validation data of spent culture media of M. smegmatis mc2 155 in the 






Figure 7.27 OPLS-DA cross-validation data of spent culture media of M. smegmatis mc2 155 in the 




Figure 7.28 OPLS-DA cross-validation data of fresh media as compared with spent culture media of 
unchallenged M. smegmatis mc2 155. 
 
 
Figure 7.29 Heatmap illustrating the correlation between metabolites identified in HR-MAS and 
liquid-state NMR spectra of M. smegmatis mc2 155. The correlation constant did not pass the 
significant threshold of 0.3 indicating there is no correlation between any of the metabolites detected 
in HR-MAS and those in liquid-NMR.   
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Appendix C: Supplementary figures for multivariate analysis of mycobacterial 
growth response assay on Mtb Bleupan 
 
 
Figure 7.30 PCA of whole cell Mtb Bleupan subjected to different challenges for 6-week. PCA score 
plot (Left) as shown for unchallenged bacteria (1.0), in the presence of 0.025% tyloxapol (1.0) or those 
challenged with ¼  MIC of D-LAK120-A (2.0), D-LAK120-HP13 (3.0), rifampicin (4.0), rifampicin in 
combination with D-LAK120-A (5.0) or D-LAK120-HP13 (6.0), isoniazid (7.0), isoniazid in 
combination with D-LAK120-A (8.0) or D-LAK120-HP13 (9.0), capreomycin (10.0), colistin (11.0), 
delamanid (12.0). PCA loadings (Right) denoted the major metabolite responsible for the clustering in 




Figure 7.31 PCA of whole cell Mtb Bleupan subjected to different challenges for 72-hour. PCA score 
plot (Left) as shown for unchallenged bacteria (1.0), in the presence of 0.025% tyloxapol (1.0) or those 
challenged with ½  MIC of D-LAK120-A (2.0), D-LAK120-HP13 (3.0), rifampicin (4.0), rifampicin in 
combination with D-LAK120-A (5.0) or D-LAK120-HP13 (6.0), isoniazid (7.0), isoniazid in 
combination with D-LAK120-A (8.0) or D-LAK120-HP13 (9.0), capreomycin (10.0), capreomycin in 
combination with D-LAK120-A (11.0) or D-LAK120-HP13 (12.0), colistin (13.0), delamanid (14.0). 







Figure 7.32 PCA of spent media of Mtb Bleupan subjected to different challenges for 6-week. PCA 
score plot (Left) as shown for unchallenged bacteria (1.0), in the presence of 0.025% tyloxapol (1.0) 
or those challenged with ¼  MIC of D-LAK120-A (2.0), D-LAK120-HP13 (3.0), rifampicin (4.0), 
rifampicin in combination with D-LAK120-A (5.0) or D-LAK120-HP13 (6.0), isoniazid (7.0), isoniazid 
in combination with D-LAK120-A (8.0) or D-LAK120-HP13 (9.0), capreomycin (10.0), colistin (11.0), 
delamanid (12.0). PCA loadings (Right) denoted the major metabolite responsible for the clustering in 





Figure 7.33 PCA of spent media of Mtb Bleupan subjected to different challenges for 72-hour. PCA 
score plot (Left) as shown for unchallenged bacteria (1.0), in the presence of 0.025% tyloxapol (1.0) 
or those challenged with ½  MIC of D-LAK120-A (2.0), D-LAK120-HP13 (3.0), rifampicin (4.0), 
rifampicin in combination with D-LAK120-A (5.0) or D-LAK120-HP13 (6.0), isoniazid (7.0), isoniazid 
in combination with D-LAK120-A (8.0) or D-LAK120-HP13 (9.0), capreomycin (10.0), capreomycin 
in combination with D-LAK120-A (11.0) or D-LAK120-HP13 (12.0),, colistin (13.0), delamanid (14.0). 






Figure 7.34 Hierarchical clustered heatmap comparing loadings obtained from cross-validated OPLS-
DA of 1H HR-MAS (A) and liquid-state (B) NMR spectra of Mtb Bleupan challenged with indicated 








Figure 7.35 Hierarchical clustered heatmap comparing loadings obtained from cross-validated OPLS-
DA of 1H HR-MAS (A) and liquid-state (B) NMR spectra of Mtb Bleupan challenged with indicated 







Figure 7.36 OPLS-DA cross-validation data whole cell Mtb Bleupan in the presence of 0.025% 






Figure 7.37 OPLS-DA cross-validation data of whole cell Mtb Bleupan in the presence of ¼  MIC of 




Figure 7.38 OPLS-DA cross-validation data of whole cell Mtb Bleupan in the presence of ¼  MIC of 






Figure 7.39 OPLS-DA cross-validation data of whole cell Mtb Bleupan in the presence of ¼  MIC of 




Figure 7.40 OPLS-DA cross-validation data of whole cell Mtb Bleupan in the presence of ¼  MIC of 






Figure 7.41 OPLS-DA cross-validation data of whole cell Mtb Bleupan in the presence of ¼  MIC of 




Figure 7.42 OPLS-DA cross-validation data of whole cell Mtb Bleupan in the presence of ¼  MIC of 






Figure 7.43 OPLS-DA cross-validation data of whole cell Mtb Bleupan in the presence of ¼  MIC of 




Figure 7.44 OPLS-DA cross-validation data of whole cell Mtb Bleupan in the presence of ¼  MIC of 






Figure 7.45 OPLS-DA cross-validation data of whole cell Mtb Bleupan in the presence of ¼  MIC of 




Figure 7.46 OPLS-DA cross-validation data of whole cell Mtb Bleupan in the presence of ¼  MIC of 






Figure 7.47 OPLS-DA cross-validation data of whole cell Mtb Bleupan in the presence of ¼  MIC of 




Figure 7.48A-F ¼  MIC Challenges induce changes in various metabolites in spent media of Mtb 
Bleupan incubated for 6 weeks. Volcano plots are shown for individual comparisons of unchallenged 
bacteria and those challenged with D-LAK120-A (A), D-LAK120-HP13 (B), rifampicin in combination 
with D-LAK120-A (C) or D-LAK120-HP13 (D), isoniazid in combination with D-LAK120-A (E) or D-
LAK120-HP13 (F). Volcano plots are of PQN normalized data and allow comparison of fold changes 
and significance of each metabolite; blue – significant reductions, red – significant increases and grey 




Figure 7.49A-F ½  MIC Challenges induce changes in various metabolites in whole cell Mtb Bleupan 
incubated for 72 hours. Volcano plots are shown for individual comparisons of unchallenged bacteria 
and those challenged with 0.025% tyloxapol (A), D-LAK120-A (B), D-LAK120-HP13 (C), rifampicin 
(D), rifampicin in combination with D-LAK120-A (E) or D-LAK120-HP13 (F). Volcano plots are of 
PQN normalized data and allow comparison of fold changes and significance of each metabolite; blue 
– significant reductions, red – significant increases and grey – non-significant changes in the 




Figure 7.49G-J ½  MIC Challenges induce changes in various metabolites in whole cell Mtb Bleupan 
incubated for 72 hours. Volcano plots are shown for individual comparisons of unchallenged bacteria 
and those challenged with isoniazid (G), isoniazid in combination with D-LAK120-A (H), capreomycin 
(I), delamanid (J). Volcano plots are of PQN normalized data and allow comparison of fold changes 
and significance of each metabolite; blue – significant reductions, red – significant increases and grey 
– non-significant changes in the indicated metabolites. 
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Figure 7.50A-F ½  MIC Challenges induce changes in various metabolites in spent media of Mtb 
Bleupan incubated for 72 hours. Volcano plots are shown for individual comparisons of unchallenged 
bacteria and those challenged with rifampicin in combination with D-LAK120-A (A) or D-LAK120-
HP13 (B), rifampicin (C), isoniazid in combination with D-LAK120-A (D) or D-LAK120-HP13 (E), 
capreomycin (F). Volcano plots are of PQN normalized data (n=9) and allow comparison of fold 
changes and significance of each metabolite; blue – significant reductions, red – significant increases 





Figure 7.50 G-K ½  MIC Challenges induce changes in various metabolites in spent media of Mtb 
Bleupan incubated for 72 hours. Volcano plots are shown for individual comparisons of unchallenged 
bacteria and those challenged with   capreomycin in combination with D-LAK120-A (G) or D-
LAK120-HP13 (H), colistin (H), delamanid (J) or Fresh Media (K). Volcano plots are of PQN 
normalized data (n=9) and allow comparison of fold changes and significance of each metabolite; 





Figure 7.51 Univariate analysis of relative metabolite levels in whole-cell Mtb Bleupan challenged for 
72 hours with ½  MIC antibiotics or in the presence of 0.025% tyloxapol. Significant differences with 
respect to unchallenged bacteria, as determined by one-way ANOVA with Tukey post-hoc test, are 
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